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A. Introduction
Living cells are producing 1011 different proteins in which the amino acid sequence from only 
a quarter is known. Proteins are large macromolecules with a molecular weight around 5-500 
kDa, which are involved in the coordination of almost all physiological processes. In the 
human body, proteins appear as structural proteins as a part of the connective tissue or in cell 
membranes as receptors or ion channels. They can also be considered as molecular machines 
since they are catalyzing chemical reactions as enzymes or providing protection as antibodies 
in the human immune system. Moreover, proteins can be used as small transporters or to 
regulate metabolic processes.1 Proteins are consisting out of polypeptides, which are 
stabilized by disulfide bonds, salt bridges or hydrogen bonds. These interactions are 
determining the three-dimensional structure of a protein and consequently its function. The 
smallest unit of polypeptides is represented by the amino acids.2 Advisably, amino acids are 
designated as the building blocks of life. The proteins essential for life as we know are build 
up RI WZHQW\ Į-amino acids, designated as proteinogenic amino acids. However, there are 
more than 400 non-proteinogenic amino acids known with different functions such as 
hormones or metabolites. In nature, mainly microorganisms produce ammonia out of 
molecular nitrogen, which is used for the construction of amino acids or proteins by plants or 
microorganisms itself. In mammals, amino acids are produced from intermediates of the 
metabolic cycles, mainly of the citric acid cycle.3,4 In industry, amino acids are synthesized
via fermentation, chemical synthesis or extraction methods in thousand ton scales per year 
and are mainly used as food additives, medical products, cosmetics, detergents or synthetic 
polymers.5
The Strecker-reaction represents the first one-pot PXOWLFRPSRQHQWV\QWKHVLVRIĮ-amino acids 
even before its isolation from natural sources. Simple condensation of acetaldehyde 1 with 
ammonia in the presence of hyGURJHQ F\DQLGH JDYH ULVH WR Į-amino nitrile 2. Subsequent 
K\GURO\VLV\LHOGHGWKHĮ-amino acid alanine 3 (Scheme 1).6
Scheme 1: Presentation of the Strecker synthesis. 
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Though this reaction was developed more than 150 years ago, it remained very popular since 
it provides a robust, direct and economically viable access towards naturally as well as non-
QDWXUDOO\Į-amino acids. It is not surprising that based on the high demand of enantioenriched 
Į-amino acids, in particular, asymmetric Strecker reactions attracted much attention in 
organic chemistry in the last fifty years.7
%HVLGHVĮ-amino acids, also ȕ- DQGȖ-amino acids represent key structural elements in various 
agrochemical or pharmaceutical target molecules and reveal interesting properties, for 
instance as anticancer agents (4),8 antibiotics (5),9 enzyme–inhibitors (6)10 or as an influenza 
neuramidase inhibitor (7)11 (Figure 1). The probably most prominent example for a naturally 
RFFXUULQJ Ȗ-DPLQR DFLG GLVSOD\V Ȗ-amino butyric acid 8 (GABA), the major inhibitory 
neurotransmitter in the mammalian central nervous system, which also plays an essential role 
in several brain malfunctions like epilepsy or Alzheimer´s disease. Due to its low lipophilicity 
and the poor availability to cross the blood-brain barrier, the synthesis of more lipophilic 
GABA derivatives like Baclofen 9, a muscle relaxant and antispastic agent, was the objective 
of a great number of studies.12
Figure 1: Presentation of selected of ȕ- and Ȗ-amino acids.
,QSDUWLFXODUFRQIRUPDWLRQDOO\FRQVWUDLQHGF\FOLFȕ- DQGȖ-amino acids have generated great 
interest in synthetic and medicinal chemistry as they are found in natural products and 
antibiotics such as amipurimycin (5).13 ,QFRPSDULVRQWRĮ-amino acids, the additional bonds 
DQG GLKHGUDO DQJOHV LQ WKH FRUUHVSRQGLQJ ȕ- DQG Ȗ-analogues result in a higher degree of 
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conformational freedom.14 In cyclic residues, the torsion angles are dependent on the 
geometry of the ring system and are more restricted (Figure 2).15
Figure 2: Torsion angles in Į-amino acid, acyclic ȕ- DQG Ȗ-DPLQR DFLG WRS DQG F\FOLF ȕ- DQG Ȗ-amino acid 
(bottom).
Due to their conformational restrictions and their well-defined geometry, cyclic amino acids 
are of particular interest in the synthesis of peptidomimetics or foldamers. Foldamers are 
defined as artificial peptides with strong tendency to adopt a specific conformation.16 Cyclic 
amino acids are known to stabilize various secondary structure motifs in synthetic oligomers 
because of their well-defined geometry and to increase the stability of Į-peptides against 
proteolytic degradation.17 Aminocyclopentane carboxylic acid 10 (ACPC) represents together 
with aminopyrrolidine carboxylic acid 11 (APC) a frequently used building block for 
foldamers synthesis. For instance, Gellman et al. used trans-ACPC among others for the 
design of homo-ȕ-peptide 13 and demonstrated that the secondary structure could be 
controlled by alternation as well as the nDWXUH RI WKH XVHG ȕ-amino acids. NMR and X-ray 
studies of 13 proved that the predicted 12-helical conformation was adopted caused by a 12-
membererd ring hydrogen bond system (Figure 3).16b Berlicki et alSXEOLVKHGĮȕ-alternating 
foldamer 14 using cis-ACPC, which revealed a stable 16/18-helical structure in methanol.18
Very recently, Burgess et al. investigated the cyclization of linear precursors containing APC 
building blocks towards cyclic peptides such as 15. They could show, that the efficiency of 
cyclization was strongly depended on the absolute stereochemistry of APC building block and 
the (S,S)-cis-APC turned out to be the best.19
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Figure 3: Selection of some ACPC and APC containing peptides.
Since for various applications HQDQWLRSXUHȕ- DQGȖ-amino acids are required, the development 
RIHQDQWLRVHOHFWLYHV\QWKHVHVRIȕ- DQGȖ-amino acids was of great interest in the last twenty 
\HDUV 7KH SUREDEO\ PRVW SURPLQHQW DQG VLPSOHVW PHWKRG WR JHW DFFHVV WR ȕ-amino acids 
GLVSOD\V WKH V\QWKHVLV IURPĮ-amino acids by an Arndt-Eistert homologation (Scheme 2).20
Activation of the carboxylic acid 16 followed by conversion to the corresponding diazo 
compound 17 HPSOR\LQJ GLD]RPHWKDQH LV WKH ILUVW VWHS WRZDUG ȕ-amino acids. Subsequent 
Wolff-rearrangement in the presence of Ag-VDOWVSURYLGHVWKHGHVLUHGȕ-amino acid 18. 
Scheme 2: Arndt-Eistert KRPRORJDWLRQRIĮ-DPLQRDFLGVWRZDUGȕ-amino acids. 
Continuous improvements and optimization demonstrate the importance of this method till 
today.21 The focus of the present thesis is on the enantioselective synthesis and application of 
cis-ȕ- DQG Ȗ-amino acids based on aminocyclopentane carboxylic acid ACPC (10) and 
aminopyrrolidine carboxylic acid APC (11 and 12).  Therefore, the following chapters will 
give an overview of asymmetric synthetic strategies exclusively toward these types of 
building blocks.22
1. Synthetic strategies towards aminocyclopentane carboxylic acid
In 1996, one of the first examples of an enantioselective synthesis of ACPC, the so-called
cispentacin synthesis, was developed by Davies et al. (Scheme 3).23 This method is based on 
the conjugate addition of homochiral lithium amide 19 to the unsaturated cyclic ester 20 and 
gives access to cis-ȕ-amino ester 21 in high yields and diastereopurity. Its big advantage is the 
A. Introduction
5
facile accessibility of both enantiomers of 21 by employing either the (R)- or (S)-enantiomer 
of the lithium amide 19. Removal of the chiral auxiliary by hydrogenolysis and the tert-butyl 
ester provided cis-ACPC 22 in 62% yield over 3 steps in enantiomerically pure form. By 
diastereoselective epimerization of compound 21 using KOtBu, the corresponding N-
protected trans-ACPC 24 can be easily prepared in 47% yield over 5 steps.24
Scheme 3: Synthesis of cis- and trans-ACPC E\ FRQMXJDWH DGGLWLRQ IURP Įȕ-unsaturated ester reported by 
Davies at al.
This method is also applicable to a broad variety of acyclic Įȕ-unsaturated acceptors25 such 
as formyl carboxylate 25, leading to hydroxy-IXQFWLRQDOL]HGȕ-amino ester 26 in a moderate 
yield of 66% but in excellent diastereoselectivities (Scheme 4).26 Subsequent transformations 
of the IXQFWLRQDOJURXSVSURYLGHGWKHIUHHK\GUR[\ȕ-amino acid 27 in 57% yield over 3 steps 
in enantiomerically pure form. 
Scheme 4: Synthesis of hydroxy-functionalized cyclic ȕ-amino acids.
Another rapid and facile procedure for the synthesis of cis-ACPC represents the ring-opening 
WUDQVIRUPDWLRQ RI ELF\FOLF ȕ-lactam 30 by Fülöp et al. (Scheme 5).27 Derived from the 
cycloaddition of chlorosulfonyl isocyanate and cyclopentane 28UDFHPLFȕ-lactam 30 can be 
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converted enzymatically to the enantiopure cis-ACPC 22 and the unreacted lactam in high 
yields each (pathway A). Moreover, the enantiomer (ent)-22 can be also prepared in 96% ee
out of racemic 32 by acidic lactam ring-opening of 30 followed by enzymatic ethyl ester 
hydrolysis (pathway B). 
Scheme 5: Enzymatically ȕ-lactam ring-opening towards cis-ACPC by Fülöp et al.
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In 2003, Bolm et al. developed a three-step cinchona alkaloid mediated asymmetric opening 
of cyclic meso-anhydride 34 in the presence of benzyl alcohol yielding the optically active 
hemiester 35 with excellent enantioselectivities (Scheme 6). A nice feature of this procedure 
represents the facile accessibility of both enantiomers of 35 by using either quinine or 
quinidine. Curtius degradation led to the N-SURWHFWHG ȕ-amino ester 36 and subsequent
recrystallization increased the enantiomeric excess to higher than 99.7%. Hydrogenolysis of 
the protecting groups furnished cispentacin 22 in 67% yield over 3 steps.28
Scheme 6: Three-step quinine mediated desymmetrization by Bolm et al.
A further interesting approach towards to enantiopure cis-ACPC was reported by Aggerwal et 
al. in 2003.29 Herein, the first key step was the conversion of dithiane 37 toward phosphonate 
dioxide 38 via asymmetric sodium periodate with in >98% ee. Subsequent Horner-
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Wadsworth-Emmons olefination gave dithioacetal 39, which was used in the following for an 
intramolecular nitrone cycloaddition (40) to obtain 41. By reductive cleavage of N-O bond in 
isoxazolidine 41 and removal of the dithioacetal unit cis-ACPC 22 was prepared in 10% over 
6 steps. 
Scheme 7: Synthesis of cis-ACPC from enantiomerically pure ketene dithioacetal reported by Aggerwal et al.
In 2013, Pou et al. developed an organocatalytic tandem Michael addition/cyclization with 
cyclopentene-2-carbaldehyde 43 and N-(benzyloxycarbonyl)hydroxylamine 44 using 
diphenylprolinol trimethylsilyl ether  45 as chiral amine catalyst. Isoxazolidinone 46 was 
obtained in 98% yield with an enantiomeric excess of 96%, which was further transformed to 
the desired cispentacin via oxidation with pyridinium dichromate and reductive ring-opening 
of the corresponding ketone over 2 steps and 95% yield.30
Scheme 8: Organocatalytic tandem Michael addition/cyclization reaction reported by Pou et al.
Gardiner et al. reported a versatile ring-closing metathesis approach by applying the chiral 
amino acid pool towards trans-ACPC starting from readily available (S)-methionine 47
(Scheme 9).31 7KHĮ-amino acid was converted WRRSWLFDOO\SXUHȕ-amino ester 48 involving 
allylation and Arndt-Eistert homologation in 3 steps. By ring-closing metathesis employing 
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Grubbs´ II catalyst the N-protected trans-ACPC 49 was finally synthesized in 34% over 4
steps.
Scheme 9: Construction of trans-ACPC from (S)-methionine reported by Gardiner et al.
2. Synthetic strategies towards aminopyrrolidine carboxylic acid
3\UUROLGLQH GHULYHG ȕ-amino acids attracting growing interest since they have been utilized 
together with ACPC as building blocks for the construction of artificial peptides with 
antimicrobial activities.32 The conjugate addition method of Davies described above (Scheme 
3) also displays DQHIILFLHQWPHWKRGIRUWKHFRQVWUXFWLRQRIS\UUROLGLQHGHULYHGȕ-amino acids 
(Scheme 10).33 For this purpose, benzyl protected N-KHWHURF\FOLFĮȕ-unsaturated acceptor 50
was a suitable starting material and cis-ȕ-amino ester 51 was obtained in 79% yield and an 
excellent diastereomeric excess. The corresponding trans-isomer 53 can be synthesized in 
analogy to its carbocyclic derivative 23 by epimerization at C-1 in the presence of KOtBu in 
refluxing tBuOH. Reductive cleavage of the benzyl groups and tert-butyl ester hydrolysis 
yielded the enantiopure cis-APC 52 in 77% over 3 steps and the trans-APC 54 in 56% over 4
steps, respectively.
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Scheme 10: Synthesis of cis- and trans-ACPC E\ FRQMXJDWH DGGLWLRQ IURP Įȕ-unsaturated ester reported by 
Bunnage at al.
With their cispentacin synthesis in 2003, Aggerwal et al. demonstrated that chiral dithio
ketenes are also applicable to get access to cis-APC 52 (Scheme 11, compare Scheme 7). This 
method displayed the first asymmetric synthesis of desired cis-APC 52.29 Dithio ketene 57, 
derived from chiral phosphonate 38 and amino acetal 56, was cyclized to fused isoxazoline 58
by a 1,3-intramolecular cycloaddition using pTsOH and BnNHOH. Isoxazoline ring-opening 
and removal of the N-protecting groups furnished cis-APC 52 in 20% yield over 9 steps.
Scheme 11: Synthesis of cis-APC from enantiomerically pure ketene dithioacetal reported by Aggerwal et al.
In the same year, Hanselmann et al. reported a methodically similar synthetic route towards 
cis-APC.34 For the construction of isoxazolines 62 and 63, a metal induced chelation-
controlled 1,3-dipolar cycloaddition was the key step. For this, aldehyde 59 was condensed
with chiral hydroxylamine 60 toward nitrone 61 resulting in a highly diastereoselective 
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isoxazoline formation. After separation of the diastereomers, reductive ring-opening and 
oxidation reaction orthogonally protected cis-APC 64 was obtained in 49% over 4 steps.
Scheme 12: Isoxazoline based synthetic approach towards cis-APC by Hanselmann et al.
3. Synthetic strategies WRZDUGVFDUERF\FOLFDQGS\UUROLGLQHGHULYHGȖ-amino acids 
The great potential of acyclic as well as cyclic Ȗ-amino acids for the synthesis of                      
Ȗ-peptides15b,35 or heterogeneous backbone foldamers36 was already demonstrated in various 
literature reports. In particular, a great variety of contributions were given by Fleet et al.,37
Kessler et al.,38 Sharma et al.39 Gellman et al.40 or Aitken et al.41 However, a closer look to 
the literature reveals, that five-membered ring Ȗ-amino acids display an minority and the 
majority of utilized Ȗ-amino acids are acyclic, four- or six-membered rings or carbohydrate 
derived sugar amino acids. Some selected syntheses for five-membered ring Ȗ-amino acids are 
presented hereinafter.  
Recently, Gellman et al. reported an enantioselective synthesis for trans-Ȗ-aminomethyl 
F\FORSHQWDQHFDUER[\OLFDFLGȖ-AMCP) in multigram quantities and its utilization as building 
EORFNVIRUĮȖ-peptides (Scheme 13).42 The stereoselective Michael addition of nitromethane 
to aldehyde 43 catalyzed by 45 and benzoic acid furnished the nitro alcohol 66 in 95% yield 
and >99% enantiomeric excess. Subsequent reduction of the nitro group and oxidation of the 
alcohol to the corresponding carboxylic acid provided the enantiopure Ȗ-AMCP 66 within 
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24% over 5 steps. However, to the best of our knowledge, synthetic approach toward the cis-
isomer of 66 was not reported yet in the literature. 
Scheme 13: Organocatalytic Michael addition  as key step towards Ȗ-AMCP by Gellman et al. 
In their studies about self-assembling cyclic peptides, Granja et al. employed 
FRQIRUPDWLRQDOO\ UHVWULFWHG Ȗ-DPLQRF\FORSHQWDQHFDUER[\OLF DFLG Ȗ-Acp) 70 which was 
derived form cRPPHUFLDOO\DYDLODEOHȖ-lactam (±)-67 (Scheme 14).43 The resolution with (R)-
Į-methylbenzylamine (MBA) after the hydrolysis of compound 67 led to the Boc protected 
cyclopentene 68 )LQDOO\ K\GURJHQDWLRQ RI WKH GRXEOH ERQG SURGXFHG WKH GHVLUHG Ȗ-amino 
acid in 69% yield over 4 steps and 97% ee. Otherwise, 70 can also be obtained by resolution 
RI WKH IXOO\ VDWXUDWHG UDFHPLFȖ-amino acid 69. However, for the crucial resolution step, no 
yield was reported in the literature.
Scheme 14: Asymmetric resolution of racemic lactam towards Ȗ-Acp reported by Granja et al.
In 2012, Kanger et al. developed a thiourea-catalyzed cascade reaction to get access to 
trisubstituted pyrrolidine derivatives (Scheme 15).44 The selectivity of this reaction was 
highly depended on the N-protecting group of the crotonate 71. While benzyl protected 
derivatives of 71 were obtained in high diastereomeric ratios but with poor enantiopurity, 
tosyl protected pyrrolidines could be isolated in a moderate diastereomeric ratio but with high 
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enantiomeric excess in the case of the major isomer 74 and modest enantiopurity for the 
minor isomer 75. By this method, pyrrolidine derived Ȗ-amino acid ester 76 was yielded in 
58% over 2 steps.
Scheme 15: Thiourea-catalyzed synthesis of trisubstitued pyrrolidines reported by Kanger et al.
As mentioned above, this review will only give an overview of the most relevant syntheses 
for building blocks employed in this work. In particular, the related derivatives of these 
building blocks have aroused enormous interest in chemistry and drug research, resulting in a 
huge amount of publications in the last twenty years. All in all, carbocyclic and heterocyclic 
five-membered ULQJȕ- DQGȖ-amino acids display important and interesting building blocks 
for a great variety of applications. In the present thesis, the five-membered ULQJȕ-amino acids 
ACPC and APC will be utilized as a central building block in short- to longer chain peptides. 
Moreover, due to the very small amount of literature known procedures for the synthesis of N-
KHWHURF\FOLFȖ-amino acids such as 12, a new enantioselective method should be developed to 
JHWDFFHVVWRWKLVW\SHRIȖ-amino acids.
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B. Main Part
1. Synthesis of APC and ACPC building blocks
The first part of the present thesis deals with the application of literature-NQRZQ F\FOLF ȕ-
amino acids aminopyrrolidine carboxylic acid 79 (APC) and aminocyclopentane carboxylic 
acid 80 (ACPC) in organocatalysis and peptides. For this application, enantiomerically pure 
building blocks are essential. The core structure of the cis-APC-7833 and cis-ACPC-2124
building blocks was built up by employing the method of Davies et al.23 (Scheme 16). Herein, 
the conjugate addition of a homochiral lithium amide 19 to a Į,ȕ-unsaturated acceptor 77/20
plays the key role. This approach guarantees a highly enantioselective and diastereoselective 
outcome of the reaction, which is crucial for the intended applications of the building blocks. 
Moreover, depending on the applied enantiomer of 19, access to both enantiomers of the 
desired building blocks is possible. To get access to orthogonally protected building blocks 79
and 80, well-established procedures in our group were employed.45,46
Scheme 16: Key step in the synthesis of APC and ACPC building blocks according to Davies et al. towards 
orthogonally protected building blocks 14 and 15.
The synthesis of APC-79 starts from glycine methyl ester 81 (Scheme 17). After Boc-
protection, the cyclization with KOtBu and tert-butyl acrylate provided the potassium salt 83,
which was subsequently reduced with NaBH4 to the corresponding alcohol 84. For the 
dehydration step, a Mitsunobu type reaction by the treatment of 84 with PPh3 and DIAD was 
initially carried out. Due to the scale of 375 mmol, the toxicity and the cost of DIAD, a one 
pot tosyl protection of the alcohol 84, followed by elimination of the tosylate with pyridine as 
base and solvent was performed. Unfortunately, this alternative method revealed preparative 
limitations of the scale and delivered the desired product 77 only in 17% yield, although first 
test reactions provided yields up to 70%.45 In summary, the Įȕ-unsaturated acceptor 77 was 
obtained in 11% yield over four 4 steps starting from glycine 81 (lit.46 39%).
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Scheme 17: Synthesis of 77 towards APC building blocks. 
The addition of homochiral lithium amide 19 to the Įȕ-unsaturated acceptor 77 is the key 
step in synthetic route towards APC building blocks (Scheme 18). Depending on the applied 
chiral amine 19, the absolute stereochemistry of the building blocks will be set in this step. 
The formation of enantio- and diastereopure addition-products was achieved by performing 
the reaction under low-temperature conditions at -95 °C and the use of the weak and bulky 
proton source 2,6-di-tert-butyl-4-methylphenol (BHT). The synthesis of the APC 78 was 
performed on a 12 times bigger scale than in literature reported33 (3.72 mmol vs. 43 mmol)
and the desired product was obtained in 25% yield (lit. 46%). The occurrence of elimination 
products caused by Ȗ-deprotonation competes with the lithium amide addition, reduced the 
yield. This fact is also discussed in the literature and may be attributable to the activating and 
directing effect of the N-Boc protection.47 However, suggestions how to prevent this 
elimination were not reported.33
Scheme 18: Synthesis of APC 79.
Reagents and conditions: (a) i) (S)-19, THF, -95 °C to -78 °C, 3h; ii) BHT, THF, -95 °C, 25%, de >99%; (b) i) 
H2 (20 bar), Pd(OH)2/C, AcOH, MeOH, rt, 24 h; ii) FmocOSu, NaHCO3, dioxane/water, 0 °C to rt , 24 h, 86%
over two steps; (c) i) TFA, DCM, rt, 24 h, quant.; ii) Boc2O, NaHCO3, dioxane/water, 0 °C to rt, 48 h, 88% over 
2 steps. 
Going forward with the desired APC 79, further transformations of 78 were necessary. The 
benzyl groups on the amine were removed by catalytic hydrogenolysis in the autoclave,
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followed by Fmoc protection to obtain 85 in 86% over 2 steps (lit.46 92%). The required free 
carboxylic acid in APC 79 was generated by hydrolysis of the tert-butyl ester with 
trifluoroacetic acid, which also caused cleavage of the Boc group. After Boc reprotection, the 
desired APC 79 was obtained in 88% over 2 steps (lit.46 51%) and 19% over 5 steps starting 
from 77 (lit.46 15%). 
The addition product (ent)-78 was prepared from 77 in analogy to its enantiomer by using 
(R)-19 as the chiral amine in 31% yield (Scheme 19). Following the same transformations of 
the functional groups, (ent)-APC 79 was obtained in 16% yield over 5 steps. 
Scheme 19: Synthesis of (ent)-APC 79. 
Reagents and conditions: (a) i) (R)-19, THF, -95 °C to -78 °C, 3h; ii) BHT, THF, -95 °C, 31%, de >99%; (b) i) 
H2 (20 bar), Pd(OH)2/C, AcOH, MeOH, rt, 24 h; ii) FmocOSu, NaHCO3, dioxane/water, 0 °C to rt , 24 h, 59%
over two steps; (c) i) TFA, DCM, rt, 24 h, quant.; ii) Boc2O, NaHCO3, dioxane/water, 0 °C to rt, 48 h, 85% over 
2 steps. 
To avoid the undesired deprotection of the Boc group during hydrolysis of 85 to 79, 
alternative methods have been explored.a) A closer look at the literature revealed that this 
could be quite challenging. Nevertheless, two promising methods were found and tested. 
Aplying Montmorillonite KSF as an acidic ion exchange resin48 was not successful: no
conversion of the starting material was observed. The second attempt was the use of I2/H2O in 
refluxing acetonitrile by in situ generation of HI, advertised as a mild deprotection method.49
Indeed, under these conditions, a selective tert-butyl ester cleavage under preservation of the 
Boc group was possible but only in poor yields (Scheme 20). Also, much longer reaction 
times were necessary compared to those reported in the literature. Taking these poor results
into account, the selective tert-butyl ester cleavage was not explored further, and the Boc 
deprotection and subsequent reprotection sequence was accepted given the satisfying yields
obtained this way. 
a) Results partially taken from Bachelor thesis of A. Röther (supervised by T. Ertl).
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Scheme 20: Attempt for selective tert-butyl hydrolysis to preserve of the Boc group.
For the synthesis of the ACPC building blocks, the same method was applied like for the APC 
building blocks. For the construction of the cyclopentane 20 and the subsequent addition of 
the chiral amines already literature-known procedures were available, allowing to get access 
to the desired compounds in multi-gram quantities. First, the cyclopentane core structure 88
was built up by the cyclization of di-tert-butyl-ester 87 (Scheme 21). After reduction of the 
keto group by NaHB4, the dehydration was carried out by mesylation of the alcohol followed 
by elimination with DBU. This way, 20 was obtained in 39% yield over 5 steps from 86 (lit.24
39%). 
Scheme 21: Synthesis of 20 towards ACPC building blocks. 
In case of the ACPC building blocks, the addition of the chiral amine to 20 was performed in 
analogy to the APC building blocks (Scheme 22). This time, no byproducts during the
addition of the chiral amine were observed and 21 was obtained in 88% yield (lit.24 87%). 
Furthermore, the same transformations of the functional groups as for the APC building 
blocks were required. Removal of the benzyl groups of 21 by hydrogenolysis was followed
the tert-butyl ester hydrolysis. The corresponding free amino acid was subsequently submitted 
to Fmoc-protection to obtain the desired building block 80 in 19% yield over 4 steps (lit.24
11%). 
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Scheme 22: Synthesis of ACPC 80. 
Reagents and conditions: (a) i) (S)-19, THF, -95 °C to -78 °C, 3h; ii) BHT, THF, -95 °C, 88%, de >99%; (b) i) 
H2 (15 bar), Pd/C, AcOH, MeOH, rt, 22 h; ii) TFA, DCM, rt, 24 h; iii) FmocOSu, NaHCO3, dioxane/water, 0 °C 
to rt, 48 h, 21% over 3 steps. 
(ent)-80 was synthesized in the same way as its enantiomer and the addition product (ent)-21
was obtained in 80% yield with excellent diastereomeric excess. After transformation of the 
functional groups, (ent)-80 was obtained in 14% yield over four steps (Scheme 23). 
Scheme 23: Synthesis of (ent)-80. 
Reagents and conditions: (a) i) (R)-19, THF, -95 °C to -78 °C, 3h; ii) BHT, THF, -95 °C, 80%, de >99%; (b) i) 
H2 (15 bar), Pd/C, AcOH, MeOH, rt, 22 h; ii) TFA, DCM, rt, 24 h; iii) FmocOSu, NaHCO3, dioxane/water, 0 °C 
to rt, 48 h, 18% over 3 steps.  
Having APC and ACPC in hand in multi-gram quantity, their utilization in (peptide-related) 
organocatalysis and peptides was investigated and will be discussed in the following chapters. 
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2. APC building block in organocatalysis
2.1 ȕ-Proline in asymmetric anti-Mannich-Type Reactions
The publication of two pioneering articles in 2000, discussing the utilization of cyclic chiral 
secondary amines as efficient catalysts for the functionalization of carbonyl compounds,
inspired an explosion of research in the field of organocatalysis. List et al. reported the 
(L)-proline catalyzed asymmetric Aldol reaction between acetone and various aldehydes.50
Almost simultaneously, MacMillan et al.51 published the first amino-catalyzed Diels-Alder-
reaction and demonstrated the activation of Į,ȕ-unsaturated aldehydes by an imidazolidinone-
based catalyst.52 Since this year a colossal amount of organocatalysts has been developed and 
applied in various organocatalytic reactions.53
The asymmetric Mannich and Mannich-type reaction represent an important method for the 
C-C bond formation, providing access to enantiomerically enriched aminocarbonyl
derivatives. The abundant occurrence of nitrogen in drugs or natural products increased the 
popularity of the Mannich reaction.54 The first proline-catalyzed three component Mannich 
reaction was discovered by List in 2000 and since then there have been intensive studies 
towards the development of more efficient catalysts.55 In the last 15 years, various metal 
catalysts such as Pd, Zn, Cu and Y as well as metal free proline-56 or cinchona alkaloid based 
organocatalysts57,58 were applied in Mannich and Mannich-type reactions. Since Į-amino acid 
derivatives can be built up by Į-imino esters, the anti-Mannich reaction and applicable 
catalysts are gaining more focus.59,60
In the case of pyrrolidine-related catalysts, the position of the acidic group on the ring is 
essential for the diastereoselectivity of the Mannich reaction (Scheme 24). Typically, the syn-
isomer is obtained, if Į-proline 91 was applied. The superior trans-enamine is forming the 
transition state 92 and the re face of the enamine reacts with the si face of the imine. 
However, the anti-isomer can be synthesized by the use of the isomeric ȕ-proline 94. 
Therefore, the syn-enamine is forming properly positioned transition state 95 and the proton 
transfer occurs from the acid at the 3-position.59,60
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Scheme 24: Syn and anti-dependency on the chosen catalyst in Mannich reactions reported by Barbas et al.59
Barbas et al.59,60 already employed ȕ-proline catalyst 94 successfully in anti-Mannich 
reactions for ketones and aldehydes with excellent yields and diastereo- and 
enantioselectivities (Figure 4). In contrast, catalyst 97 was ineffective for the conversion of 
ketones contrary to aldehydes because of the unfavorable steric interaction of the enamine 
with the methyl group in position 5. In the previous chapter, the synthesis of APC building 
blocks was described. An intermediate of the synthetic sequence, the addition product (ent)-
78 already contains the core structure of ȕ-proline 94. (ent)-78 also contain two benzyl groups 
at position 4 of the pyrrolidine ring. This was thought to be beneficent for catalysis in two 
ways: on the one hand, the increased steric bulk could lead to higher selectivities (Figure 4) 
while on the other hand, being in 4-position should not have a significant detrimental effect as 
in the aforementioned 5-position.
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Figure 4: Comparison of addition product (ent)-78 with literature catalysts 94 and 97 and proposed preferred 
transition state of (ent)-78. 
Also, the phenyl groups would increase the lipophilicity of the catalyst, improving its 
solubility in a broader variety of organic solvents.61 Due to these considerations, it was 
envisioned to submit this new ȕ-proline derivative to anti-Mannich type reactions to evaluate 
its catalytic activity. 
2.2 Synthesis of the ȕ-proline derivative and its catalytic activity in the anti-Mannich 
reaction
With the addition product (ent)-78 in hand, only the tert-butyl ester and the Boc group needed 
to be removed to obtain the free ȕ-proline derivative (ent)-100 as its TFA salt. The counter 
ion was removed by ion exchange chromatography which unfortunately decreased the yield of 
the desired catalyst dramatically. It was found, that the benzyl groups of the catalyst are not 
stable against aqueous ammonia which was initially used for eluation of the catalyst from the 
ion exchange resin. Nevertheless, the desired ȕ-proline derivative (ent)-100 was isolated in 
17% yield (Scheme 25).
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Scheme 25: Synthesis of ȕ-proline derivative (ent)-100. 
As benchmark reaction, the indirect anti-Mannich reaction between diethyl ketone 104 and 
imine 103 was chosen as it is well studied in the literature.59,60 The required imine 103 was 
synthesized out of ethyl 2-oxoacetate 101 and 4-methoxyaniline 102 in 45% yield (Scheme 
26).
Scheme 26: Synthesis of imine 103 for the indirect anti-Mannich test reaction.59
With imine 103 in hand, different solvents were examined (Table 1). First results proved that
the new ȕ-proline derivative (ent)-100 is indeed capable of catalyzing anti-Mannich reactions. 
In contrary, literature catalyst 97 (entry 1) was almost unreactive in the conversion of ketones. 
But yields in DMSO were low and could not be increased by longer reaction times (Table 1, 
entry 3 vs. 4). Nevertheless, the best diastereoselectivities were achieved in DMSO and were
quite comparable to the literature results (entry 2). However, changing the solvent to protic 
solvents like iPrOH or MeOH improved the yields up to 21%. The best yield of anti-Mannich 
product was achieved by using the TFA salt of the catalyst but accompanied with the dramatic
decrease of diastereoselectivity (entry 7). It seems that the catalytic amount of acid supports
the conversion of the imine but with poor selectivity. Even the increased lipophilicity of the 
catalyst did not lead to an improvement of the yield or the selectivity in DCM (entry 10). A 
plausible explanation for the slow conversion of (ent)-100 could be the sterical interaction of 
the benzyl groups similar to the methyl group in catalyst 97. Another reason for the decreased 
catalytic activity could be the additional backbone nitrogen, which might be involved in 
hydrogen bonding of the intermediate and may interrupt the proton transfer in catalytic step 
(Figure 5).
B. Main Part
22
Table 1: Solvent screening and evaluation of catalyst (ent)-100 in anti-Mannich reaction.b
entry catalyst solvent
time 
(h)
yield a)
(%)
dr b)
(anti/syn)
ee c)
(%)
1d) 97 (20 mol%) DMSO 72 <10 n.d. n.d.
2e) 91 (10 mol%) iPrOH 20 91 97:3 97
3 (ent)-100 DMSO 23 13 88:12 67
4 (ent)-100 DMSO 65 10 93:7 70
5 (ent)-100
DMSO/iPrOH 
(1:1)
65 9 78:22 53
6 (ent)-100 iPrOH 23 20 82:18 54
7f) (ent)-100 iPrOH 72 44 51:49 n.d.
8 (ent)-100 MeOH 23 21 74:26 n.d.
9 (ent)-100 THF 23 22 56:44 n.d.
10 (ent)-100 DCM 23 21 65:35 n.d.
a) isolated yield (containing anti- and syn-diastereomers); b) determined by 1H NMR and/or chiral 
HPLC; c) determined by chiral HPLC; d) taken from ref59; e) taken from ref59; f) TFA-salt of the catalyst.
In summary, the new ȕ-proline derivative (ent)-100 did not produce results as well as ȕ-
proline catalyst 94 in anti-Mannich reactions. Moreover, with ȕ-proline 94 a much simpler 
catalyst was already available and therefore no further attempts were tried to apply ȕ-proline 
derivative (ent)-100 as an organocatalyst.
Figure 5: Presentation of the transition states of (ent)-100 (left) and 91 (right) in anti-Mannich reaction and a
possible explanation for the poor catalytic activity of (ent)-100 caused by intramolecular hydrogen bonding. 
b Results are partially taken from the Bachelor thesis of M. Schmalzbauer (supervised by T. Ertl). 
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3. APC and ACPC building blocks in tripeptide organocatalysis 
3.1 High pressure as an alternative activation mode in organocatalysis
While the advantages of organocatalysis such as low costs, utilization of non-toxic, metal-free
catalysts and new activation modes are often praised, one of the main disadvantages cited are
the low reaction rates, often causing the use of high catalysts loadings compared in metal 
catalysis.62,63,64 To overcome this problem, various activation modes such as microwave 
irradiation, heating and ultrasonic sounds are practicable. However, these activation modes
often result in a decrease of selectivity or decomposition of reactants.65,66
An alternative to thermal activation is the use of high pressures, as it is milder and a non-
destructive activation mode, which can accelerate a chemical reaction by compression.
Compression of a reaction medium initiates a higher concentration of the reactants, changes 
the rate of intermolecular diffusion and therefore the rate of effective collisions increases.67 In 
principle, every reaction can be accelerated by pressure if its volume of activation ∆V‡ is 
negative. The volume of activation is defined as the difference between the volume of the 
transition state and the volume of reactants.68 That also means that the generation of side 
products or decomposition can be suppressed upon pressurization.65,67 Especially reaction 
types like Mannich, Aldol, Michael, Baylis-Hillman, cycloadditions and cross-coupling 
reactions are susceptible for pressure activation.69,70,71
For example, a dramatic increase of turnover numbers in palladium-catalyzed arylation of 2,3-
dihydrofuran by high-pressure activation was published by Reiser et al. in 1996.72 Recently, 
Kwiatkowski et al. demonstrated the construction of quaternary stereocenters such as 107 via 
1,4-conjugate addition under high-pressure activation, obtaining products which were not 
accessible under ambient pressure conditions (Scheme 27).73
Scheme 27: Construction of quaternary stereocenters via 1,4-addition reported by Kwiatkowski et al.73c
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Meanwhile, Hayashi and co-workers demonstrated that the generation of high pressure does 
not require complicated device. They were able to generate pressures up to 2 kbar by simply
freezing water inside a sealed autoclave vessel at -20 °C.74,75,76
3.2 Organocatalysts containing short-chain peptides
With the pioneering work of Miller et al.77,78 two decades ago, the value of short-chain 
peptides for asymmetric catalysis was recognized. Since then, the field of peptide-based
organocatalysis has constantly been expanded by a variety of contributions, especially of the 
Wennemers79,80group. Nowadays, peptidomimetic organocatalysts are applied in different 
reaction types like Michael,81,82,83 Friedel-Crafts-type,84 aldol-type,85,86,87,88 conjugate 
additions,89 epoxidations,90,91,92 1,4- or 1,6-additons93 and cyclopropanation reactions94
(Scheme 28). Especially their ability for immobilization on resins95 makes peptidic catalysts 
interesting for continuous flow catalysis96 and facilitating the overall recyclability.97
Scheme 28: Two examples of short-chain peptides applied in the asymmetric aldol reaction98 (A) and 
cyclopropanation94 (B). 
In short-chain peptide catalysts, the right balance between flexibility and rigidity is crucial for 
their efficiency. It is known, that constrained backbone building blocks like cyclic ȕ-amino 
acids can stabilize secondary structure motifs in oligomers.99,100,45
In the Reiser group, there is particular interest in the synthesis and investigation of tripeptide 
organocatalysts of the sequence H-Pro-Xxx-Pro-OH, wherein Xxx is a rigid cyclic ȕ-amino 
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acid. The rigidity of this central building block should bring the two functional groups of the 
proline units in close proximity for efficient catalysis. In previous studies, tripeptides 116 and 
117, containing rigid ȕ-ACC101 building block (Figure 6), proved to be an effective catalyst in 
aldol reaction and were investigated under ambient- and high-pressure conditions.102,103,75 It 
was found out, that tripeptide 116 acts as a superior catalyst compared to its isomer 117, due 
to internal hydrogen bonding leading to a fixed conformation of 117, in contrast to a more 
flexible conformation of 116. This flexibility is necessary to take position of the functional 
groups for an optimal conformation for catalysis. 
Figure 6: Series of tripeptides organocatalysts of the sequence H-Pro-Xxx-Pro-OH.
The increasing ring size of the different building blocks is accompanied with a higher degree 
of conformational freedom. This should result in a change of conformation upon 
pressurization and hopefully in a more effective catalytic system compared to that under 
ambient pressure. In the row of small and rigid building blocks towards bigger ring systems 
the cyclopropane derivative 116 was already examined in detail in our group,102,103,75 the 
synthesis and evaluation of cyclobutyl104 and cyclohexyl105 120 derivatives is part of ongoing 
investigations in the Reiser group. 
Following this concept, the synthesis of APC and ACPC derived tripeptides will be described
in the following chapters. Also, the catalytic activity of these new derivatives will be 
evaluated in the aldol reaction under ambient- and high-pressure conditions. 
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3.3 Synthesis of APC based tripeptides
The initial idea was the use of previously synthesized APC and ACPC building blocks 
(chapter 1) without any further modification of the protecting groups.c) In the beginning, the 
first step was the coupling of 79 with (L)-proline benzyl ester to arrive dipeptide 121 (Scheme 
29). For this coupling step, a protocol106 using n-propane phosphonic acid anhydride (T3P) as 
coupling reagent was followed. This protocol was known to give promising features such as
high yields, low epimerization, simple reaction setup and product isolation. Indeed, the 
desired dipeptide 121 was isolated in a good yield of 77% and no epimerization was detected
by NMR analysis or mass spectrometry. The Fmoc group in 121 was removed under basic 
conditions followed by coupling of the corresponding amine with N-Cbz protected (L)-proline 
to obtain the protected tripeptide in 56% yield. As both protecting groups are susceptible to 
hydrogenolysis, the free tripeptide could be easily synthesized by hydrogenation. However,
cleavage of both groups at atmospheric pressure was not successful and required hydrogen 
pressure up to 40 bar. This provided the desired free catalyst 118 in 43% yield over 4 steps 
from 79.
Scheme 29: Synthesis of APC-tripeptide organocatalyst 118 from 79. 
The low yield of 56% during the Fmoc deprotection and subsequent coupling step can be 
explained by the formation of a diketo-diazepane derivative 124 (Scheme 30). Initially, the 
c) Partially taken from the Bachelor thesis of T. Götz (supervised by T. Ertl).
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Fmoc deprotection/coupling sequence was performed at ambient temperature which led to 
complete conversion of 121 to 123. During the base-induced deprotection of the Fmoc group,
the corresponding free amine 123 cleaved off the benzyl ester to form the diazepane 
derivative 124.
Scheme 30: Side product formation during Fmoc deprotection/coupling sequence. 
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This kind of side reaction is also known from Fmoc SPPS, which is depending on the 
structure of the C-terminus and can cause complete cleavage of the peptide of the resin.107 To 
avoid this side reaction, the literature suggests the application of a bulky resin linker.
Regarding the intended use of the catalyst and the required quantity, a resin supported 
synthesis was not deemed the method of choice. Decreasing the temperature during the 
deprotection to 0 °C by cooling in an ice bath partially suppressed the conversion to the 
diazepane derivative 124 and the desired tripeptide could be isolated in 56% yield. 
Scheme 31: Synthesis of tripeptide organocatalyst 127 from (ent)-79. 
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The corresponding diastereomer 127 was synthesized in analogy to 118 with similar yields of 
38% over 4 steps (Scheme 31). Although the Fmoc deprotection/coupling sequence was 
challenging, it still delivered the desired tripeptide 126 in 54% yield. 
After all coupling steps, the isolated products were investigated towards the occurrence of 
epimerization. This was accomplished by 1H NMR analysis or HPLC/mass spectrometry.
Especially on the stage of the (protected/unprotected) tripeptide, NMR analysis was quite 
tricky up to impossible, as the flexibility of the compounds caused significant signal doubling 
and broadening. This signal broadening was induced by the free rotatable C-N bonds in the 
Fmoc and Boc protecting groups, as well as partially hindered rotation around the amidic
peptide bonds placed at the N-terminus of the proline units. This occurrence can lead to the 
formation of cis- and trans-conformers.108
It is important to note that in both isomers of the APC organocatalysts, the Boc group of the 
APC building block should remain, as it should negate any influence of the additional 
nitrogen on catalysis. Moreover, this additional amine also gives the opportunity to 
immobilize the APC catalysts onto a solid phase resin for a possible recovery of the catalysts. 
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3.4 Synthesis of ACPC based tripeptides
For the synthesis of the ACPC based tripeptides, the same synthetic route as for the APC 
isomers was followed. The first coupling of the ACPC building blocks with (L)-proline 
benzyl ester gave rise to the dipeptides 128 and 130 in 73% and 61% yield respectively,
similar to the APC derivatives. However, applying the same conditions for the Fmoc 
deprotection/coupling sequence did not provide any of the desired tripeptides, leading only to
the formation of the corresponding diketo-diazepane (Scheme 32). 
Scheme 32: First attempts at the synthesis of the ACPC based tripeptides. 
As side product formation could not be circumvented through the usage of lower 
temperatures, a new coupling strategy needed to be investigated to get access to the ACPC 
based tripeptides. A first alternative method was a change in the coupling sequence (Scheme 
33). Therefore, it was decided to start from the addition product (ent)-21 first. The 
hydrogenolysis of the benzyl groups in (ent)-21 yielded the free amine (ent)-132 which would 
not undergo undesired cyclization. The free amine (ent)-132 should be submitted to coupling 
with preactivated Cbz-protected (L)-proline to provide the dipeptide 133. After hydrolysis of 
the tert-butyl ester, the corresponding free carboxylic acid could then be coupled with (L)-
proline benzyl ester to get 131, followed by removal of all protecting groups by 
hydrogenolysis.
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Scheme 33: New intended route towards ACPC based tripeptides
After hydrogenolysis of (ent)-21, the free amine (ent)-132 was directly submitted to the first 
coupling reaction under the same conditions as employed for the synthesis of 128.
Surprisingly, this method did not show any conversion of the starting material, in contrast to 
the good results of the previous couplings. Even the application of EDC or HATU as coupling
reagents did not provide the desired dipeptide 133 (Scheme 34). 
Scheme 34: Attempts to get access to dipeptide 133. 
A possible explanation could be the sterical hindrance of the tert-butyl ester impeding the 
coupling of the amine and the activated Cbz-proline. To prove this concept, the tert-butyl
ester in (ent)-132 was converted to the corresponding methyl ester 134 (Scheme 35). 
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Scheme 35: Conversion of tert-butyl ester in (ent)-21 to methyl ester (ent)-134 and attempted coupling towards 
dipeptide 136.
For the synthesis of methyl ester (ent)-134, two different procedures were employed. In a first 
attempt, a transesterification procedure by Fox et al.109 using NaOMe in refluxing MeOH was 
applied. However, no conversion of the starting material was observed. Another attempt 
provided the desired methyl ester (ent)-134 in moderate yield of 42% after tert-butyl ester 
hydrolysis with TFA and subsequent esterification with DCC and methanol. After 
hydrogenolysis of the benzyl groups in (ent)-134, the corresponding amine (ent)-135 was 
again submitted to coupling with Cbz-proline. However, this modified strategy did not 
provide the desired dipeptide, suggesting that the sterical hindrance of tert-butyl ester was not 
decisive. 
Another reason could be the less reactivity of the free amine undergoing coupling reaction 
with the activated carboxylic acid. Regarding this, Suppo et al.110 reported an alternative 
method with inverted reactive components, using activated Į-aminoesters which then react 
with the free carboxylic acid. Transferred to the here discussed challenge, the required 
activated ȕ-aminoester 138 can be readily prepared by coupling the free amine (ent)-132 with 
1,1-dicarbodiimidazole 137 (CDI) yielding 138 in a moderate yield of 51% (Scheme 36). 
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Scheme 36: Preparation of the activated ȕ-aminoester 138. 
This reaction was strongly dependent on the concentration of the solution and the rate of 
addition of the amine. In all attempts, the formation of the ȕ-aminoester was accompanied by 
the occurrence of a side-product. If amine addition to the CDI solution was too rapid, the 
activated ȕ-aminoester coupled with the free amine to the corresponding urea 139 (Scheme 
37). Even decreasing the temperature did not circumvent this problem and just resulted in a 
slower conversion to the dimer.
Scheme 37: Formation of the urea 139 during the preparation of desired ȕ-aminoester 138.
In principle, the occurrence of this class of substance is interesting since it can normally be
obtained by Curtius rearrangement,111 presents a chiral urea core structure and may be utilized
in urea organocatalysis.112 Due to the excessive reactivity of the generated ȕ-amino ester, the 
method was rendered to be inapplicable. A method needed to be found in which the reactivity 
of the coupling partners is high enough, while a trapping reagent could be used to prevent the 
formation of side products. 
Fortunately, a similar problem was already investigated in the Reiser group during the 
synthesis of ȕ-ACC dipeptides 141, which required special coupling techniques to prevent 
ring-opening during Fmoc-deprotection of 140b.113 In a batch reaction, the Boc protecting
group in 140a was removed by HCl in EA to isolate to corresponding hydrochloride salt, 
followed by coupling with an activated amino acid (Scheme 38 top). Since these acidic 
conditions could not be applied in peptide synthesis following Fmoc strategy, another N-
protecting group which can be removed under neutral or weakly basic conditions needed to be 
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found. Considering these facts, the Alloc group seemed to be the protecting group of 
choice.114 It can be cleaved off by a catalytically amount of Pd(0)-source under non-acidic 
conditions in the presence of an allyl scavenger to avoid allylation of the corresponding free 
amine.115 Therefore, coupling of Alloc-protected 142 can be performed easily by in situ
deprotection in the presence of an activated amino acid 143 (Scheme 38 bottom). Moreover, 
its applicability in a tandem deprotection/coupling reaction and the suppression of forming 
diketopiperazines was already proven.116
Scheme 38: Utilization of the Alloc group in peptide synthesis reported to Zorn et al.113
Regarding the task of coupling the ACPC based dipeptide 128 with Cbz protected (L)-proline,
this method was thought to inhibit the diketodiazepane formation. An additional advantage 
would also be the toleration of the benzyl ester group under the applied conditions, hence
chosen Cbz or benzyl protected (L)-proline units could still be used. Only the Fmoc protecting 
group in the ACPC building blocks needed to be replaced by the Alloc group (Scheme 39). 
This was accomplished in a similar fashion to the introduction of the Fmoc group (compare 
chapter 1, Scheme 22) by removal of the benzyl groups by hydrogenolysis in 21 and tert-butyl
ester hydrolysis with TFA. The corresponding amino acids were isolated as their
hydrochloride salts and were subsequently submitted to Alloc protection to obtain the desired 
building blocks 144 and (ent)-144 in 30% and 65% yield respectively over 3 steps.
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Scheme 39: Preparation of Alloc-protected ACPC building blocks 144 and (ent)-144. 
The new Alloc-protected ACPC building blocks 144 and (ent)-144 were submitted to 
dipeptide coupling under the same conditions as for the APC based dipeptides, achieving 
comparable yields (Scheme 40 and Scheme 41). The subsequent key step was the tandem 
Alloc deprotection/coupling reaction of Zorn et al.113 Using preactivated Cbz protected (L)-
proline with EDC/HOBt, the desired tripeptides 129 and 131 were obtained in 61% and 87% 
yield respectively after 20 minutes by using DABCO as a scavenger and 10 mol% of 
Pd(PPh3)4.
117 Unfortunately, remaining triphenylphosphineoxide from the Alloc-coupling 
could not be separated completely from the product, although different solvent mixtures for 
column chromatography or various attempts for recrystallizations were tried. Nevertheless, 
after the final deprotection step triphenylphosphineoxide residues could be easily removed by 
simple washing with hexanes.
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Scheme 40: Synthesis of tripeptide organocatalyst 119. 
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In this way, tripeptide organocatalyst 119 was prepared in 12% yield over 6 steps (from 
addition product 21) (Scheme 40) and its isomer 147 in 38% yield (Scheme 41). 
Scheme 41: Synthesis of tripeptide organocatalyst 147.
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No epimerization was observed after the coupling steps, determined by 1H NMR or 
HPLC/mass spectrometry. 
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3.5 Evaluation of catalytic activity of APC and ACPC based tripeptides in 
organocatalysis
The obtained APC and ACPC based tripeptide organocatalysts were tested in a benchmark 
reaction between acetone 148 and p-nitrobenzaldehyde 149 under ambient- and high-pressure
conditions. Special focus was whether high pressure was influencing the reactivity of the 
different catalysts as well as the conformational equilibrium, which could affect the 
selectivity. The obtained results of the five-membered ring derivatives were compared to
those of three-membered ring derivate 11675 to investigate if the different ring size can be a 
decisive factor regarding reactivity and selectivity (Table 2).  
Interestingly, entry 1 and 2 show that an uncatalyzed background reaction occurred at ambient 
pressure, but to a much lower degree than under high-pressure conditions. Nevertheless, no 
product was formed. A further conclusion can be drawn, that high pressure increased the 
reactivity of all organocatalysts. In the case of the APC derivatives, (entries 3 vs. 4 and 5 vs.
6) elevated pressures led to a more than eightfold increase of reactivity (reaction time reduced 
from 24 to 6 h), similar to the ȕ-ACC derivative (entries 11 vs. 12). The ACPC derivatives 
(compare entries 7 vs. 8 and 9 vs. 10) showed lower (factor of three for 119, a factor of two 
for 147), although still significant increase in reactivity. Interestingly, the ACPC tripeptides 
revealed an increase of selectivity upon pressurization contrary to the ACC or APC 
derivatives. 
B. Main Part
37
Table 2: Organocatalyzed aldol reaction under ambient- and high-pressure conditions. 
O
H
O
NO2
OH
NO2
O
catalyst (1 mol%) 
acetone/H 2O 
(10:1), rt
+
148 149 150
entrya) catalyst
time
(h)
pressure
(bar)
conversion
(%)b)
yield
(%)c)
ee
(%)d)
1 - 24 1 37 - -
2e) - 24 4600 14 n.d. -
3 118 H-Pro- -Pro-OH 24 1 23 10 49 (R)
4 118 H-Pro- -Pro-OH 6 4600 43 21 43 (R)
5 127 H-Pro- -Pro-OH 24 1 49 37 33 (R)
6 127 H-Pro- -Pro-OH 6 4600 91 75 20 (R)
7 119 H-Pro-À-Pro-OH 24 1 97 82 31 (R)
8 119 H-Pro-À-Pro-OH 6 4600 80 57 41 (R)
9 147 H-Pro-Á-Pro-OH 24 1 48 28 15 (R)
10 147 H-Pro-Á-Pro-OH 6 4600 36 14 22 (R)
11e) 116 H-Pro-p-Pro-OH 24 1 84 68 69 (R)
12e) 116 H-Pro-p-Pro-OH 4 4800 97 73 67 (R)
a) 1.0 mmol aldehyde; b) determined by isolated starting material after column chromatography; c) isolated yield 
after column chromatography; d) determined by chiral HPLC; e) taken from ref75, 10 mol% catalyst. 
Based on this observation it can be assumed that a rigid ring system (ȕ-ACC) with a low 
degree of conformational freedom appears to be necessary for efficient catalytic performance. 
Moreover, a more flexible system (ACPC) with a higher degree of conformational freedom 
shows less selectivity in catalytic performance at ambient pressure, but the latter could be 
increased by pressure. 
In the case of APC- and ACPC derivatives, one diastereomer of the catalysts always showed
higher catalytic activity compared to the other. This observation may be explained by 
intramolecular hydrogen bonding resulting in a fixed conformation. It can be assumed from 
1H NMR of the free catalysts, that more active catalysts 127 and 119 reveal very broad 
signals. This indicates that a high flexible system allows functional groups to be positioned
into a desired conformation, similar to the ȕ-ACC catalyst 116.75 In contrast, the signals of 
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118 and 147 are much sharper and this might be induced by intramolecular hydrogen bonding 
leading to a fixed conformation and resulting in a lower catalytic activity. 
It could also be observed, that the APC-derived catalysts showed a lower catalytic activity as 
their ACPC-derived isomers. This effect may be explained by the lower solubility of the 
APC-derived catalysts caused by the additional Boc group. Another reason for the decreased 
catalytic activity could be that the additional nitrogen of the pyrrolidine ring system is 
involved in internal hydrogen bonding and might interrupt the proton transfer in the catalytic 
step. To get an insight into the possible conformations of the APC- and ACPC-derived 
tripeptide organocatalysts, further NMR studies, especially under high-pressure conditions 
and molecular modeling calculations need to be carried out, which will be the objective in 
future studies in the Reiser group.  
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4. APC building block in peptide foldamers
The previous chapter described the introduction of the APC into short tripeptides. Before the 
APC building block would be introduced into longer chain naturally occurring neuropeptide 
Y (NPY) ligands (chapter 5), it was intended to introduce the APC building block into an 
artificial peptide to investigate its influence on secondary structure formation. Artificial 
peptides, with a strong tendency to adopt a specific conformation, are defined as foldamers.16
Gellman118 and Seebach119 pioneered this chapter in chemistry in the late 1990´s and ever 
since the developments in this field have thrived enormously.120 Since many biological 
processes are mediated by protein-protein interactions, the main motivation of foldamer
design is the development of scaffolds adopting specific structures, to mimic parts of these 
poly-peptides and their functions. However, the interruption of protein-protein interactions is
associated with a major amount of diseases. Therefore, peptidic foldamers can be a crucial 
instrument for the investigation and manipulation of these interactions.16b,120b
To compare the APC building block with its structurally related cyclopentane derivative 
ACPC, which was already employed in foldamers, the APC building block was introduced
into Į,ȕ-peptide 151. This peptide was previously designed in our group46 according to the 
stereochemical patterning approach of Martinek and Fülöp et al.121 Following this approach, 
every adjacent amino acid revealed the opposite stereochemistry of the one used before. The 
Į,ȕ-alternating foldamer 1418 was already shown to form a stable right-handed helix in 
organic solvents contrary to its behaviour in aqueous media and served as an idol peptide. 
Since 151 should serve as a model peptide to investigate the properties of the APC building 
block, only three ACPC building blocks in 14 were exchanged by APC building blocks for 
facile determination of the possible influence on the adopted secondary structure. 
Figure 7: Synthesized 13-mer foldamer 151 based on model peptide 14. 
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151 was synthesized in cooperation with Prof. Dr. C. Cabrele (University of Salzburg) on an 
automated peptide synthesizer, applying Fmoc-chemistry and double-coupling strategy with 
HBTU/HOBt/DIPEA. The synthesis was performed on a Rink-amide MBHA polystyrene 
resin for C-terminal amidation followed by acidic cleavage and purification by preparative 
HPLC.
In order to get an insight into the solution structure of 151, circular dichroism (CD) spectra in 
four different solvent systems were recorded. CD spectroscopy displays a valuable and
commonly applied tool for the conformational analysis of peptides and proteins. Circular 
dichroism is defined by the different absorption of left- and right-handed circular polarized 
light by treatment of a chiral sample, resulting in the generation of elliptically polarized light.
This method affords insight into the secondary structure motifs of peptides and proteins from 
amide chromophores and the tertiary structure from aromatic amino acid residues such as Phe, 
Tyr or Trp. The peptide bonds display the main chromophore in peptides which are encircled
by a chiral environment caused by the three-dimensional orientation of the peptide backbone. 
The peptide bond absorption can be observed between 180 and 300 nm. The peptide 
chromophore displays the lowest energy transition, which occurs between 210 and 220 nm 
and reflects the nĺʌWUDQVLWLRQRIQRQ-bonding electrons of the carbonyl group. 7KHʌĺʌ
WUDQVLWLRQRIʌ-electrons of the carbonyl group can be observed around 190 nm. The energy 
and intensity of these transitions is dependent of the dihedral angles of the amino acid units 
and is related to the secondary structure.  Consequently, CD spectroscopy is a highly sensitive
method to determine changes in the secondary structure and allows identification of different 
VHFRQGDU\ VWUXFWXUHV OLNHĮ-KHOLFHVȕ-sheets or random coils due to characteristic shapes of 
the graphs.114,122 However, contrary to Į-peptides, where an correlation between CD spectra 
and the secondary structure exists, for unnatural peptides these correlations can be only 
accumulated by experience and need to be proved by alternative methods as NMR 
spectroscopy or X-ray diffraction. Nevertheless, CD spectra can give a first hint of the 
adopted conformation of unnatural peptides.123
CD spectra were recorded in water, methanol and phosphate buffer (100 mM, pH 7.0) to 
determine the conformation under physiological conditions (Figure 8). To mimic the
membrane environment, 151 was investigated in phosphate buffer mixed with trifluoroethanol 
(TFE, 30%) which is known as a structure-inducing co-solvent.124 All spectra were 
normalized to the peptide concentration and the number of amide bonds. 
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Figure 8: CD spectra of 151 in water, methanol, buffer (100 mM, pH 7.0) and buffer + TFE. Peptide 
concentration was 125 µM.
In general, the shapes of the graphs of 151 are comparable to the spectra of 14. In particular, 
in methanol and buffer mixed with TFE the graphs are in accordance with idol peptide 14,
which was shown by 2D-NMR investigations and molecular dynamics calculations to adopt a 
right-handed helix.18 The CD spectra in all solvents have a strong maximum near 200 nm, 
indicating a helical structure of 151. However, the CD signal of 151 in water was 
considerably more intense than of 14, indicating that 151 is more structured in water contrary 
to 14. This can be explained by the presence of the polar APC building block in the peptide 
sequence stabilizing secondary structure motifs in aqueous media. Though the intensity of 
151 in buffer is weaker than in water, it showed considerably higher intensity in buffer mixed 
with TFE. Regarding this, APC containing peptides should adopt stable structures under 
physiological conditions in a membrane environment, a crucial aspect regarding further 
application of the APC building blocks in NPY ligands. It can be concluded, that the 
influence of the APC building blocks on the secondary structure of peptides is similar to that 
of the ACPC building block. This finding allows and facilitates a comparison of the APC 
containing NPY analogues with its ACPC analogues, which will be discussed in the following 
chapter. 
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5. Neuropeptide Y Analogues
5.1 Neuropeptide Y
Neuropeptide Y (NPY) is one of the most abundant neuropeptides in our central and 
peripheral nerve system.125 It contains 36 amino acids and has considerable sequence 
similarities with its closely related pancreatic polypeptide (PP) and peptide YY (PYY)
analogues.126,127,128 NPY was first isolated from the porcine brain,129 along with PP from the 
pancreas and PYY from the intestine which constitutes the NPY family.130,131,132 It was 
assumed that this peptide family reveals a similar secondary structure due to the high 
sequence homology. The first three-dimensional structure was determined by X-ray from 
avian pancreatic polypeptide where a turn (amino acids 9-13) connects a polyproline-like 
helix (1-8) with an anti-parallel Į-helix (14-31). The amidated C-terminus (32-36) exists in a 
flexible loop conformation (Figure 9).133,134
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Figure 9: Structure of porcine NPY according to Allen.135
The highly conserved C-terminus of NPY was shown to be crucial for its biological activity 
by single amino acid substitutions (point mutation studies). In particular, by performing (L)-
alanine scan, a significant decrease or loss of affinity was observed due to replacing the 
arginine residues in position 33/35 as well as C-terminal tyrosineamide.136 The significance 
of C-terminal area was also emphasized in other reports by different amino acid substitution 
of several NPY analogues.127,137
In humans, NPY activates four to the G-protein coupled receptors (GPCR), the so-called
NPY-receptors (Y1R, Y2R, Y4R, Y5R) which are involved in the regulation of various central 
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and peripheral biological processes (Table 3).138 So far, five NPY receptor have been cloned
from mammals (y6 was found to be functional in mice), and several additional receptors like 
Y3 have been postulated based on pharmacological investigations.
139
Table 3: Overview of receptor subtypes in human and mediated biological effects by NPY.140
receptor subtype mediated biological effect
Y1
blood pressure, food intake (+), ethanol consumption, depression, 
anxiolysis sedation, hormone release, pain sensitivity, angiogenesis.
Y2
food intake (-), blood pressure, seizures (-), bone formation, pain 
sensitivity, angiogenesis, depression, gastrointestinal motility, circadian 
rhythms.
Y4 gastrointestinal motility, food intake. 
Y5
food intake (+), circadian rhythms, seizure, anxiety, luteinizing hormone 
secretion (-). 
The Y4R differs from the other subtypes since it shares only low sequence identity. NPY 
binds strongly to Y1R, Y2R, Y5R contrary to Y4R which prefers PP over NPY and PYY.
141
Nevertheless, the Y4R was considered to play a key role in the regulation of energy 
metabolism or feeding behavior since Y4R agonists were proposed as potent agents against 
obesity. Moreover, expression of Y1 and Y2 receptor was found in different tumors like breast 
cancer or prostate cancer142,143 and have been proposed as potential tumor markers.144
Due to the various functions of the different receptor subtypes, synthetic analogues of NPY 
ligands with high receptor selectivity and affinity would be desirable as a pharmacological
tool for elucidation of biological roles and as a potential therapeutic device.145 Referring to 
this and the fact the number of known selective Y4R ligands is very low
127 this project deals 
with the search for new selective Y4R NPY analogues and this will be described in the 
following chapters. 
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5.2 Dimeric pentapeptide derived from hNPY C-terminus as high-affinity Y4R 
radioligand146
d) As already mentioned above, there is particular interest in the investigation of new selective 
Y4R ligands. In the literature, the diastereomeric mixture of dimeric peptide 152 was 
described as a high-affinity Y4 receptor agonist. Generally, the arginine residues in the C-
terminal area of NPY are important for receptor binding147 and D/L-2,7-Diaminooctanedioyl-
bis-(YRLRY-NH2) 152 comprises the same pentapeptide sequence of the C-terminus (Figure 
10). But the data reported for 152 refer only to the diastereomeric mixture.148
Figure 10: Diastereomeric mixture of D/L-2,7-Diaminooctanedioyl-bis-(YRLRY-NH2) 152 as high-affinity Y4R 
agonist according to Balasubramaniam et al.
It was intended to synthesize diastereomerically pure isomers of 152 for the following
pharmacological investigation of each diastereomer. The retrosynthetic approach is displayed
in Scheme 42. It was envisioned to build up 152 out of two C-terminus derived pentapeptides 
and enantiopure 2,7-diaminosuberic acid 153 as a linker. 
Scheme 42: Retrosynthetic analysis of 152.
d) Reprinted (adapted) with permission from Kuhn, K. K.; Ertl, T.; Dukorn, S.; Keller, M.; Bernhardt, G.; Reiser, 
O.; Buschauer, A. J. Med. Chem. 2016, 59, 6045–6058. Copyright 2017 American Chemical Society. The 
synthesis of compounds 164, 166 and 167 was performed by T. Ertl. Synthesis of allylglycine esters 165 and 
(2R,7R)-152 and (2S,7S)-152 and related radioligand [3H](2R,7R)-169 was performed by K. Kuhn. 
Pharmacological investigations and characterizations were performed by K. Kuhn and S. Dukorn (AK 
Buschauer, Institute of Pharmacy, University of Regensburg) and are added for completion and better 
understanding of the current and following chapter. 
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Linker 153 and its pre-structure 154 could be synthesized from enantiopure allylglycine ester 
155 in cross-metathesis reaction. 
Construction of differently protected 2,7-diaminosuberic acid structures was already 
attempted by methods such as Kolbe electrolysis of appropriate glutamic acid derivatives,149
Pd-catalyzed coupling of dihalides and iminobenzophenones derived from the chiral pool Į-
amino acids,150 Pd-catalyzed Suzuki coupling of organoborane reagents,151 or dimerization of 
bislactim ethers also derived from the chiral amino acid pool.152
Similar to the intended route, Aguilera et al. used enantiopure alkynes 156 which were 
coupled to cyclic acetylenes 158 to get access to 2,7-diaminosuberic acid structures (Scheme 
43). Utilization of tungsten catalyst in the key cross-coupling step provided 158 with a 
moderate yield of 60% and yielded (R,R)-2,7-diaminosuberic acid 159 in 21% over 4 steps.153
Scheme 43: Cross-coupling reaction applying tungsten catalyst by Aguilera et al.
Grubbs and co-workers used more familiar Ruthenium catalyst (Grubbs´ I)154 for cross-
metathesis of acyclic alkene 160, since direct coupling of allylglycine was not possible
(Scheme 44). The cyclic alkene 161 was obtained in a very good yield of 85% in the key step 
and (S,S)-2,7-diaminosuberic acid 159 was yielded in 77% over 4 steps.155
Scheme 44: Construction of (S,S)-159 applying Grubbs´ I catalyst reported by Grubbs et al.
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The utilization of anchored amino acids like in 160 also reveals the advantage of getting 
access to unsymmetrical dimers with different protecting groups. Previous methods of 
connecting different units of amino acids required the separation of undesired self-metathesis 
products.156 Therefore, employing this anchored templates provides an unambiguous and 
flexible technique towards unsymmetrical 2,7-diaminosuberic acid structures or related 
compounds.157,158
In their studies about the spacer dependency to the biological activity of novel 
thiocolochicine-podophyllotoxin conjugates, Passarella et al. applied Grubbs´ II catalyst159
for the construction of (S,S)-2,7-diaminosuberic acid structure 164 from N-Boc-allylglycine 
benzyl ester 162 (Scheme 45). Next, core structure 163 was obtained in a moderate yield of 
64% and subsequent hydrogenolysis of the benzyl ester could be combined with the reduction 
of the double bond in a one-pot step providing 164 in 63% yield over 2 steps.160
Scheme 45: Two steps synthesis of (S,S)-165 applying Grubbs´ II catalyst according to Passarella et al.
In respect to the literature syntheses, commercially available enantiopure (R)- and (S)-
allylglycine was used for cross-metathesis after esterification and N-Boc protection (165) by 
analogy with procedures reported from literature.161,162 Employing Grubbs´ I catalyst 
provided the desired cross-metathesis product in an unsatisfactory yield of 18% with 49% 
conversion of starting material (Table 4, entry 1). However, utilization of Grubbs´ II catalyst 
increased the yield of 166 up to 89%, whereas changing the solvent to reach higher 
temperatures didn´t succeed and led to the occurrence of various side-products. Reduction of 
the double bond was accomplished by catalytic hydrogenation using Pd/C and EtOH as 
solvent to obtain 167 in 70% yield. 
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Table 4: Construction of 2,7-diaminosuberic acid core structure 166 by cross-metathesis reaction. 
OEt
O
BocHN
NHBoc
O
EtO
OEt
O
BocHN
NHBoc
O
EtO
OEt
O
BocHN
catalyst
(10 mol%)
solvent, T
H2 (1 bar)
Pd/C
EtOH, rt, 6 h
70%
165 166 167
entry catalyst solvent T (°C) time (h) yield 166 (%)
1 Grubbs I DCM 70 28 18a)
2 Grubbs II DCM 70 11 89
3 Grubbs II toluene 110 3 67
a) 49% conversion. 
Although hydrogenation with Pd/C worked quite well, it was envisioned using Grubbs´ II
catalyst would make a nicer feature since it was shown to be also an effective catalyst 
mediating hydrogenation reactions.163 Employing this strategy, allylglycine ester 165 was 
submitted to cross-metathesis reaction to build up 166 without isolation, followed by 
hydrogenation using the same Grubbs´ catalyst (Table 5). The first approach, by simply
adding hydrogen balloon after performed metathesis reaction did not lead to any conversion 
towards 167. 
Table 5: Tandem cross-metathesis/hydrogenation sequence applying with Grubbs´ II catalyst.
entry solvent H2 (p) time (h) yield 167 (%)
1 DCM 1 bar 16 -
2a) EtOH 1 bar 151 83
3 EtOH 20 bar 20 95
a) In total 25 mol% of Grubbs´ II was used. 
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After exchanging the solvent from DCM to EtOH, the hydrogenation was performed at 
ambient pressure of hydrogen gas. Under these conditions, full conversion of metathesis 
product 166 was achieved after almost one week and required the further addition of the
catalyst. Finally, hydrogenation at 20 bar in the autoclave afforded the desired product in 95% 
yield. Improved yields and no need of isolation and workup after metathesis display the 
convenience of this protocol contrary to other reported procedures applying Pd/C as a
catalyst.160 Then, hydrolysis of the ethyl ester quantitatively provided the diacids (R,R)-164
and (S,S)-164 in 95% and 74% yield, respectively over 2 steps from N-Boc-protected 
allylglycine ethyl ester (R)-165 and (S)-165 (Scheme 46).146
Scheme 46: Two-step enantioselective synthesis of (R,R)-164 and (S,S)-164.
The pentapeptide synthesis was carried out manually on a Siber amide resin applying double 
coupling and following Fmoc-strategy (Scheme 47). After cleavage from the resin, the 
pentapeptides were coupled with in situ activated (R,R)-164 and (S,S)-164 providing the 
dimeric peptides (2R,7R)-152 and (2S,7S)-152 after deprotection.146
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Scheme 47: Synthesis of dimeric peptides (2R,7R)-152 and (2S,7S)-152.146
Reagents and conditions: a) Pentapeptide synthesis, SPPS, Fmoc-strategy: Fmoc-AA/HBTU/HOBt/DIPEA, 
DMF/NMP (8:2), double coupling at rt, 60 min, Fmoc deprotection was carried out with 20% piperidine in 
DMP/NMP (8:2), rt, 2x10 min; b) DCM/TFA (97:3), 10x6 min; c) HBTU/HOBt/DIPEA, DMF, 35 °C, 16 h; d) 
TFA/H2O (95:5), rt, 2.5 h, 29% for  (2R,7R)-152 and 34% for (2S,7S)-152.
With respect to the decelerated Y4R agonistic activity of the diastereomeric mixture 152, 
dimeric peptides (2R,7R)-152 and (2S,7S)-152 were investigated for Y4R agonism in an 
aequorin Ca2+ assay and a luciferase gene reporter assay on genetically engineered CHO and 
HEK293 cells, respectively. Indeed, the Y4R potency was affected by the configuration of the 
stereocenters in the 2,7-diaminosuberic acids. In the luciferase assay, (2R,7R)-152 (EC50 = 
1.6 nM) was twelve times more potent than (2S,7S)-152 (EC50 = 19 nM). In the aequorin 
assay, the difference was less noticeable ((2R,7R)-152 (EC50 = 6.9 nM), (2S,7S)-152 (EC50 = 
18 nM)).146
Based on the results obtained from the functional assays, (2R,7R)-152 was selected for the 
synthesis of the corresponding tritiated analogue 169 by treating (2R,7R)-152 with
commercially available succinimidyl [3H]propionate 168 (Scheme 48).146
Scheme 48: Preparation of radioligand [3H](2R,7R)-169. 
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The newly obtained radioligand [3H](2R,7R)-169 was characterized by saturation binding 
experiments, performed on intact CHO-hY4-Gqi5-tAEQ cells in a HEPES (sodium free) buffer 
according to Balasubramaniam et al.148 (Kd = 0.67 ± 0.1 nM).
146 Subsequently, [3H](2R,7R)-
170 was used for the determination of binding data of (2R,7R)-152 and (2S,7S)-152 at the Y4
receptor in competition binding experiments. Also herein, (2R,7R)-152 (Ki = 0.45 ± 0.14 nM) 
revealed a higher affinity compared to (2S,7S)-152 (Ki = 2.3 ± 0.16 nM).
146
In parallel to this project, Thompson et al.164 independently synthesized peptide analogues of 
152, including the pure diastereomers (2R,7R)-152 and (2S,7S)-152. Pharmacological data are 
in good agreement with those to here reported,146 but affinities and potencies were obtained
from different assays.
In summary, the synthesis of enantiopure diaminosuberic acids (R,R)-164 and (S,S)-164 was
accomplished by cross-metathesis reaction promoted by Grubbs´ II catalyst giving access to 
single diastereomers of (2R,7R)-152 and (2S,7S)-152 individually. In competition binding 
experiments, (2R,7R)-152 revealed to be superior to (2S,7S)-152. Moreover, [3H](2R,7R)-169
was established as a useful new pharmacological tool for the Y4R which will be applied in the 
following chapter as high-affinity radioligand in competition binding studies.146
B. Main Part
51
5.3 APC and ACPC building blocks in truncated NPY analogues
On the way to selective Y4 receptor ligands, also a different approach was pursued. As 
mentioned above, Y4 receptor prefers PP over PYY or NPY in contrast to Y1, Y2 or Y5. A 
comparison of the amino acid sequence of hNPY (human neuropeptide Y) and hPP (human 
pancreatic polypeptide) reveals an accordance of 47%, especially the C-terminus (32-36) 
shows an identical sequence with the exception that proline (P, hPP) is replaced by glutamine 
(Q, hNPY) (Figure 11). As already mentioned in the previous chapter, the important residues 
for Y4 receptor binding were located in the C-terminal region (Tyr
20,27,36; Arg25,33,35 and 
Thr32), based on Ala-scan studies on pNPY (porcine neuropeptide Y), which differs only at 
position 17 (Leu instead of Met) from hNPY.127
Figure 11: Amino acid sequence of hNPY and hPP.
It was also shown by previous studies, that the length of the NPY molecule is essential for 
receptor subtype recognition. Full length of NPY (1-36) was required for binding to Y1R, 
whereas truncated analogues as NPY (13-36), NPY (18-36) and NPY (25-36) were only 
tolerated at the Y2R.
165,166 Moreover, manipulation of the C-terminus of truncated NPY 
analogues (25-36 or 28-36) by single amino acid substitution revealed a shift of the selectivity 
profile of these analogues.127,167,168
Cyclic ȕ- or Ȗ-amino acids are known to induce or stabilize secondary structure motifs and 
can increase the stability of Į-peptides due to proteolytic degradation.17,169 ȕ-ACC,167,170 ȕ-
ACBC171 (amino cyclobutyl carboxylic acid) and ȕ-ACPC18,120b,172 have already been used in 
our group together with collaborators for the investigation of peptidomimetics or peptide 
foldamers. Recently, constrained ȕ-ACC 140 was introduced to position 32 and/or 34 in the 
C-terminal region of truncated NPY (25-36), directly next to crucial arginine units in position
33 and 35. The introduction of ȕ-ACC building blocks induced a shift of the selectivity profile 
from the Y2R of unsubstituted NPY (25-36) to the Y1R and its affinity was strongly depended
on the position of substitution and the applied stereochemistry of the ȕ-ACC (Figure 12). It 
was assumed that the introduction of ȕ-ACC rigidifies the flexible C-terminus to induce or 
stabilize a distinct secondary structure motif which is responsible for the selectivity shift. One 
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ȕ-ACC in position 34 was enough to achieve nanomolar affinity (Ki 37 nM) whereas the 
introduction of a second ȕ-ACC did not improve the affinity. Analogues containing ȕ-ACC 
with opposite stereochemistry (q, compare Figure 6, 117) were inactive at all investigated 
receptors.167
Figure 12: Overview of Ki values (nM) of selected literature reported compounds. 
Analogues substituted with ȕ-ACBC and ȕ-ACPC building blocks gained affinity at the Y4
receptor, wherein the ȕ-ACPC analogues were superior to the ȕ-ACBC, achieving the best 
results by the introduction of one ȕ-ACPC in position 34 (Ki 10 nM). Similar to ȕ-ACC 
containing analogues, the introduction of a second ȕ-ACPC lead to a four-fold decrease in
affinity (Ki 37 nM).
173
Due to the geometric similarity to ȕ-ACPC, we envisioned the introduction of ȕ-APC building 
blocks into truncated NPY (25-36) analogues. Under physiological conditions, the cyclic 
amine of ȕ-APC will be protonated and could improve the affinity of corresponding NPY 
analogues, since ȕ-APC would be placed next to positively charged arginine residues, which 
were discussed to be crucial for the selectivity and affinity of NPY ligands.
The APC containing NPY analogues were synthesized in cooperation with Prof. C. Cabrele in 
her laboratory at the University of Salzburg on an automated peptide synthesizer, applying 
Fmoc-chemistry and double-coupling procedure with HBTU/HOBt/DIPEA. The synthesis 
was performed on a Rink-amide MBHA polystyrene resin for C-terminally amidation. In 
accordance to the previous analogues, ȕ-APC building blocks were introduced in position 32 
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and/or 34 (170, 171, 172, 173) as well together with ȕ-ACPC building blocks (174, 175)
(Figure 13). 
The binding profile of all synthesized NPY analogues was determined by radioligand
competition binding assay in the group of Prof. Dr. A. Buschauer under the supervision of K. 
Kuhn and S. Dukorn. The tests were carried out according to previously described 
procedure146 on MCF-7 cells expressing Y1R, CHO cells expressing Y2R and Y4R, and HEC-
1B cells expressing Y5R by displacement of radioligands [
3H]propionyl-pNPY (Y1R, Y2R, 
Y5R) and [
3H](2R,7R)-169 ([3H]UR-KK193, Y4R) (Table 6 and Figure 14).
For comparison of the binding data of the APC analogues with the ACPC analogues,
literature compound 180 ([Y32,À34]-NPY(PP)-(32-36))173 was also tested in here applied 
radioligand competition binding assay, since the ACPC analogues were investigated in a flow 
cytometry binding assay (Table 6, entry 5). Indeed, the Ki value obtained from radioligand 
binding assay is in good agreement as reported in the literature reported173 (124 nM vs. 105 
nM) and permits comparison of the new APC analogues with the ACPC analogues. 
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Figure 13: Amino acid sequences of synthesized NPY (25-36) analogues. 
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Table 6: Binding data of synthesized NPY analogues at human Y1R, Y2R, Y4R, Y5R subtypes.
entry compound Y1 
a) Y2 
b) Y4 
c) Y5 
d)
1e) 176 [p
32,34]-NPY-(25-36) 50 >1000 - 617
2f) 177 [¢
34]-NPY-(25-36) >1000 >1000 72 ± 7 >1000
3f) 178 [À
34]-NPY-(25-36) >1000 >1000 10 ± 2 >500
4f) 179 [À
32,34]-NPY-(25-36) >1000 >1000 37 ± 7 >500
5 180 [Y
32,À34]-NPY(PP)-(32-36) – – 124 ± 14[105 ± 42]f) –
6 170 [ 34]-NPY-(25-36) >5000 >5000 413 ± 76
4102 
±1220
7 171 [
32,34]-NPY-(25-36) >5000 >5000 40 ±2 >5000
8 172 [
34]-NPY-(25-36) >5000 >5000 4252 ± 1396 >5000
9 173 [
32,34]-NPY-(25-36) >5000 >5000 446 ± 69 >5000
10 174 [À32 34]-NPY-(25-36) >5000 >5000 42 ± 9 4546 ±1367
11 175 [ 32À34]-NPY-(25-36) >5000 >5000 20 ± 4 4753 ± 1091
Sequences and affinities (as Ki-values (nM)) of truncated NPY analogues on hY receptors (Ki-values were 
provided by K. Kuhn and S. Dukorn); a) – d) Data represent mean values ± SEM of at least two independent 
experiments performed in triplicate. Assays were performed as previously described: ref146,174 a) Radioligand 
competition binding assay with [3H]propionyl-pNPY (Kd = 3.4 nM, c = 5 nM) using MCF-7-hY1 cells; b) 
Radioligand competition binding assay with [3H]propionyl-pNPY (Kd = 1.4 nM, c = 1 nM) using CHO-hY2-Gqi5-
mtAEQ cells; c) Radioligand competition binding assay with [3H](2R,7R)-169 ([3H]UR-KK193) (Kd = 0.67 nM, 
c = 0.6 nM) using CHO-hY4R-Gqi5-mtAEQ cells; d) Radioligand competition binding assay with [
3H]propionyl-
pNPY (Kd = 4.83 nM, c = 4 nM) using HEC-1B hY5R cell; e) Taken from ref 
167; f) Taken from ref 173.
All APC containing NPY analogues revealed Y4R selectivity (Table 6, entry 6-11) except
compounds 170, 174 and 175, which also showed very less affinity at the Y5R . In accordance 
with the ACPC and ACBC containing ligands (entry 2-4), all new analogues were 
biologically inactive at the Y1R and Y2R. Moreover, the affinities of APC analogues were
strongly depended on the stereochemical configuration of the APC building blocks, similar to 
ȕ-ACC derivatives.167
The disubstituted APC analogues 171 and 173 [APC32,34]-NPY-(25-36) showed about ten
times higher affinities than its monosubstituted analogues 170 and 172 (entry 7 vs. 6, Ki 40 vs.
413 nM and entry 9 vs. 8, Ki 446 vs. 4252 nM). This is in contrast to the corresponding ACPC 
containing analogues (entry 3 and 4) and may indicate that APC32 substitution is more 
tolerated than in position 34. This is supported by the about 40-fold less affinity of 170
[APC34]-NPY-(25-36) compared to corresponding analogue 178 [ACPC34]-NPY-(25-36)
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(entry 6 vs. 3, Ki 413 vs. 10 nM). The best affinity of compounds containing APC only was 
achieved with 171 [APC32,34]-NPY-(25-36) (entry 7, Ki 40 nM) in similar range to the 
corresponding ACPC analogue 179 [ACPC32,34]-NPY-(25-36) (entry 4, Ki 37 nM), 
designating that double APC substitution is better tolerated than single substitution.
For direct comparison of ACPC and APC substitution, both building blocks were introduced 
together in position 32 and 34 alternately to obtain a kind of hybrid NPY analogues. In these 
analogues, the order of substitution was essential for their affinities. Analogue 175 [APC32 
ACPC34]-NPY-(25-36) was superior by a factor of two in Y4 affinity in comparison to its 
corresponding analogue 174 [ACPC32 APC34]-NPY-(25-36) (entry 11 vs 10, Ki 20 vs. 42 nM)
indicating that an aliphatic residue as ACPC  is more preferred in position 34 than a charged
building block as APC.
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Figure 14: Binding curves of new APC containing NPY analogues 170, 171, 172, 173, 174 and 175 on human 
Y4R obtained by radioligand competition binding assay on CHO-hY4R-Gqi5-mtAEQ cells using [
3H](2R,7R)-169
as radioligand (c = 0.6 nM); log c on the x-axis refers to the decadic logarithm of the molar ligand concentration.
The binding curves were provided by K. Kuhn. At least two independent experiments were performed in 
triplicate.
In summary, by the introduction of APC building blocks to truncated NPY (25-36) new Y4R 
selective analogues were obtained. In particular, the best results were achieved with 171
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[APC32,34]-NPY-(25-36) and 175 [APC32 ACPC34]-NPY-(25-36) analogues and the affinities 
are quite comparable to its analogue 179 [ACPC32,34]-NPY-(25-36).
5.4 Conformational studies of truncated APC containing NPY analogues
The new APC containing NPY analogues were investigated by CD spectroscopy to get insight 
into their solution conformation. CD spectra of each peptide were recorded in phosphate 
buffer (100 mM, pH 7.0) to determine the conformation under physiological conditions. For
mimicking membrane environment, the peptides were investigated in phosphate buffer mixed 
with trifluoroethanol (TFE, 30%), which is known as a structure-inducing co-solvent. 
Figure 15: CD spectra of 170 and 172 in buffer and buffer + TFE. Peptide concentration was 125 µM in buffer 
(100 mM, pH 7.0) and 96 µM in buffer + TFE.
The monosubstituted peptides 170 and 172 were flexible in buffer, as indicated by the 
negative CD band below 200 nm and the weak CD contribution between 200 and 230 nm
(Figure 15). Upon addition of TFE, the peptides adopted a short helical structure, shown by 
the CD maximum around 195 nm and two local minima around 208 and 220 nm. But 170 and 
172 showed around 40-fold and 400-fold respectively less affinity at Y4R than their ACPC 
containing analogue 178 (Table 6, entry 3). 178 was reported to adopt helically structure173
which is indicating, that the charge of APC34 has a negative influence on the Y4R binding of 
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the APC containing NPY-ligands, but is not disturbing the formation of a short helix. The 
negative influence of the charged building block is supported by comparison with the native 
sequence of hPP, which contains an uncharged amino acid at position 34 (Pro34) and is more 
preferred of Y4R. Moreover, 170 was a bit less helical than 172 demonstrated by less intense 
CD band and by a slight blue shift of the band around 208 nm. This is in correlation with the 
binding profile of both ligands, wherein 170 was 10-fold more affine to Y4R than 172 and 
supports the finding, that high helically structures are not required alone for Y4R binding. 
Figure 16: CD spectra of 171 and 173 in buffer and buffer + TFE. Peptide concentration was 125 µM in buffer 
(100 mM, pH 7.0) and 96 µM in buffer + TFE.
Similar to the monosubstituted peptides, 171 and 173 were flexible in buffer (Figure 16). But 
there is already a significant difference in the intensity observable, implying that 173 is 
already more structured in buffer and 171 is arranged as a random coil. However, upon 
addition of TFE, 173 adopted a turn-like structure motif, as shown by weak CD intensities 
around 195 nm, 208 and 220 nm, which seems not to be tolerated for binding at the Y4R. This 
weak intensity of 173 may also occur from building aggregates. However, 171 seems to be
very less helical upon the addition of TFE but shows good binding on Y4R. Obviously, the 
less helically character in 171 permits the formation of a preferred C-terminally conformation, 
which compensates the negative influence of the charged APC building blocks and allows 
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binding on Y4R, contrary to 170. However, due to the weaker intensities of the CD-bands, it 
can be concluded, that both APC building blocks act as a Į-helix breaker. 
Figure 17: CD spectra of 174 and 175 in buffer and buffer + TFE. Peptide concentration was 100 µM in buffer 
(100 mM, pH 7.0) with or without 30% TFE. 
The hybrid peptide 174 showed similar behavior as its analogue 171 (Figure 17). It was 
flexible in buffer and adopted less helically structure motifs by the addition of TFE resulting 
in similar affinity (Table 6, 171: Ki 40 nM; 174: Ki 42 nM). 175 was also flexible in buffer
and adopted helically structure motifs by the addition of TFE, but less intensive than 174 or 
171. As mentioned above, a charged building block in position 34 is less tolerated than in 
position 32 and supports the 2-fold higher affinity of 175 compared to 174.
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5.5 Conclusion and Outlook 
In this chapter, it was described that the introduction of charged APC building blocks into 
truncated NPY (25-36) delivered selective Y4R ligands with comparable affinities like its 
ACPC containing analogues. The best results were obtained with hybrid analogue 175 [APC32
ACPC34]-NPY-(25-36) suggesting that introduction of a charged amino acid at position 32 is 
more tolerated than in position 34, whereas aliphatic residue is more preferred  in position 34.
This is supported by comparison of literature compound 178 [ACPC34]-NPY-(25-36) (Ki 10 
nM)173 with 170 [APC34]-NPY-(25-36) (Ki 413 nM) and 174 [ACPC
32 APC34]-NPY-(25-36)
(Ki 42 nM) with 175 [APC
32 ACPC34]-NPY-(25-36) (Ki 20 nM). All ligands containing an 
aliphatic residue in position 34 revealed a better affinity than its analogue with a charged
building block in position 34. This result is in accordance with the native hPP sequence, 
containing an aliphatic residue such as Pro in position 34 which was discussed to be more 
preferred for Y4R binding than the native hNPY sequence.
The method of introducing cyclic amino acids shows high potential as it offers a great variety 
of possible substituents. Considering the already applied cis-building blocks, the next logical 
step would be the incorporation trans-building blocks and their corresponding Ȗ-amino acids 
too (Figure 18).
Figure 18: Possible trans-β-amino acid building blocks for application in truncated NPY analogues. 
For this purpose, trans-ACPC 185 was synthesized from addition product 21 by epimerization 
with KOtBu in refluxing tBuOH (Scheme 49).24 This method delivered the desired building 
block (S,S)-23 in diastereomerically pure form in 70% yield. Contrary to the previously
described route towards cis-ACPC building blocks (chapter B1, Scheme 22) the order of the 
following modification steps was slightly changed. After hydrogenolysis of the benzyl 
groups, the free amine was subsequently functionalized with the Fmoc group for later 
intended solid phase peptide synthesis. Finally, hydrolysis of the tert-butyl ester provided 185
in 46% over 4 steps from 21, ready for SPPS. However, utilization of 185 in NPY analogues
was not possible anymore in this project. 
B. Main Part
61
Scheme 49: Synthesis of trans-ACPC building block 185 ready for SPPS.
Reagents and conditions: (a) KOtBu, tBuOH, reflux, 8 h, 70%; (b) i) H2 (20 bar), Pd/C,  MeOH, rt, 14 h; ii) 
FmocOSu, NaHCO3, dioxane/water, 0 °C to rt, 48 h, 65%; c) TFA, Et3SiH, DCM, 0 °C to rt, 24 h, quant.
Corresponding trans-APC building block 54 is also reasonable for NPY substitution and 
would be accessible by the same route as trans-ACPC building block 185. 
A logical continuation of the cis-APC building block is the installation of various functional 
groups on the secondary ring amine and its evaluation in truncated NPY analogues (Scheme 
50).
Scheme 50: Possible functionalized APC building blocks for NPY substitution.
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Getting access to functionalized APC building blocks should be simple by making use of the 
undesired Boc deprotection during APC building block synthesis (Chapter 1, Scheme 18) 
which provides 186. This enables the installation of the desirable functional groups. 
Following this route, it would be possible to add the guanidine group, which is part of the 
amino acid arginine and designated to be crucial for NPY receptor recognition and activity. 
Furthermore, it is also possible to investigate the influence of hydrophobic groups such as 
phenyl or long-chained alkyl groups. The development and investigation of new building 
blocks for NPY substitution is still worthwhile and is the objective of current projects in the 
Reiser group. 
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6. Transformation of monocyclopropanated N-Boc-pyrrole 
6.1 Ring-opening of monocyclopropanated N-Boc-pyrrole
6.1.1 Synthesis of homo-ȕ-proline
e) Homo-ȕ-proline (3-pyrrolidineacetic acid, 188) is a structural analogue of the 
nonproteinogenic Ȗ-amino acid and neurotransmitter Ȗ-aminobutyric acid (GABA) and was 
first mentioned in the late 1950s in a series of Japanese patents.175 Studies on its biological 
potential appeared around twenty years later when a group of Danish scientists discovered 
that 188 is an inhibitor of GABA uptake.176 Further studies on N-substituted derivatives of 
188 emphasized its potential as a modulator of neuronal and glial GABA’ergic function.177
Besides its biological activity, the core structure of 188 is a common structural element in 
many classes of natural products178 and is also used as a central building block and/or
pharmacophore in drug development, as proved by the large body of literature making use of 
this particular scaffold.179
Racemic homo-ȕ-proline (±-188) is commercially available from a handful of suppliers 
ranging at approx. 20-200 USD/mmol. Commercial sources for the enantiopure material are 
scarce with higher costs. This may be due to the limited number of reported syntheses for 
either racemic or enantiopure 188. Until now there are a total of ten synthetic protocols 
reported in the literature that aim for the synthesis of 188,180 and only two of these are of 
enantioselective nature.181
Given the highly interesting properties combined with the restricted accessibility, it was
envisioned to synthesize enantiomerically pure 188 from monocyclopropanated pyrrole 190
(Scheme 51) utilizing the unique properties of donor-acceptor cyclopropanes that allow the 
ring-opening of the weakest bond in the three-membered ring.182
Scheme 51: Retrosynthesis of homo-ȕ-proline 189 from N-Boc-pyrrole 192.
e) Reprinted (adapted) with permission from Pilsl, L.; Ertl, T.; Reiser, O. Org. Lett. 2017, 19, 2754–2757. 
Copyright 2017 American Chemical Society.
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While furans can be cyclopropanated with ethyldiazoacetate in high enantioselectivities 
(>90% ee) using Cu-(I)-bis(oxazoline) complexes,183,184 the corresponding transformation of 
N-Boc pyrrole 191 has proven to be challenging in the past (<50% ee).185 Sterically more 
demanding aryldiazoacetates derived from arylglycines in combination with chiral Rh(II)-
catalysts were reported to achieve the cyclopropanation of 191 in 79% ee,186 however, with 
the parent diazoacetates derived from glycine attempts to utilize Rh(II)-catalysts only led to 
alkylation products rather than cyclopropanation of 191.187
Nevertheless, the asymmetric cyclopropanation of N-Boc-pyrrole was recently achieved in the 
Reiser group by Pilsl with enantioselectivity up to 93% ee by a combination of tert-butyl 
substituted diazoacetate 192 with the tert-butyl substituted aza-bis(oxazoline) ligand 193
(azabox). Getting access to the enantiopure product was achieved based on the fact that
suitable conditions for an enantioenrichment by recrystallization from hexanes could be 
found. Furthermore, pioneering experiments of cyclopropane ring-opening towards homo-ȕ-
proline 188 were already carried out but accompanied with dramatic erosion of enantiopurity
(Scheme 52).75
Scheme 52: Successful cyclopropanation of N-Boc-pyrrole 191 and original experiments towards homo-ȕ-
proline 188 by Pilsl.75
Therefore, it became obvious that the cyclopropane ring-opening under complete conservation 
of enantiopurity would be the major challenge in this route towards 188. The following 
chapter describes the attempts in optimization for the synthesis of homo-ȕ-proline 188 and 
represents a continuation of the work of Pilsl.75
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For the asymmetric cyclopropanation of N-Boc-pyrrole 191, azabox ligand 193 needed to be 
synthesized first. The azabox ligands were developed in the Reiser group188,189 and are 
sterically demanding, similar to bis(oxazoline) ligands.190 Azabox ligands were already 
successfully applied in various applications,191 allow the possibility of electronic variation 
through alkylation on the central nitrogen and can be readily immobilized on various 
supports, which facilitates catalyst recovery.192
The synthesis of azabox ligand 193 started with the reduction of commercially available 
amino acid L-tert-Leucine 195 to the corresponding amino alcohol 196 (Scheme 53).193
Oxazolidinone 197 was obtained by cyclization of aminoalcohol 196 with diethyl carbonate, 
which was subsequently alkylated by using Meerwein´s reagent to afford ethoxyoxazoline
198 in 86% yield over two steps. As second coupling partner towards azabox ligand 193, 
aminooxazoline 199 was generated by the reaction of amino alcohol 196 with cyanogen 
bromide. Finally, desired azabox ligand 193 was obtained by acid catalyzed coupling of 
ethoxyoxazoline 198 and aminooxazoline 199 in 60% yield.
Scheme 53: Synthesis of aza-bis(oxazoline) ligand 193 according to Werner et al.189
Subsequently, N-Boc-pyrrole 191 was cyclopropanated with tert-butyldiazoacetate 192 under 
the previously reported conditions75 and cyclopropane 190 was obtained in 37% yield (lit.: 
39% average) (Scheme 54) and with enantioselectivities up to 75%. However, 
recrystallization from hexanes gave access to enantiopure cyclopropanated pyrrole 190.  
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Scheme 54: Asymmetric cyclopropanation of N-Boc-pyrrole 191 using azabox ligand 193 according to Pilsl. 
Focused on the steps forward to homo-ȕ-proline 188, reduction of the double bond in 
cyclopropane 190 was accomplished by hydrogenation using Pd/C at ambient pressure. 
However, application of this condition required chromatographic purification since the 
hydrogenation was accompanied by the occurrence of a byproduct which could be isolated in 
6% yield (Table 7, entry 1). This byproduct could be identified as the 6-membered ring 
derivative 200 of desired fully-saturated cyclopropane 194 and will be discussed in detail in 
chapter 6.3. 
Table 7: Optimization attempts for the hydrogenation of cyclopropanated N-Boc-pyrrole 190. 
entry catalyst mol% H2 (bar) time (h) 194 (%) 200 (%)
1 Pd/C (10%) 2.4 1 1.5-6 85 6
2 Pd/C (10%) 2.4 20 4 99 -
3 Rh/C (5%) 1.3 1 1 >99 -
3 Rh/C (5%) 0.14 1 8 >99 -
Optimization of the hydrogenation step was carried out by changing the pressure of hydrogen 
gas or the catalyst, resulting in a complete suppression of the formation of 200. Quantitative 
yields of 194 without the necessity for a chromatographic purification were achieved using 
either Pd/C (Table 7, entry 2) or Rh/C (Table 7, entry 3). Moreover, the amount of applied 
Rh/C was reduced to 0.14 mol% (Table 7, entry 4) based on starting material 190 which 
elongated the reaction time up to 8 h. However, desired 194 could be obtained in quantitative 
yield under optimized conditions.
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Next, suitable conditions for cyclopropane ring-opening with the full conservation of 
enantiopurity needed to be found. We envisioned the use of Sc(OTf)3 for cyclopropane ring-
opening, which was already applied in our group by Roy for Lewis acid-catalyzed 
multicomponent Povarov reactions getting access to compounds like 205 (Scheme 55). In this 
type of reaction, intermediary iminium ion 204 originating from cyclopropane ring-opening 
was trapped by furan migration.194
Scheme 55: Sc(OTf)3 catalyzed multicomponent reaction towards 205 by Roy et al.
Based on these studies, first attempts using a combination of Sc(OTf)3 and Et3SiH for ring-
opening of 194 were tried under microwave irradiation (Table 8, entry 1), but the desired 
ring-opening product 189 was not detected and only starting material 194 was recovered. 
However, conversion was detected by the occurrence of highly polar spots on TLC, which 
might suggest the formation of the partially or already fully deprotected product 188. Indeed, 
applying higher temperatures under microwave irradiation provided the fully deprotected 
ring-opening product 188. Making use of this feature of simultaneous ring-
opening/deprotection of the Boc group and tert-butyl ester provided 188 after simple isolation 
by centrifugation (entry 2). Removal of the triflate counter-ion by ion-exchange 
chromatography yielded the free amino 188 acid in 83%. However, comparison of the optical 
rotation value with the literature reports revealed a dramatic loss of enantiopurity (+ 3.0 vs.
+9.6, c 1, H2O, ref
176c). 
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Table 8: First attempts of cyclopropane ring-opening using Sc(OTf)3.
entry
acid
(equiv)
T
(°C)
time
conversion
(%)
yield
(%)
ee a)
(%)
[Į]ଶ଴஽
1 Sc(OTf)3 (0.3)
30-80 
(MW)
60 min
(6x10) 46 194 (54) - -
2 Sc(OTf)3 (0.3)
150 
(MW) 15 min 100 188 (83) - +3.0
3 Sc(OTf)3 (0.3)
115 
(MW)
15 min 100 189 (22)b 4 -
4 Sc(OTf)3 (0.3) 82 24 h 100 189 (25)
b 11 -
5 Sc(OTf)3 (0.1) 25 3 d 9 194 (91) - -
a) Determined by chiral HPLC; b) isolated yield of 189 after reprotection/derivatization for chiral HPLC 
analysis. 
Optical rotation alone is not always ideal to judge the enantiopurity of a compound. Hence, it 
was tried to get access to the ring-opened pyrrolidine 189 in order to determine the 
enantiomeric ratio by chiral HPLC. Indeed, after microwave irradiation at lower temperatures
or under reflux conditions, the crude contained a mixture of completely and partially 
deprotected ring-opening product (188 and 206) (entry 3 and 4). Therefore, it was decided to 
submit 206 to Boc-reprotection for the determination of enantiopurity by chiral HPLC, since 
HPLC conventional analysis for 206 was not possible due to the lack of a suitable 
chromophore. On the contrary, analysis of 189 was possible and conditions for chiral HPLC 
separation were already available from previous studies.75 It became obvious from HPLC 
analysis that 189 could be only obtained in racemic form and the temperature for the 
cyclopropane ring-opening step is crucial for keeping the enantiopurity of the product. Since
the conversion of starting material at ambient temperature was very slow, further 
investigations applying Sc(OTf)3 were refrained (entry 5). 
Regarding the temperature dependence of the ring-opening/deprotection sequence, it was 
decided to apply TFA/Et3SiH under milder conditions as previously employed. The decreased 
temperature required longer reaction times, but due to the relatively slow conversion during 
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the ring-opening/deprotection cascade, it was possible to obtain fully protected cyclopropane-
opening product 189, which was isolated, purified and investigated by chiral HPLC (Table 9, 
entry 2). By this way, it could be confirmed that the temperature is crucial for the 
cyclopropane ring-opening step and 189 could be isolated with >99% ee. However, achieving 
full conversion of 194 into 189 required longer reaction time up to 17 days and sequential 
addition of TFA and Et3SiH (entry 3), but finally desired homo-ɴ-proline 188 was obtained in
89% yield. The results from the chiral HPLC analysis of intermediate 189 nicely support the 
optical rotation data of the obtained products and are fitting quite well to the literature 
reports.195 The scalability of the newly developed synthetic route was demonstrated by 
starting from 1.00 g (3.6 mmol) of cyclopropanated pyrrole 190, followed by hydrogenation 
towards 194, resulting in 457 mg of 188 in an overall yield of >99% without the necessity to 
isolate either 194 or 189 (entry 4 and Scheme 58).
Table 9: Optimization of cyclopropane ring-opening. 
entry
acid
(equiv)
Et3SiH
(equiv)
T
(°C)
time
(d)
conversion
of 194 a) (%)
yield
(%)
ee b)
(%)
>Į@ଶ଴ୈ
1c) TFA (2) 3 25 3 100 189 (50) 72 7.7
2 TFA (2) 3 0 5 47 189 (33) >99 -
3 TFA (8) 12 0 17 100 188 (89) - 9.1
4d) TFA (8) 12 0 17 100 188 (>99) - 9.5
5e) BF3·OEt2 (1.2) 10 0 2 95 189 (53) 97 -
6 BF3·OEt2 (1.2) 10 0 2 100 188 (99) - 8.6
a) Based on reisolated starting material 194; b) determined by chiral HPLC; c) taken from ref75 d) 1.00 g 
(3.6 mmol) of 190 used as starting material; e) reaction was stopped after 2 days to for HPLC analysis of 189.
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When BF3·OEt2 was applied under the same conditions, the reaction time could be decreased 
dramatically to 2 days along with only a slight erosion of enantiopurity. For analytical 
purposes, 189 was isolated and characterized (entries 5 and 6, Scheme 56); however, the 
crude could also be directly converted to 188 in overall quantitative yield starting from 194.
Scheme 56: Optimized ring-opening/deprotection cascade towards homo-ȕ-proline 188. 
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Epimerization during the ring-opening sequence can occur due to the abstraction of the proton 
in position 3 by the conjugate base of TFA, the trifluoroacetate anion (Scheme 57). 
Obviously, this abstraction occurs faster at higher temperature (Scheme 57, Pathway B) than 
the competitive trapping of the corresponding iminium ion 207 with a hydride ion as provided 
by Et3SiH (Scheme 57, Pathway A). This may be explained by the high acidity of the proton 
in position 3 caused by the electron-withdrawing iminium ion moiety and the stability of 208
in a conjugated system. As a matter of fact, this proton must be acidic enough to be abstracted 
by a weak base such as the trifluoroacetate anion. 
Figure 19: Analytical HPLC chromatograms of 189 after ring-opening at ambient temperature (left, 73% ee) and 
at 0 °C (right, >99% ee). Phenomenex Lux Cellulose-1, n-heptane/iPrOH 99:1, 0.5 mL/min, 200 nm (tr = 18.16 
min; 19.31 min). 
at 0 °Cat rt
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Scheme 57: Proposed mechanism for cyclopropane ring-opening and possible epimerization.
In summary, based on enantiopure cyclopropanated N-Boc-pyrrole 190, a two-step route 
towards enantiomerically pure homo-ȕ-proline 188 was developed, which can be obtained in 
quantitative yields and without the need for chromatographic purification of the intermediates 
(Scheme 58).196
Scheme 58: Optimized two-step synthesis of homo-ɴ-proline 188 from cyclopropanated pyrrole 190. 
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6.1.2 Synthesis of orthogonally protected 4-aminopyrrolidin-3-yl acetic acid
As already mentioned in chapter 5.5, besides the incorporation of cyclic ȕ-amino acids in the 
C-terminal area of NPY ligands it would also be interesting to introduce cyclic Ȗ-amino acids. 
After the successful ring-opening of 194, it was envisioned to make use of this well-
established method to get access to the Ȗ-amino acid 4-aminopyrrolidin-3-yl acetic acid 210
(Scheme 59). Therefore, it was intended to open the cyclopropane ring in amine 209, which 
can be accessible by functionalization of the enecarbamate double bond of 190.
Scheme 59: Retrosynthesis of 4-aminopyrrolidin-3-yl acetic acid 210.
The introduction of the amine function can be accomplished by azidomethoxylation of the 
enacarbamate double bond in 211, based on the studies of Norton Matos et al.197 Herein, they
utilized ceric ammonium nitrate (CAN) as an oxidizing reagent in the presence of NaN3 and 
methanol for the preparation of N-heterocycles like 212. 
Scheme 60: Azidomethoxylation of an enecarbamate by Norton Matos et al.
According to this method, enantiopure cyclopropane 190 was submitted to 
azidomethoxylation providing the corresponding azide 213 in a moderate yield of 43%
(Scheme 61).  
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Scheme 61: Azidomethoxylation of tert-butyl cyclopropane 190. 
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N
Boc
CO2tBu
H
H
N3
MeO
190 213
However, in the 1H NMR of 213, a partial splitting of the signals was observed, indicating the 
presence of inseparable diastereomers or rotational isomers, so called rotamers (restricted 
rotation around the C-N bond due to steric hindrance). The presence of rotamers can be 
proven and distinguished from the existence of diastereomers by the dynamic behavior of 1H 
NMR signals in variable temperature NMR measurements. 
Therefore, three 1H NMR spectra at different temperatures were measured. It is clearly visible 
that the signals start melting together from lower to higher temperatures, which proves the 
rotameric behavior and excludes the presence of diastereomers. 
Figure 20: Excerpts from 1H NMR spectra of 213 at 273, 293 and 313 K in CDCl3 (400 MHz kryo). Upon 
heating, the signals melt together, proving the existence of rotamers. 
The absolute configuration of 213 was determined by performing NOESY experiments. 
Regarding that the absolute configuration of the cyclopropane ring hydrogens was already 
known, the configuration of the azide and methoxy group could be determined by NOE cross 
peaks revealing that the azide and methoxy group are syn-orientated to each other (Figure 21). 
Moreover, it was determined that the azide and the methoxy group orientate on the convex
face of the bicycle. As a result, the trans-configured γ-amino acid will be obtained after 
cyclopropane ring-opening.
313 K
293 K
273 K
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Figure 21: Determination of absolute configuration of 213 by the presence (left) or absence (right) of NOE cross
peaks.
Concerning the synthesis of the desired Ȗ-amino acid, the azide function was reduced to the 
corresponding amine 214 by hydrogenation under atmospheric pressure using Pd/C, whereas
the application of Staudinger conditions198 did not result in any conversion of azide 213
(Scheme 62). Since the Ȗ-amino acid should be prepared ready for use in later intended SPPS, 
the free amine was Fmoc-protected providing compound 215 in 88% yield over 2 steps from 
azide 213.  
Scheme 62: Synthesis of Fmoc-protected cyclopropane 215 from azide 213. 
The next goal was to establish suitable conditions for the removal of the methoxy group. In 
their studies about diastereoselective functionalization of enecarbamates, Dhimane et al. 
applied BF3·OEt2 and Et3SiH under low-temperature conditions for reduction of Į-aminoether
moieties.199 As demonstrated in chapter 6.1, cyclopropane ring-opening was also 
accomplished by using BF3·OEt2 and Et3SiH, revealing the opportunity to perform the 
demethoxylation and ring-opening in a one-pot reaction. 
Indeed, even under low-temperature conditions, demethoxylation occurred quite fast under 
full conversion of the starting material. The subsequent ring-opening reaction was performed
at 0 °C and accelerated by the addition of accessory BF3·OEt2 and Et3SiH (Scheme 63). 
Moreover, the simultaneous deprotection of the Boc group took also place. Consequently,
complete deprotection of the Boc group and tert-butyl ester was accomplished by addition of
an excess of TFA. However, for later intended utilization in peptide synthesis the free 
carboxylic acid function as well as Boc-protected side chain amine were required. Complying 
with this, the free ring amine was submitted to Boc protection again providing the 
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orthogonally protected Ȗ-amino acid 217 in 51% yield over 4 steps from Fmoc protected fused 
ring 215.
Scheme 63: Demethoxylation/ring-opening/deprotection sequence towards γ-amino acid 217.
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FmocHN CO2H
Boc
1) BF3·OEt2
Et3SiH, DCM
-78 °C to 0 °C
25 h
N
FmocHN CO2tBu
Boc
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0 °C to rt, 25 h
3) Boc2O, NaHCO3
dioxane/water
0 °C to rt, 25 h
51% (over 4 steps) 217216
N
FmocHN
MeO
Boc
H
CO2tBu
H
215
The demethoxylation/ring-opening/deprotection sequence was performed without the 
necessity to isolate the intermediates. For analytical purposes demethoxylated and ring-
opened pyrrolidine 213 was isolated, purified, characterized and analyzed by chiral HPLC to
determine the enantiopurity. Indeed, no epimerization during reaction cascade could be
observed and the orthogonally protected trans-Ȗ-amino acid was obtained in 19% yield over 7
steps from cyclopropanated N-Boc pyrrole 190.
Getting access to the corresponding cis-Ȗ-amino acid 220 should be possible by adapting an 
iodocarbamation protocol of Norton Matos197 providing iodo-carbamate bicycle 218 (Scheme 
64). Treatment of compound 218 with a strong base in methanol would result in a 
migration/methanolysis and introduce the amine function in the desired position. Applying the 
above established demethoxylation/ring-opening/deprotection method would provide the 
desired cis-Ȗ-amino acid 220.
Figure 22: Analytical HPLC chromatogram of 216 after demethoxylation/ring-opening (left, rac; right, >99% 
ee). Phenomenex Lux Cellulose-1, n-heptane/iPrOH 80:20, 1.0 mL/min, 215 nm (tr = 14.72 min; 16.89 min). 
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Scheme 64: Reasonable synthetic route towards cis-Ȗ-amino acid 220 according to Norton Matos et al.197
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In summary, an enantiopure synthesis for orthogonally protected trans-4-aminopyrrolidin-3-
yl acetic acid 217 from enantiopure monocyclopropanated N-Boc pyrrole 190 was developed. 
As the key step, a demethoxylation/ring-opening/deprotection cascade was performed under 
full conservation of enantiopurity and without the need for chromatographic purification of 
the intermediates. 
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6.1.3 Further functionalization attempts on monocyclopropanated N-Boc-pyrrole
Based on the ring-opening procedure developed in the previous chapters, further 
investigations on nucleophiles to trap the proposed iminium species 207 were carried out. 
Therefore, different nucleophiles with different (Lewis)-acids were applied in the ring-
opening reaction of 194 to generate 221 (Table 10). At first, weak heteroatom nucleophiles 
were tried, but the desired product 221 was not formed (Table 10, entries 1-4). Instead, 
another product was isolated which could be identified as the ring-opening/lactonization 
product 222.200 Obviously, the employed nucleophiles were not strong enough to trap the 
iminium ion and lactonization occurs. 
Table 10: Investigation of different trapping reagents for ring-opening reaction.
entry
acid
(equiv)
nucleophile
(equiv)
T
(°C)
time
(d)
conv. a)
(%)
product 
(%)
1 TFA (2) BnOH (3) 25 6 72 222 (40)
2 TFA (2) AllylOH (5) 25 7 58 not identified
3 TFA (2) BocNH2 (5) 25 7 n.d. not identified
4b) TFA (2) H2O (5) 25 7 90 222 (52)
5 TFA (2) TMS-allyl (5) 25 2 45 221 (4)
6 TFA (8) TMS-allyl (12) 0 17 85 222 (55)
7 TFA (8) TMS-vinyl (12) 0 14 n.d. 222 (15)
8 TFA (2) TMS-CN (5) 25 2 20 complex 
mixture
9 BF3·OEt2 (1) TMS-allyl (10) 0 3 h n.d. 221 (22)
10 BF3·OEt2 (1) TMS-vinyl (10) 0 3 90 222 (n.d.)
11 BF3·OEt2 (1) TMS-vinyl (20) 0 5 99 222 (n.d.)
12 BF3·OEt2 (1) TMS-CN (10) 0 2.5 h 100
complex 
mixture
a) Determined by recovered starting material 194; b) MeCN was used as solvent instead of DCM. 
When carbon nucleophiles were applied, only with TMS-allyl, the desired product could be 
generated but in poor yield (entry 5). Even multiple additions of acid and nucleophile over 17 
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days only led to the formation of lactonization product 222, indicating that even at lower 
temperature ring-opening and deprotection occur faster than nucleophilic addition (entry 6). 
Nevertheless, the yield of allyl-221 could be improved up to 22% by using BF3·OEt2 and 
excess of the nucleophile. Another nucleophile, TMS-vinyl was unreactive and only 
lactonization product was obtained (entries 7, 10 and 11) contrary to TMS-CN, which resulted 
in the generation of a complex mixture due to the high reactivity (entries 8 and 12).
Since the addition of the allyl-group was the only successful, a one-pot reaction towards 224
was performed (Scheme 65). TMS-allyl was used in combination with BF3·OEt2 as Lewis
acid, followed by the complete deprotection of 223 by using TFA since partial deprotection 
during ring-opening was expected. The unprotected amino acid of 224 was then obtained as a 
diastereomeric mixture, which was submitted to Boc-protection to enable separation of 
diastereomers. However, separation of diastereomers of 224 was not possible (dr 1:1.2). 
Scheme 65: Ring-opening/allyl addition/reprotection cascade towards 224.
In particular, the addition of vinyl- or cyanide-functionality would be a worthwhile objective, 
since it would give access to the synthesis of kainoids (227),201 a group in which kainic acid
(228)202 is a prominent representative (Scheme 66). Kainoids are an important class of natural 
non-proteinogenic amino acids, revealing a pyrrolidine moiety with two carboxylic acid 
groups as their characteristic structure.
Scheme 66: Reasonable synthetic routes towards kainoid core structure 228. 
N
CO2tBu
CN
N
H
CO2H
CO2H
(-)- -kainic acid
N
H
H
CO2tBu
Boc
N
Boc
CO2tBu
Boc
N
H
CO2H
CO2H
LA
TMS-vinyl
LA
TMS-CN
Ozonolysis
Hydrolysis
228227
225
226
194
B. Main Part
78
However, the attempts applying different nucleophiles in the ring-opening reaction were not 
successful, so it was tried to improve the yield of the lactonization product 222. Therefore, 
cyclopropane 194 was treated only with TFA at ambient temperature to obtain the desired 222
in 53% yield (Scheme 67). The reason why the yield could not be increased may be due to the 
simultaneous deprotection of the Boc-group. In order to determine the enantiopurity, the 
reaction was performed at 0 °C with an elongated reaction time of seven days. However, 222
was obtained in 16% yield and though enantiopure starting material was used, isolated 
product revealed the enantiomeric excess of 39%. This indicates that epimerization takes 
place even at lower temperature when there is no suitable trapping reagent available.
Scheme 67: Synthesis of racemic and optical active 222. 
In summary, application of different nucleophiles as trapping reagents in the ring-opening 
emphasized to be challenging due to the less nucleophilicity of applied nucleophiles.
However, a variety of nucleophiles can be still investigated accompanied by different reaction 
conditions since nucleophilicity can differ according to the applied solvents. Moreover, it 
turned out that a suitable nucleophile is necessary for trapping the iminium ion to prevent
epimerization during the ring-opening reaction. Further investigations would be worthwhile
since such reactions give access to core structures of interesting natural products. 
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6.2 Transesterification of monocyclopropanated N-Boc-pyrrole 
f) As in chapter 6.1.1 mentioned, the cyclopropanation of N-Boc-pyrrole was a challenging 
objective, and thus, the corresponding monocyclopropanated N-Boc-pyrrole methyl ester has 
not been accessible via an enantioselective route. It was only obtained via enzymatic 
resolution101c or by chiral separation203 of racemic 201. Since methyl ester 201 was proven to 
be a valuable building block for the construction of pyrrolidinones such as 205194 and 229203
or ȕ-ACC 140 (Figure 23),204 it would be desirable to get access to methyl ester 201 in 
enantiopure form.
Figure 23: Excerpt of chosen applications based on methyl-cyclopropane 201.
Since the cyclopropanation of N-Boc-pyrrole can be performed in an enantioselective way by 
using tert-butyl acetoacetate, it would be logical to utilize 190 for transesterification from 
tert-butyl ester to methyl ester to get access to 201. First attempts were already performed in 
our group75 following a procedure of Fox et al.109 by using sodium methoxide in refluxing 
methanol for the transesterification. Indeed, the transesterification was proven to transform 
190 into 201 without erosion of enantiopurity. However, it was carried out only with 
enantioenriched starting material (80% ee). Nevertheless, it was intended to perform the 
f Reprinted (adapted) with permission from Pilsl, L.; Ertl, T.; Reiser, O. Org. Lett. 2017, 19, 2754–2757. 
Copyright 2017 American Chemical Society.
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transesterification under the same conditions but with enantiopure starting material (Scheme 
68). Compared to previous results75 the yield could be improved from 46% to 67% by a 
modified work-up procedure. Furthermore, the desired methyl-cyclopropane 201 was 
delivered in enantiopure form (Figure 24). 
Scheme 68: Conversion of tert-butyl-cyclopropane 190 into methyl-cyclopropane 201 according to the 
procedure of Fox et al.
Moreover, Otera’s205 tin oxide catalysts 232 and 233 were also utilized in the above-described
transesterification. These catalysts can be simply synthesized out of dibutyltinoxide, 
dibutyltinchloride and NaSCN (Scheme 69) and were used in transesterifications or 
acetalizations and were frequently applied in our group in the synthesis towards Ȗ-
butyrolactones such as 236 (Scheme 70).204
Scheme 69: Synthesis of tin oxide catalysts according to Otera et al.
Reagents and conditions: (a) Toluene, reflux, 5.5 h, 98%; (b) NaSCN, EtOH, reflux, 5.5 h, 99%.
Figure 24: Analytical HPLC chromatogram for tert-butyl-cyclopropane 190 (left, >99% ee (Phenomenex 
Lux Cellulose-2, n-heptane/iPrOH 98:2, 0.5 mL/min, 254 nm; tr = 10.95 min, 19.02 min)) and methyl-
cyclopropane 201 (right, >99% ee (Phenomenex Lux Cellulose-1, n-heptane/iPrOH 99:1, 1 mL/min, 240 nm;
tr = 6.02 min, 10.12 min)).
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Scheme 70: Example for applied Otera catalysts in the Reiser group by Kreuzer.206
However, the applied catalysts turned out to be inactive in the conversion of tert-butyl ester 
190 (Table 11).
Table 11: Attempts to apply Otera catalysts for the transesterification step.
entry cat. mol% time (h) yield (%) a)
1 232 5 24 <5
2 233 10 45 ~7
a) Estimated from 1H NMR of the crude of reaction mixture 
without an internal standard.
Nevertheless, from now on methyl ester cyclopropane 201 is accessible again by 
transesterification of enantiopure tert-butyl cyclopropane 190 by using NaOMe in refluxing 
methanol. This compound was established to be a key building block for a great amount of
applications in the Reiser group in the last 20 years.
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6.3 Ring-expansion of monocyclopropanated N-Boc-pyrrole
As described in chapter 6.1.1 (Table 7), a byproduct was formed during the hydrogenation of
monocyclopropanated N-Boc-pyrrole 190, which was identified as the 6-membered ring 200
(Figure 25). 
Figure 25: Single crystal X-ray structure of (±)-200 (C = grey, H = white, O = red, N = blue). 
The formation of 200 stands for an interesting result since it would be expected that the bond 
between the donor (D) and acceptor (A) (dashed) moiety of the cyclopropane should be 
cleaved. It’s a known fact that the bond between D and A on the cyclopropane is typically the 
longest and thus the weakest. Nonetheless, the inner bond of the cyclopropane ring was 
cleaved (Scheme 71).182
Scheme 71: Expected and isolated byproducts of hydrogenolysis of 190. 
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The 6-membered ring 200 represents the N-Boc protected tert-butyl ester derivative of 
Nipecotic acid 237. To access 237, hydrogenation of enantiopure 190 was performed and the 
desired 6-membred ring 200 was obtained in improved yield of 19%. It should be mentioned, 
that in previous experiments (compare chapter 6.1.1) 200 was isolated in only 5-6% yield.
Finally the hydrolysis of the Boc group and tert-butyl ester was followed to afford the free 
amino acid 237 (Scheme 72).
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Scheme 72: Hydrogenation of cyclopropanated pyrrole 190 towards Nipecotic acid 237.
The absolute configuration of 200 could be determined by optical rotation measurement since 
optical rotation value for the free amino acid 237 was already reported in the literature.207
Spectroscopic data of 237 were in agreement with those in the literature and in particular, the 
optical rotation value (+4.7, (c 1, H2O) smoothly fitted to the reported data (+4.7, (c 1, H2O, 
(S)-enantiomer)).207 The result from optical rotation measurement nicely supports the chiral 
HPLC analysis of 200 which proves, that no epimerization during the hydrogenation occurred
and 200 was isolated as the (S)-enantiomer.
Nipecotic acid 237 can be considered as a conformationally restricted GABA analogue and it 
builds the core structure of various GABA uptake inhibitors such as Tiagabine 238, which is 
used in the treatment of epilepsy.208,209 It is accessible via classical hydrogenation210 or by 
electrolytic hydrogenation211 of its aromatic analogue, Nicotinic acid (239). The (R)-
enantiomer of Nipecotic acid was found to be more potent than the (S)-enantiomer and each 
enantiomer can be obtained by resolution of the racemate via enzymatic N-acetylation,212
fractional crystallization207,213 or by asymmetric hydrogenation214 of Nicotinic acid.215
Figure 26: Chemical structures of Tiagabine and Nicotinic acid. 
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Due to its various medicinal applications and the fact that N-Boc-protected Nipecotic acid 
tert-butyl ester 200 can be obtained as a byproduct in enantiopure form hydrogenation of 190,
it was envisioned to find the best conditions for a selective cyclopropane ring-opening 
towards 200. 
6.3.1 Hydrogenolysis of cyclopropanated N-Boc-pyrrole towards Nipecotic acid 
Nipecotic acid ester 200 was obtained during hydrogenation of 190, so it was obvious to 
investigate the hydrogenation step more in detail. Hydrogenolysis of small rings with a high 
degree of ring strain is well-known in the literature as it is a valuable tool for synthetic 
chemistry. First examples were reported in 1907 by Willstätter and Bruce, obtaining alkane 
241 from hydrogenolysis of cyclopropane 240 by using Nickel catalysts (Scheme 73).216
Danishefsky et al.217 or de Meijere et al.218 demonstrated that highly strained spiro-annelated 
cyclopropanes such as 242 or 244 even react under milder conditions to the corresponding 
compounds 243 and 245. Very recently, Nishii et al. reported a highly regioselective reductive 
Pd-catalyzed ring-opening of 2-arylcyclopropane-1,1-dicarboxylic diesters such as 246 under
mild conditions.219
Scheme 73: Literature precedents for the catalytic hydrogenolysis of cyclopropane moieties. 
Therefore, in this study different catalysts were tested if the yield of desired 6-membered ring 
could be improved (Table 12). Compared to the original conditions providing 200 (entry 1), 
only Platinum catalysts led to the formation of the desired 6-membered (entries 2,3 and 6,7). 
Application of Rhodium catalyst delivered the fully saturated product 194 exclusively and 
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without the need of further purification (entries 4,5 and see chapter 6.1.1, Table 7). Due to the 
fast conversion of the starting material, it was decided to extend the reaction time to
determine possible conversion of the fully saturated fused ring towards the 6-membered ring. 
However, no further conversion towards the 6-membered ring was observed.  Furthermore, a 
Nickel- and the Lindlar catalyst were employed (entries 10 and 11). Particularly, the Lindlar
catalyst was believed to show promising results because it is known to prevent the formation
of alkanes during the hydrogenations of alkynes to alkenes. As expected, the rate of 
conversion was very slow but also the fully saturated fused ring was formed exclusively. The 
Nickel catalyst proved to be ineffective in the hydrogenation of 190. 
Table 12: Catalyst screening for hydrogenation of 190.
entry a) catalyst time yield (%) b)
1 Pd/C (10%) 1.5 h 194 (85), 200 (6)
2 Pt/C (10%) 2 h 194 (97), 200 (3)
3 Pt/C (10%) 24 h see entry 2
4 Rh/C (5%) 1 h 194 (>99)
5 Rh/C (5%) 24 h see entry 4
6 Pt2O·H2O 2 h 194 (87), 200 (1)
7 Pt2O·H2O 5 d see entry 6
8 Rh/Al2O3 (5%) 2 h 194 (97)
9 Rh/Al2O3 (5%) 24 h see entry 8
10 Ni(PPh3)4(CO)2 24 h no conversion
11 c) Lindlar 17 h 194 (n.d.)
a) In all entries, the total amount of used Pd/C was 10 wt% based on the starting material 190; b) isolated yield; 
c) Lindlar catalyst: 5% Pd deposited on CaCO3 poisoned with Pb. 
In order to prove, if the double bond in 190 is essential for the formation of the 6-membered 
ring, the fully saturated fused ring 194 was submitted to hydrogenation under increased
pressure and temperature (Table 13). Platinum on charcoal was chosen as the catalyst since it 
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is a more active catalyst than Pd/C. However, no conversion of the starting material was 
observed. Even forcing conditions only led to decomposition of starting material due to 
exothermic reaction in the autoclave vessel (entry 3) (caution: if the solvent is not degassed, 
Pt/C catalyzes the oxyhydrogen reaction and results in an ignition).
Table 13: Hydrogenolysis of 194 towards 200.
entry a) H2 (bar) T (°C) time (h) observation
1 10 25 1 no conversion
2 20 40 1 no conversion
3 60 40 0.25
decomposition
exothermic reaction
a) In all entries, the total amount (wt%) of applied Pt/C was based on the starting material 190.
It became clear that the double bond in 190 seems to be crucial for the formation of the 6-
membered ring. Moreover, different solvents like EA, acetone, EtOH or trifluoroethanol 
(TFE) were tested, partially resulting in a more sluggish reaction due to the formation of 
various side-products. Nevertheless, the fully saturated fused ring 194 was formed as the main 
product and no preference for the desired 6-membered ring was observed.
Considering the recent results, it can be concluded that the double bond is essential for the 6-
membered ring formation. But in the previous attempts, by using balloon or autoclave vessel, 
an excess of hydrogen gas was available, resulting in a faster reduction of the double bond 
compared to the formation of the 6-membered ring. In order to prevent prolonged contact 
time of the substrate with the catalyst and hydrogen gas, hydrogenation was performed in a 
continuous flow system by using ThalesNano H-Cube ProTM. For this purpose, the substrate 
was dissolved in THF and passed through the reactor, containing a cartridge loaded with the 
catalyst (Figure 27). 
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Figure 27: Display of the reaction setup for condition screening using the ThalesNano H-Cube ProTM. A: solvent 
THF; B: sample in THF; C: HPLC pump; D: control panel, display and adjustment of reaction parameters; E: 
reaction chamber containing catalyst cartridge and heating block; F: collected product mixture in solvent; G: 
waste drain.
Different conditions were screened but the desired 6-membered ring was only detected in 
traces amounts (Table 14). Interestingly, starting material was converted under increased 
temperature and missing hydrogen gas resulting in a complex mixture (entry 3). Similar to 
previous experiments, poisoned Pt-catalyst was employed to reduce the rate of hydrogenation, 
but even under forcing conditions only the fully saturated fused ring 194 was obtained as the 
main product (entries 4-7).
Table 14: Screening of reaction conditions for the catalytic hydrogenolysis of 190 under flow conditions.
N
Boc
CO2tBu
H
H N
H
H
CO2tBu
Boc
H2, catalyst
THF N
Boc
CO2tBu
190 194 200
+
entry a) catalyst T (°C) H2 (bar) conv. (%) 
b) observation
1 Pd/C (10%) 25 5 100 194
2 Pd/C (10%) 90 5 100 194, 200 traces
3 Pd/C (10%) 90 - 10 complex mixture
4 Pt/C (5%) sulfided 90 5 90 194, 200 traces
5 Pt/C (5%) sulfided 110 5 90 194, 200 traces
6 Pt/C (5%) sulfided 130 20 90 194, 200 traces
7 Pt/C (5%) sulfided 150 40 90 194, 200 traces
a) 0.35 mmol (100 mg) 190, 15 mL THF, 1 run, 1 mL/min; b) Estimated from TLC. 
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In a next step, it was studied, if the rate of hydrogenation and consequently the formation of 
200 could be increased, by raising the amount of Pd/C (Table 15). Indeed, by using 100 wt% 
of Pd/C based on 190 the yield of desired 6-membered ring 200 could be improved up to 20% 
yield. However, this positive result was accompanied by the occurrence of various side-
products, which hampered the purification and isolation of the desired products. Moreover, 
the fully saturated fused ring 194 was still the main product. Nevertheless, this observation 
indicated, that a complexation of the palladium to double bound could take place, which 
resulted activating the double bond and facilitating the formation of the 6-membered ring and 
further products.
Table 15: Hydrogenolysis of 190 with increased amount of Pd/C.
entry a) Pd/C (wt%) time (h) yield (%)
1 10 1.5 194 (85), 200 (5)
2 100 2 194 (n.d.), 200 (20)
a) In all entries, the total amount of applied Pd/C (wt%) was based on the starting material 190.
This is why an additional Pd-source was added to achieve complexation to the double bond
(Table 16). It can be seen, that the additional Pd-source caused a decreased rate of 
hydrogenation displayed by elongated reaction time. It was assumed that the complexed Pd-
source blocks the double bond to the Pd/C and delays the reduction of the double bond. 
However, in both cases, no increased formation of the 6-membered ring was observed. In 
particular, when Pd-(II)-acetate was used, the yield of 194 dropped dramatically caused by the 
formation of various side-products (entry 1). In the case of Pd-(0)-tetrakis exclusively the 
fully saturated fused ring 194 was formed again. 
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Table 16: Hydrogenolysis of 190 with an additional Pd-source. 
entry a) Pd source (equiv) time (h) yield (%)
1 Pd(OAc)2 (0.5) 24 194 (67), 200 (2)
2 Pd(PPh3)4 (0.5) 24 194 (99), 200 (-)
a) In all entries, the total amount of Pd/C (wt%) was based on the starting material 190.
It became obvious that the selective hydrogenolysis of cyclopropanated N-Boc-pyrrole 190 to 
the desired 6-membered ring 200 will be a challenging objective. It was assumed, if proper 
conditions for the hydrogenolysis of 190 can not be found, maybe 190 can be manipulated in 
a way undergoing the desired transformation. Since hydrogenolysis of substituted
cyclopropanes using Pd or Ni catalysts was already studied, selective scission of 
cyclopropane in 190 should be possible.220 However, the background information of the 
literature on hydrogenolysis of cyclopropanes is not sufficient to establish common rules for 
the regioselective bond cleavage.221 Nevertheless, there have been studies on influences of 
substituents on cyclopropanes. For example, Gröger et al.222 investigated hydrogenolysis of 
1,1-disubstituted cyclopropanes based on the studies of Hoffmann et al.223 and Günther.224 In 
their studies they observed, that electron donating substituents are weakening the where the 
very substituent is not connected, whereas electron-withdrawing groups are weakening the 
adjacent bonds.222
As a manipulation, the electron-withdrawing tert-butyl ester in 190 was reduced to the 
corresponding less electron withdrawing alcohol. The desired alcohol 248225 was obtained in 
51% yield by using LAH (Scheme 74). Subsequently, hydrogenation was performed under the 
same conditions as in the previous experiments, however, showed no conversion of 248. After 
changing the solvent from THF to MeOH, the desired 6-membered ring was obtained in 31% 
yield, although the fully saturated fused ring 249 was still the main product. Nevertheless, the 
isolated yield of the 6-membered ring could be increased from initially 5% to 31%. In order to
prove the formation of the 6-membered ring 250, the Boc group was removed to yield the free 
amino alcohol 251 which is a literature known comound. The spectroscopic data of 251 were 
in agreement with the literature data.226
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Scheme 74: Hydrogenolysis of 248 towards desired 6-membered ring 250. 
Also the influence of the N-protecting group in the hydrogenolysis reaction was investigated. 
For this, the Boc group was exchanged to the tosyl protecting group which would have less 
conjugation of enamine moiety with the N-protecting group. 252 was provided by S. R. Park
and submitted to hydrogenolysis reaction. Interestingly, 252 was converted exclusively to the 
fully saturated fused ring 253 without any trace for the formation of the desired 6-membered 
ring. A possible explanation would be that the Ts-substituted 252 is more reactive to the 
hydrogenation since the double bond is more exposed to the other reaction components due to 
less conjugation with the N-protecting group. On contrary due to its involvement in a 
conjugated system with the sp2 hybridized nitrogen, the double bond in 190 is less reactive to 
hydrogenation. 
Scheme 75: Hydrogenation of 252 towards 253.
In summary, the yield of desired 6-membered ring in hydrogenolysis of 190 could be 
improved up to 31% by manipulation of the cyclopropane substituent. However, the literature 
studies are limited to the simple cyclopropanes with few numbers of substituents and when it 
comes to complex cyclopropanes, precedents are not fitting to the here employed system and 
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contradict themselves. Therefore, further attempts for selective ring-opening via 
hydrogenolysis were not performed anymore.
6.3.2 Further attempts at ring-expansion 
From previous experiments, it was concluded that coordination of the palladium source to the 
double bond could facilitate the formation of the 6-membered ring. Therefore, it was 
envisioned WR DSSO\ ʌ-allylpalladium chemistry for ring expansion.227 The palladium-
catalyzed substitution has been developed in the early 1970s and there has been an enormous 
achievement in this field.228,229,230,231 ,Q SULQFLSOH WKH ʌ-allylpalladium complex 257 can be 
generated by binding of a Pd(0)-species to allylic compound 255. Subsequent ionization by 
expelling of the allylic leaving group X, leads to the intHUPHGLDWHʌ-allylpalladium complex 
257. This complex is electrophilic and accommodates the nucleophilic attack onto it. After 
nucleophilic attack, the Pd-species is released and takes part in the catalytic cycle again
(Scheme 76). The probably most prominent representative displays the Tsuji-Trost reaction. 
Scheme 76: General reaction scheme of a palladium catalyzed allylic substitution.231
It was assumed, that 190 would undergo the typical Pd-catalyzed reaction initiated by the 
ring-RSHQLQJRIWKHF\FORSURSDQHVRWKDWȘ3- ʌ-allyl complex 260 can be made on the enamide 
moiety. Then applied nucleophile attacks and finally the substituted 6-membered ring 261 can 
be formed. Therefore, 190 was submitted to allylic substitution reaction catalyzed by 
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Pd2(dba)3·CHCl3 in which various nucleophiles were applied (Table 17). But even under 
reflux conditions, no conversion of the starting material was observed. A plausible 
explanation would be that the cyclopropane ring-opening doesn´t occur to initiate the 
reaction, which hampers further nucleophilic attack. 
Table 17: Attempts for the allylic substitution on 190. 
entry nucleophile (equiv) T (°C) time (h) result
1
2
25 1 no conversion
2 70 24 no conversion
3
(Pyridine 0.2 equiv)
2
25 1 no conversion
4 70 24 no conversion
5
(NaH 1 equiv)
2
25 1 no conversion
6 70 24 no conversion
7
2
25 1 no conversion
8 70 24 no conversion
As the substrate was inactive to Pd-(0)-species and showed no conversion, no further attempts 
at ʌ-allylpalladium formation were made in this work. Another possibility could be
employing Pd-(II)-species in vinylcyclopropane activation.232 For instance, Wilhelm et al.
reported a chloropalladation of (+)-2-carene 262 by using PdCl2(MeCN)2 to generate the 
GLPHULF ʌ-olefin complex 263, on the convex face of 262.233 In chloroform (pathway A),
palladium induced 1-7 bond cleavage which resulted in electrophilic activation of the 
cyclopropane ring and the formation of the preferred 6-membered ring complex 264, followed 
by final trapping of the positive charge with a nucleophile. On the other hand, in benzene, 
cleavage of the 1-6 bond led to the preferred 7-membered ring complex 266, which is similar
to a Ș4-1,3-diene complex. Then, nucleophilic attack of the chloride led to 7-membered ring 
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267. This drastic change in product selectivity was explained, that the increased polarity of 
the solvent increases the electrophilicity at the tertiary carbon of 262. This means that the 
nucleophilic attack at the tertiary carbon may change to an SN1-type reaction on going to a 
more polar solvent. 
Scheme 77: Solvent dependent chloropalladation reported by Wilhelm et al. 
In the following scheme, the corresponding transformation of 190 according to the 
chloropalladation method of Wilhelm et al. is proposed. 
Scheme 78: Proposed mechanism for chloropalladation of 190 towards 6-membered ring 271.
It looks promising to apply Pd-(II)-species in non-polar solvents to the transformation of N-
Boc cyclopropanated pyrrole 190 towards the corresponding 6-membered ring as in the 
literature precedents. Further attempts at palladium-induced ring-opening of cyclopropane
compounds are currently ongoing in the Reiser group.
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6.3.3 Metal-free dipolar cycloaddition of cyclopropanated N-Boc-pyrrole
The following chapter describes an alternative method of cyclopropane ring-opening without 
any metal based Lewis acid or hydrogen gas. Inspired by the pioneering work of Fowler et 
al., we envisioned thermal activation of cyclopropane ring to get access to 6-membered ring 
systems (Scheme 79). With the closely related compounds 272 and 276, Fowler et al. already 
demonstrated in the 1970´s, that cyclopropanated pyrrole derivatives undergo cycloaddition 
reaction with suitable dipolarophiles. However, in this reaction, the scope of dipolarophiles is 
limited to highly activated alkenes and alkynes such as maleic anhydride, N-Phenylmaleimide 
and acetylene dicarboxylates. Moreover, discussion on the mechanism and many yields 
remain unreported.234,235
Scheme 79: Cycloaddition examples reported by Tanny and Fowler.
In 2013, the first mechanistic investigation of this cycloaddition was published by Yu et al.
with homopyrrole 272 as the model substrate.236 They showed by density functional theory 
calculations (DFT), that the low distortion energy from 272 to 278 is the main reason why 
such cyclopropanated pyrrole undergoes dipolar cycloaddition reactions. Under thermal 
activation, 272 can rearrange to 278, a 1,3-dipole being a highly reactive species that can 
undergo dipolar cycloaddition reactions with suitable dipolarophiles. According to their 
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calculations, a diradical (pathway A) and a concerted (pathway B) mechanism were proposed 
(Scheme 80). The activation energy to the diradical intermediate 280 was calculated to be 
lower than that of the intermediate 281 by about 3.0 kcal/mol. 
According to the IUPAC guidelines, the formed product 282 can be defined as a (5+2) or 
[4+2] cycloaddition product. There are two different notation systems to determine the type of 
cycloadditions.237 In the first one, a (i + j +...) cycloaddition is a reaction in which two or 
more molecules (or parts of the same molecule), respectively, provide units of i, j, ... linearly 
connected atoms: these units become joined at their respective termini by new ı-bonds so as 
to form a cycle containing (i + j + ...) atoms. In this notation, (a) a Diels–Alder reaction is a 
(4+2) cycloaddition, (b) the initial reaction of ozone with an alkene is a (3+2) cycloaddition 
[…] (N.B.: parentheses (...) are used in the description based on numbers of atoms).237 On the 
other hand, in the second one, the symbolism [i + j+ ...] for a cycloaddition identifies the 
numbers i, j, ... of electrons in the interacting units that participate in the transformation of 
reactants to products. In this notation the reaction (a) and (b) of the preceding paragraph 
would both be described as [2+4] cycloadditions […].237
Scheme 80: Proposed diradical and concerted reaction pathways for the 1,3-dipolar cycloaddition reported by Yu 
et al.
Based on the precedent studies, 190 was submitted to cycloaddition reactions employing N-
Phenylmaleimide, maleic anhydride and acetylene dicarboxylate (Table 18). In contrary to the 
results of Fowler et al., the reaction of tert-butyl ester-substituted cyclopropane 190 showed 
only poor results. In the reaction with N-Phenylmaleimide (entry 1) and dimethyl 
acetylenedicarboxylate (entry 3), almost no conversion of starting material was observed. In
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the case of the reaction with maleic anhydride (entry 2), it occurred with full conversion of 
190. However, the low yield was thought to explain by decomposition of the maleic 
anhydride moiety during the reaction. To overcome the poor reactivity of 190, the 
corresponding alcohol 248 was employed. As already implied in chapter 6.3.2, manipulation 
of the electronic and steric properties of substituents on the cyclopropane to less electron 
withdrawing could change the reactivity of the cyclopropane ring. Indeed, the reactivity of 
248 was improved resulting in full conversion and products 286 and 288 (entries 4 and 6) 
could be isolated in satisfying yields. Besides to prevent the decomposition of the anhydride 
moiety in the product, the reaction temperature was reduced to 40 °C, but the yield of product 
285 (entry 5) was dropped again. It was found that the purification by column 
chromatography triggered the anhydride ring-opening and dropped the yield dramatically.
Table 18: Cycloaddition reactions of cyclopropanated N-Boc-pyrroles 190 and 248.
entry R R1 T (°C) time (h) result
1 CO2tBu 100 24
2 CO2tBu 100 24
3 CO2tBu 100 24
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4 CH2OH 100 17
5 CH2OH 40 3
6 CH2OH 100 14
In summary, it was demonstrated in this chapter, that cyclopropanated pyrrole derivatives 
could be utilized in metal-free or thermal cycloaddition reactions. This method gives access to 
complex fused ring systems and has potential to be utilized in the synthesis of Cocaine 
derivatives since the obtained cycloaddition product contains already the its core structure 
(Scheme 81). Further investigations on the cycloaddition and its applications to the Cocaine 
synthesis are already in progress in the Reiser group.
Scheme 81: Possible application of the cycloaddition product as precursor for the Cocaine synthesis. 
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C. Summary
The present thesis deals with the synthesis and application of β- and γ-amino acids based on 
aminopyrrolidine carboxylic acid (APC) and aminocyclopentane carboxylic acid (ACPC) as 
organocatalysts, as structural elementes in peptides and as building blocks for total syntheses. 
In the first part, APC and ACPC were investigated regarding their catalytic activity in 
organocatalysis. The use of the cis-APC based organocatalyst (ent)-100 in anti-Mannich 
reactions gave only poor results, whereas tripeptides containing cis-APC or cis-ACPC as 
central building block proved successful. In these tripeptides, both enantiomers of each five-
membered ring amino acid were used (Scheme 82). The tripeptides were tested in terms of
their catalytic performance related to the application of pressure, which could cause a change 
in the conformation of the catalysts, possibly resulting in an increased catalytic activity. For 
the APC-tripeptides as well as for the ACPC-tripeptides a three- to eightfold increase in the 
reaction rate upon pressurization from 1 bar to approximately 5 kbar was observed, but this 
was rather assigned to the general effect of pressure than to a change in the conformation of 
the catalysts. Only for the ACPC-tripeptides, a slight increase of enantioselectivity was 
observed upon pressurization, which could imply a change of the active catalytic
conformation. As well, one isomer was found to be catalytically more active than the other, 
which might be explained by internal hydrogen bonding resulting in a conformationally less 
flexible catalyst. 
Scheme 82: Chemical structures of tripeptide organocatalysts 127 and 119 for the intermolecular aldol reaction 
of acetone 148 and p-nitrobenzaldehyde 149. 
The second part of this thesis describes the introduction of APC and ACPC into longer-
chained peptides. It could be implied by the exchange of unpolar ACPC to polar APC 
building blocks in aQ Įȕ-alternating model peptide that these more polar APC units can
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stabilize helical structure motifs in aqueous media. By the introduction of APC into the highly 
conserved C-terminal area of truncated neuropeptide Y (NPY) analogues in position 32 and/or
34, new Y4 receptor (Y4R) selective ligands were obtained (Figure 28). Herein, ligands 
containing APC as well as ACPC building blocks could be identified as the most potent ones. 
It could be shown by the results of competition binding assays in combination with CD 
spectroscopy, that a helical structure of the ligand is not required alone for Y4R binding. 
Moreover, it could be shown that ligands containing nonpolar residues (ACPC) at position 34 
are preferred for Y4R binding over ligands containing a polar residue (APC) at this position.
Figure 28: Chemical structure of an NPY analogue containing an APC as well as an ACPC building block.
The diastereomeric mixture of 152 was described in the literature as a high affinity Y4R 
agonist. Therefore, in cooperation with K. Kuhn (Institute of Pharmacy), the (R,R)- und (S,S)-
diastereomeres each of 152 were synthesized via Grubbs´ metathesis cross coupling reaction 
starting from enantiopure allylglycine esters 165 (Scheme 83). As (R,R)-152 was superior to 
(S,S)-152 in binding assays, [3H]-propionylation of (R,R)-152 gave access to high affinity 
Y4R radioligand [
3H](2R,7R)-169, which was used as radioligand in the above mentioned 
competition binding assays. 
Scheme 83: Two-step synthesis of diaminooctane diacid building block 165 for the synthesis of the new 
radioligand 169.
In the third part, cyclopropananted N-Boc-pyrrole 190 served as a platform for the synthesis 
of cyclic Ȗ-amino acids. The biologically active GABA analogue (S)-(+)-homo-ȕ-proline 188
could be obtained in a two-step synthesis starting from enantiopure 190 in quantitative yields 
(Scheme 84). The (Lewis)-acid catalyzed cyclopropane ring-opening under full conservation 
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of the enantiopurity represented the key step in this synthesis, in which the temperature of the 
reaction turned out to be the crucial parameter. 
Scheme 84: Two-step synthesis of (S)-(+)-homo-ȕ-proline 188 starting from 190. 
Moreover, the optimized reaction conditions for the cyclopropane ring-opening were applied 
to get access to the orthogonally protected trans-Ȗ-aminopyrrolidine carboxylic acid 217 in 
enantiomerically pure form (Scheme 85). Since synthetic protocols towards this kind of Ȗ-
APC amino acids were not reported in the literature yet, this procedure represents the first 
enantioselective synthesis towards such compounds.
Scheme 85: Enantioselective synthesis of orthogonally protected Ȗ-APC 217.
Moreover, cyclopropanated N-Boc-pyrrole 248 served as platform for the cycloaddition with 
various dipolarophiles to get access to fused cycles such as 288, which contain already the 
core structure of cocaine (289). Current ongoing projects in the Reiser group were initiated by 
these findings.
Scheme 86: Cycloaddition reaction of cyclopropanated N-Boc-Pyrrole 248 towards the cocaine core structure 
288.
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D. Zusammenfassung
'LH YRUOLHJHQGH 'LVVHUWDWLRQ EHVFKUHLEW GLH 6\QWKHVH XQG $QZHQGXQJ YRQ ȕ- XQG Ȗ-
Aminosäuren, basierend auf Aminopyrrolidin Carbonsäure (APC) und Aminocyclopentan 
Carbonsäure (ACPC) als Organokatalysatoren, als strukturgebende Elemente in Peptiden und 
als Bausteine für die Totalsynthese. Im ersten Abschnitt wurden APC und ACPC hinsichtlich 
ihrer Fähigkeit als Organokatalysator  untersucht. Während der auf cis-APC basierende 
Organokatalysator (ent)-100 in anti-Mannich Reaktionen nur unzureichende Ergebnisse 
lieferte, erzielten Tripeptide, welche als zentralen Baustein cis-APC oder cis-ACPC 
enthielten, positivere Resultate (Schema 1). Hierbei wurden beide Enantiomere der Fünfring 
Aminosäuren verwendet. Diese Tripeptide wurden bezüglich ihrer katalytischen Aktivität 
unter dem Einfluss von Druck untersucht, welcher eine konformative Änderung der 
Katalysatoren und somit eine Steigerung der katalytischen Aktivität bewirken sollte. Sowohl 
für die APC- als auch für die ACPC-basierenden Tripeptide konnte ein bis zu achtfacher 
Anstieg der Reaktionsgeschwindigkeit bei einem Druckanstieg von 1 Bar auf ca. 5 kBar 
beobachtet werden. Dieser Anstieg scheint jedoch eher auf den generellen Einfluss des 
Druckes zurückzuführen zu sein, als auf eine konformative Änderung des Katalysators. 
Lediglich die auf ACPC basierenden Tripeptide zeigten bei Druckanlegung einen leichten 
Anstieg der Enantioselektivität, was auf eine Änderung der katalytisch aktiven Konformation 
schließen lässt. Ebenso erwies sich je ein Isomer als katalytisch aktiver als das andere, was 
sich durch interne Wasserstoffbrückenbindungen und eine damit eingeschränkte Flexibilität 
der Katalysatoren erklären lässt. 
Schema 1: Chemische Strukturformeln der katalytisch aktiveren Tripeptide 127 und 119 für die intermolekulare 
Aldolreaktion von Aceton und p-Nitrobenzaldehyd. 
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Der zweite Abschnitt behandelt den Einbau von APC- und ACPC-Bausteinen in längerkettige 
Peptide. Durch den Austausch von unpolaren ACPC- durch polare APC-Bausteine in einem 
Įȕ-alternierenden Modellpeptid konnte mittels CD-Spektroskopie gezeigt werden, dass 
positiv geladene APC Einheiten helikale Sekundärstrukturen in wässrigen Medien 
stabilisieren können. Durch den Einbau von APC-Bausteinen in den hochkonservierten C-
Terminus von verkürzten Neuropeptid Y (NPY) Analoga in Position 32 und/oder 34 konnten 
neue Liganden gefunden werden, welche selektiv an den Y4 Rezeptor (Y4R) binden 
(Abbildung 1). Hierbei konnten Liganden, welche sowohl den APC- als auch den ACPC-
Baustein enthielten, als potenteste Analoga identifiziert werden. Ebenso konnte anhand der 
Ergebnisse von Kompetitionsbindungtests in Kombination mit CD-Spektroskopie gezeigt 
werden, dass nicht zwingend eine helikale Struktur der NPY Liganden benötigt wird, um eine 
Bindung am Y4R zu erreichen. Außerdem konnte gezeigt werden, dass Liganden mit 
ungeladenen, aliphatischen Resten (ACPC) in Position 34 gegenüber geladenen, polaren 
Resten (APC) deutlich bevorzugt an den Y4R binden. 
Abbildung 1: Chemische Strukturformel eines NPY Analogon, welches sowohl einen APC- als auch einen 
ACPC-Baustein enthält.
In der Literatur wird die Diastereomerenmischung von 152 als hoch affiner Y4R Agonist 
beschrieben. Deshalb wurden in Kooperation mit K. Kuhn (Institut für Pharmazie) die 
jeweiligen (R,R)- und (S,S)-Diastereomere von 152 mittels Grubbs´ Metathese ausgehend von 
enantiomerenreinen Allylglycin Estern 165 dargestellt (Schema 2). In pharmakologischen 
Untersuchungen zeigte sich (R,R)-152 gegenüber (S,S)-152 als überlegen und wurde mittels 
[3H]-Propionylierung weiter zum Radioliganden 169 umgesetzt. [3H](2R,7S)-169 erwies sich 
als hoch affiner Y4R Radioligand und wurde in den zuvor erwähnten 
Kompetitionsbindungstests als Radioligand verwendet. 
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Schema 2: Zweistufensynthese von Diaminooctan Dicarbonsäure Bausteinen 165 für die Darstellung eines 
neuen dimerartigen Radioliganden 169.
Im dritten Abschnitt diente cyclopropaniertes N-Boc-Pyrrol 190 als Basis für die Synthese 
YRQ F\FOLVFKHQ Ȗ-Aminosäuren. Ausgehend von enantiomerenreinen 190 konnte das 
biologisch aktive GABA Analogon (S)-(+)-homo-ȕ-Prolin 188 in einer Zweistufensynthese in 
quantitativen Ausbeuten dargestellt werden (Schema 3). Schlüsselschritt war hierbei die 
(Lewis)-säurekatalysierte Cyclopropanöffnung unter vollem Erhalt des Stereozentrums, wobei 
die Reaktionstemperatur entscheidend war. 
Schema 3: Zweistufensynthese von (S)-(+)-homo-ȕ-Prolin 188 ausgehend von 190.
Ebenso konnte unter Verwendung der optimierten Bedingungen der Cyclopropanöffnung die 
orthogonal geschützte trans-Ȗ-Aminopyrrolidin Carbonsäure 217 enantiomerenrein dargestellt 
werden (Schema 4 (LQ =XJDQJ ]X VROFKHQ Ȗ-APC Aminosäuren wurde in der Literatur 
bisher noch nicht beschrieben und somit stellt diese Route die erste enantioselektive Methode 
für diese Art von Aminosäuren dar.
Schema 4: Enantiomerenreine Darstellung von orthogonal geschützter Ȗ-APC 217.
190
N
FmocHN
MeO
Boc
H
CO2tBu
H
215
1) BF3·OEt2
Et3SiH, DCM
-78 °C 0 °C
25 h
N
FmocHN CO2H
Boc
2) TFA, DCM
0 °C RT, 25 h
3) Boc2O, NaHCO3
Dioxan/H2O
0 °C RT, 25 h
51% (über 4
Schritte)
217
3 Schritte
40%
>99% ee
19% (über 7 Schritte)
>99% ee
D. Zusammenfassung
104
Außerdem konnte ausgehend von 248 durch Cycloaddition mit unterschiedlichen 
Dipolarophilen der Zugang zu Bicyclen wie 288 erreicht werden, welche bereits die 
Grundstruktur von Kokain 289 enthalten (Schema 5). Damit konnte die Grundlage für weitere 
Projekte gelegt werden,  welche Gegenstand aktueller Forschungen am AK Reiser sind.
Schema 5: Cycloaddition von cyclopropaniertem N-Boc-Pyrrol 248 hin zur Kokaingrundstruktur 289.
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E. Experimental Part
1. General Information
All moisture sensitive reactions were performed in prior flame-dried septum-sealed flasks 
under nitrogen atmosphere.
Solvents and chemicals: DCM, ethyl acetate and hexanes (60/40) were distilled prior to use 
for column chromatography. Anhydrous solvents were prepared according to standard 
procedures. Commercially available chemicals were used as received, without further 
purification.
1H NMR spectra were recorded on Bruker Avance 300 (300 MHz), Bruker Avance 400 (400 
MHz) and Bruker Avance III 600 TCI Cryo (600 MHz). The chemical shifts are reported in į
(ppm) relative to chloroform-d (CDCl3 7.26 ppm), methanol-d3 or methanol-d4
(CD3OH/CD3OD 3.34 ppm), acetone-d6 ((CD3)2CO 2.05 ppm), deuterium oxide (D2O, 4.79 
ppm) or diemthylsulfoxide-d6 ((CD3)2SO 2.50 ppm). The spectra were analyzed by first order, 
the coupling constants (J) are reported in Hertz (Hz). Characterization of the signals: s,
singulet; d, dublet; t, triplet; q, quartet; quin, quintet; m, multiplet; dd, double dublet;  dt,
double triplet; sept, septet. Integration is determined as a relative number of atoms. 
13C NMR spectra were recorded on Bruker Avance 300 (75.5 MHz) and Bruker Avance 400 
(100.6 MHz). The chemical shifts are reported in įppm) relative to chloroform (CDCl3, 77.0 
ppm, or methanol-d4 (CD3OD 49.0 ppm), acetone-d6 ((CD3)2CO 29.84 ppm) or 
diemthylsulfoxide-d6 ((CD3)2SO 39.52 ppm).
13C NMR resonance assignment was aided by 
the use of DEPT 135 techniques (DEPT = Distortionless Enhancement by Polarization 
Transfer) to determine the number of hydrogens attached to each carbon atom and is declared 
as: + = primary or tertiary (positive DEPT signal), - = secondary (negative DEPT signal), Cq
= quaternary (no DEPT signal) carbon atoms.
High-performance liquid chromatography (HPLC) was performed on a Varian 920-LC 
with DAD. Phenomenex Lux Cellulose-1 and 2, Chiracel OD-H and AS served as chiral 
stationary phase and mixtures of n-heptane and iPrOH were used for elution. 
RP-High performance liquid chromatography (RP-HPLC) was performed on a Shimadzu 
LC20A series, Agilent 1100 series (AK König), Agilent UHPLC-MSD-system (AK König) or 
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on a system from Knauer (AK Buschauer). Machery-Nagel EC 250/4 Nucleodur 100-5 
C18ec, Machery-Nagel VP 250/10 Nucleodur 100-5 C18ec, Phenomenex Luna 10 C18(2) 
100A 250/21.2, Phenomenex Luna C18(2) 100A 150/2.0 or Machery-Nagel Nucleodur 
250/21 100 C18 served as stationary phase and mixtures of MeCN + 0.05% TFA and 
Millipore water + 0.05% TFA were used for elution. Acetonitrile was removed before
lyophilization. Lyophilization was carried out with a Christ Alpha 2-4 LD equipped with a 
vacuubrand RZ 6 rotary vane vacuum pump. 
Infra-red spectroscopy (IR) in form of ATR-IR spectroscopy was carried out on a Biorad 
Excalibur FTS 3000 Spectrometer, equipped with a Specac Gate Diamond Single Reflection 
ATR-System or on an Agilent Cary 630 FT-IR.
Mass spectrometry (MS) was performed in the Central Analytic Department of 
the University of Regensburg on a Finnigan MAT 95, a Agilent Q-TOF 6540 UHD, a 
Finnigan MAT SSQ 710 A and a ThermoQuest Finnigan TSQ 7000.
Melting points (mp) were measured on a Büchi SMP-20 apparatus in a silicon oil bath. 
Values thus obtained were not corrected.
Optical rotations were determined in a Perkin Elmer 241 polarimeter or an Anton Paar MCP 
500 at 589 nm wavelength (sodium-d-line) in a 1.0 dm measuring cell of ca. 2 mL volume 
and the specified solvent.
Circular dichroism spectroscopy (CD) was performed on a JASCO model J-710/720 at 
indicated temperatures and wavelengths between 260 and 190 nm in water, phosphate buffer 
pH = 7 (30% TFE added respectively) or MeOH by using the following parameters: 0.25 s 
response, 100 nm/min speed, 5 scans. The length of the cuvette was 1.0 mm. The CD 
Spectrum of the sole was recorded and subtracted from the raw data. The CD intensity is 
given as mean residue molar ellipticity /deg cm2 dmol-1).
Thin layer chromatography (TLC) was performed on alumina plates coated with silica 
gel (Merck silica gel 60 F 254, d = 0.2 mm, Machery-Nagel ALUGRAM® Xtra SIL 
G/UV254, d = 0.2 mm). Visualization was accomplished by UV light (Ȝ = 254 nm), 
ninhydrin/acetic acid solution, potassium permanganate solution, vanillin/sulfuric acid 
solution or Seebach´s Magic Stain. 
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High-pressure reactions up to 5 kbar were performed using a self-custom-built hydraulic 
high-pressure apparatus from Unipress (Warsaw) using screw capped PTFE vials (1.9 mL) as 
reaction vessels. A 1:1 (v/v) mixture of decahydronaphthalene (a mixture of cis & trans) and
2,2,4-trimethylpentane was used as pressurizing medium.
Radioligand competition binding assay was performed in the group of Prof. Dr. A. 
Buschauer (Institute of Pharmacy at the University of Regensburg) under the supervision of S. 
Dukorn and K. Kuhn according to previously reported procedures.146,174 Purity of tested 
compounds was >95% as determined by HPLC. Buffer I was used. IC50 values were 
converted to Ki values according to the Cheng-Prussoff
238 equation and were provided by S. 
Dukorn and K. Kuhn. 
2. Synthesis of compounds
Following compounds were already available on stock in our laboratories:
Grubbs catalyst I , 1,3-dimesityl-4,5-dihydro-1H-imidazol-3-ium tetrafluoroborate, N-Boc-
pyrrole 191.
Following compounds were synthesized according to literature procedures and spectroscopic 
data matched well with those reported:
chiral amine 19 und ent-19,46 Grubbs catalyst II, 159b Pd(PPh3)4,
117 tert-Leucinol 196,193 232
and 233.205
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Methyl-(tert-butoxycarbonyl)glycinate (82)46
Glycine methyl ester hydrochloride salt 81 (90.15 g, 718 mmol, 1 equiv) was dissolved in 
MeOH (1.5 L) and cooled down to 0 °C. NaHCO3 (180.9 g, 2.15 mol, 3 equiv) and Boc2O 
(156.7 g, 718 mmol, 1 equiv) were added and stirred in the defrosting ice bath for 17 h. The 
solvent was removed under reduced pressure and the resulting white residue was treated with 
DCM (400 mL) and water (400 mL). Phases were separated and the aqueous phase was 
extracted with DCM (2x). The combined organic layers were dried over MgSO4, filtered and 
concentrated under reduced pressure to obtain the product as a colorless oil (114 g, 604 mmol, 
84%).
1H NMR (400 MHz, CDCl3) į = 5.04 – 4.97 (m, 1H), 3.91 (m, 2H), 3.75 (s, 3H), 1.45 (s, 
9H).
Potassium 1,4-bis(tert-butoxycarbonyl)-2,5-dihydro-1H-pyrrol-3-olate (83)33
N-Boc-glycine methyl ester 82 (114.4 g, 604 mmol, 1 equiv) and tert-butyl acrylate (87.7 mL, 
604 mmol, 1 equiv) were dissolved in THF (500 mL anhydrous) and cooled down to 0 °C. 
KOtBu (81.4 g, 725 mmol, 1.2 equiv) was added portionwise and the reaction mixture was 
stirred for 20 h at ambient temperature. To the resulting thick mixture hexanes (100 mL) was 
added and the solid was collected by filtration. The yellow solid was washed with cold Et2O 
(2x) and dried under high vacuum to obtain the product as a pale yellow powder (155 g, 479 
mmol, 79%). 
1H NMR (400 MHz, CD3OD) į = 4.12 – 4.05 (m, 2H), 3.79 – 3.72 (m, 2H), 1.49 – 1.42 (m, 
18H).
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di-tert-Butyl 2,5-dihydro-1H-pyrrole-1,3-dicarboxylate (77)33
83 (155 g, 479 mmol, 1 equiv) was dissolved in EtOH (800 mL) and cooled down to 0 °C. 
NaBH4 (18.1 g, 479 mmol, 1 equiv) was added portionwise and the mixture was stirred for 15 
min at this temperature, then at ambient temperature for 2 h. The mixture was again cooled to 
0 °C, followed by the addition of water (150 mL), NH4Cl sat. solution (150 mL) and 2M HCl 
(300 mL) till no evolution of hydrogen gas was observed. Phases were separated and the 
aqueous phase was extracted with DCM (2x). The combined organic layers were dried over 
MgSO4, filtered and concentrated under reduced pressure to obtain the corresponding alcohol 
(117 g, 407 mmol, 85%) which was used in the following step without further purification.
The alcohol (107.6 g, 374.5 mmol, 1 equiv) was dissolved in pyridine (500 mL), tosyl 
chloride (356.9 g, 1.8 mol, 5 equiv) was added and the reaction mixture was stirred for 4 h at 
100 °C. Then the solvent was removed under reduced pressure and the resulting solid was 
treated with water (250 mL) and DCM (250 mL). The phases were separated, the organic 
layer was washed with 0.1M HCl (1x) and brine (1x), dried over MgSO4, filtered and 
concentrated. The crude mixture was purified by column chromatography (PE/EA 19:1) and 
recrystallization (PE 2 mL/g) to obtain the product as a white solid (21.9 g, 81.5 mmol, 17% 
over two steps)
Rf = 0.56 (PE/EA 5:1). –
1H NMR (300 MHz, CDCl3) į = 6.65 – 6.58 (m, 1H), 4.33 – 4.18 
(m, 4H), 1.51 – 1.43 (m, 18H).
E. Experimental Part
110
di-tert-Butyl-(3R,4R)-4-(benzyl((S)-1-phenylethyl)amino)pyrrolidine-1,3-dicarboxylate
(78)33
In a flame dried flask under N2-atmosphere chiral amine (S)-19 (14.56 g, 68.9 mmol, 1.6 
equiv) was dissolved in THF (70 mL anhydrous) and cooled down to -78 °C in an 
acetone/CO2(s) bath. n-Butyllithium (40.0 mL, 64.5 mmol, 1.5  equiv) was added dropwise 
and the resulting pink solution was stirred for 15 min at this temperature. Then the mixture 
was cooled down to -95 °C in an acetone/N2(l) bath and 77 (11.60 g, 43 mmol, 1 equiv) in 
THF (20 mL anhydrous) was added dropwise. The mixture was stirred for 3 h at -78 °C 
before cooling down -95 °C again, followed by the dropwise addition of BHT (28.40 g, 129 
mmol, 3 equiv) in THF (15 mL anhydrous). The yellow mixture was stirred in the defrosting 
ice bath for 1.5 h, followed by the addition of Et2O (50 mL) and sat. NH4Cl solution (50 mL). 
The phases were separated and the aqueous phase was extracted with Et2O (3x). The 
combined organic layers were washed with 10% citric acid solution (1x), sat. NaHCO3
solution (1x) and brine (1x), dried over MgSO4, filtered and concentrated under reduced 
pressure. The crude was purified by column chromatography (PE/EA 19:1) to obtain the 
product as a white solid (5.24 g, 10.9 mmol, 25%).
Rf = 0.32 (PE/EA 5:1). –
1H NMR (300 MHz, CDCl3) į = 7.41 – 7.11 (m, 10H), 4.33 – 4.14 
(m, 1H), 4.04 – 3.89 (m, 1H), 3.66 – 3.17 (m, 6H), 3.12 – 3.02 (m, 1H), 1.45 (s, 9H), 1.43 –
1.33 (m, 11H) (signal doubling due to rotamers). – 13C NMR (101 MHz, CDCl3) į = 171.9, 
171.7, 154.4, 154.1, 141.9, 141.6, 141.2, 141.1, 128.23, 128.19, 128.1, 127.2, 127.1, 126.81, 
126.76, 81.02, 80.96, 79.2, 79.1, 62.6, 61.1, 57.7, 57.5, 51.9, 51.6, 48.4, 48.3, 47.7, 47.6, 47.3, 
28.52, 28.45, 28.2, 28.1, 17.4, 16.4 (signal doubling due to rotamers).
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di-tert-Butyl-(3R,4R)-4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)pyrrolidine-1,3-
dicarboxylate (85)46
Due to the maximal capacity of the applied autoclave vessel the amount of the used 
compound 78 (3.55 g, 7.38 mmol) was divided into three portions and the subsequent 
hydrogenation/Fmoc-protection sequence was performed for each. 
A solution of 78 (901 mg, 1.87 mmol) in MeOH (20 mL) and a catalytically amount of acetic 
acid was transferred into an autoclave, charged with Pd(OH)2 (180 mg, 20wt% based on 
starting material, 20% Pd on charcoal, 13.7 mol% Pd) and stirred rapidly at ambient 
temperature under 20 bar of hydrogen gas for 24 h. The mixture was filtered over a plug of 
celite, washed with MeOH and the solvent was removed under reduced pressure to obtain the 
crude product as a white solid (731 mg, 2.55 mmol, >100%).  
The crude was dissolved in water/dioxane (1:1, 10 mL each) and cooled down to 0 °C. 
NaHCO3 (439 mg, 5.23 mmol, 2.05 equiv) and FmocOSu (861 mg, 2.55 mmol, 1 equiv) was 
added and the mixture was stirred in the defrosting ice bath for 24 h. The solvent was 
removed under reduced pressure and the resulting white residue was treated with sat. NH4Cl 
solution (20 mL) and extracted with DCM (3x). The combined organic layers were dried over 
MgSO4, filtered and concentrated under reduced pressure. The crude was purified by column 
chromatography (PE/EA 5:1) to yield the product as a white fluffy solid (801 mg, 1.57 mmol, 
84% over two steps). In total 3.23 g (6.35 mmol, 86%) of 85 were obtained.
Rf = 0.15 (PE/EA 5:1). –
1H NMR (300 MHz, CDCl3) į = 7.76 (m, 2H), 7.64 – 7.54 (m, 2H), 
7.44 – 7.36 (m, 2H), 7.36 – 7.27 (m, 2H), 5.56 – 5.25 (m, 1H), 4.59 – 4.44 (m, 1H), 4.44 –
4.32 (m, 2H), 4.26 – 4.16 (m, 1H), 3.76 – 3.51 (m, 3H), 3.49 – 3.27 (m, 1H), 3.22 – 3.06 (m, 
1H), 1.46 (s, 9H), 1.44 (s, 9H) (signal broadening due to rotamers). – 13C NMR (75 MHz, 
CDCl3) į = 170.6, 170.1, 155.8, 154.3, 143.8, 141.3, 127.8, 127.6, 127.1, 125.0, 124.8, 120.0, 
82.3, 79.9, 67.1, 51.9, 51.5, 51.1, 50.4, 47.2, 47.1, 46.7, 46.1, 28.5, 28.0 (signal doubling due 
to rotamers). – HPLC analysis (Phenomenex Lux Cellulose-1, n-heptane/iPrOH 90:10, 1.0 
mL/min, 215 nm): tr = 23.57 min, 27.34 min, >99% ee.
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(3R,4R)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-carboxypyrrolidin-1-ium 
2,2,2-trifluoroacetate (187)46
85 (1.65 g, 3.24 mmol) was dissolved in DCM, TFA (10 mL) was added and the mixture was 
stirred at ambient temperature for 24 h. The volatiles were removed under reduced pressure 
und the resulting brown solid was dried under high vacuum for 24 h. Then the solid was 
dissolved in CHCl3 and n-pentane alternately and the solvent was removed under reduced 
pressure. This step was repeated 5 times each to obtain a pale fluffy solid (1.47 g, 3.15 mmol, 
97%). The product was used in the following step without further purification.
(3R,4R)-4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-1-(tert-
butoxycarbonyl)pyrrolidine-3-carboxylic acid (79)46
TFA salt 187 (2.14 g, 4.59 mmol, 1 equiv) was dissolved in water/dioxane (1:1, 20 mL each), 
NaHCO3 (1.93 g, 22.93 mmol, 5 equiv) was added and the mixture was cooled down to 0 °C. 
Subsequently Boc2O (1.50 g, 6.55 mmol, 1.5 equiv) in dioxane (20 mL) was added dropwise 
and the mixture was stirred at ambient temperature for 48 h. Afterwards, EA (10 mL) was 
added, the phases separated and the aqueous phase was extracted with EA (2x). The combined 
organic layers were back extracted with sat. NaHCO3 solution (1x) and the combined aqueous 
phases were acidified with 2M HCl to a pH of 2-3. The aqueous phase was extracted with EA 
(3x) and the combined organic layers were dried over MgSO4, filtered and the solvent was 
removed under reduced pressure. The crude was purified by column chromatography (PE/EA 
1:1 + 1 vol% AcOH) to obtain the product as a white fluffy solid (1.86 g, 4.07 mmol, 88%). 
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Rf = 0.46 (PE/EA 1:1 + AcOH). –
1H NMR (400 MHz, CDCl3) į = 7.79 – 7.68 (m, 2H), 7.62 
– 7.47 (m, 2H), 7.44 – 7.27 (m, 2H), 6.99 – 6.89 (m, 0.5H) + 5.83 – 5.61 (m, 0.5H), 4.65 –
4.44 (m, 2H), 4.43 – 4.29 (m, 1H), 4.29 – 4.13 (m, 1H), 4.12 – 3.96 (m, 0.5H), 3.85 – 3.51 (m, 
2H), 3.50 – 3.31 (m, 1H), 3.29 – 3.14 (m, 1H), 3.04 – 2.76 (m, 0.5H), 1.46 (s, 9H) (signal 
broadening and doubling due to rotamers). – 13C NMR (101 MHz, CDCl3) į = 175.0, 174.4, 
157.7, 156.2, 154.8, 154.3, 143.9, 143.7, 143.5, 141.3, 129.0, 128.9, 127.8, 127.2, 127.1, 
125.1, 124.9, 120.0, 80.5, 80.3, 68.0, 67.9, 67.2, 52.3, 51.9, 51.8, 51.4, 50.6, 50.0, 49.8, 47.21, 
47.1, 46.6, 46.2, 45.4, 45.1, 28.5 (signal doubling due to rotamers). – LRMS (ESI): m/z = 
397.1399 [M+H-C4H8]
+, 475.1837 [M+Na]+, 805.3443 [2M+H-C4H8]
+, 905.3964 [2M+Na]+.
di-tert-butyl-(3S,4S)-4-(benzyl((R)-1-phenylethyl)amino)pyrrolidine-1,3-dicarboxylate
((ent)-78)33
(ent)-78 was prepared in analogy to its enantiomer 78 by using chiral amine (R)-19 (8.79 g, 
41.58 mmol, 1.6 equiv), n-butyllithium (24.37 mL, 38.98 mmol, 1.5 equiv), 77 (7.00 g, 25.99 
mol, 1 equiv) and BHT (17.18 g, 77.97 mmol, 3 equiv). (ent)-78 (3.85 g, 8.01 mmol, 31%) 
was obtained as colorless sticky solid. Spectroscopic data were identical to those for its 
enantiomer 78. 
di-tert-Butyl-(3S,4S)-4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)pyrrolidine-1,3-
dicarboxylate ((ent)-85)46
(ent)-85 was prepared in analogy to its enantiomer 85 by using (ent)-78 (1.86 g, 3.88 mmol) 
and Pd(OH)2 (300 mg, 20wt% based on starting material, 20% Pd on charcoal, 11.0 mol% 
Pd). For the Fmoc protection NaHCO3 (668 mg, 7.95 mmol, 2.05 equiv) and FmocOSu (1.31 
g, 3.88 mmol, 1 equiv) were used. The product was obtained as a white fluffy solid (1.17 g, 
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2.3 mmol, 59% over two steps). Spectroscopic data were identical to those for its enantiomer 
85. – HPLC analysis (Phenomenex Lux Cellulose-1, n-heptane/iPrOH 90:10, 1.0 mL/min, 
215 nm): tr = 23.57 min, 27.34 min, >99% ee.
(3S,4S)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-carboxypyrrolidin-1-ium 
2,2,2-trifluoroacetate ((ent)-187)46
(ent)-187 was prepared in analogy to its enantiomer 187 by using (ent)-85 (2.65 g, 5.21 
mmol) and 10 mL TFA to obtain the product as a pale fluffy solid (2.30 g, 4.94 mmol, 94%). 
The spectroscopic data were identical to those for its enantiomer 187. 
(3S,4S)-4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-1-(tert-
butoxycarbonyl)pyrrolidine-3-carboxylic acid ((ent)-79)46
(ent)-79 was prepared in analogy to its enantiomer 79 by using (ent)-85 (2.05 g, 4.39 mmol), 
NaHCO3 (1.85 g, 21.97 mmol, 5 equiv) and Boc2O (1.44 g, 6.59 mmol, 1.5 equiv). The 
product was obtained as a white fluffy solid (1.69 g, 3.72 mmol, 85% over two steps). The 
spectroscopic data were identical to those for its enantiomer 79. – LRMS (ESI): m/z = 
397.1400 [M+H-C4H8]
+, 475.1837 [M+Na]+, 805.3454 [2M+H-C4H8]
+, 905.3977 [2M+Na]+.
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di-tert-Butyl adipate (87)24,239
Adipic acid (40.0 g, 273 mmol, 1 equiv) was treated carefully with SOCl2 (60 mL, 821 mmol, 
3 equiv) and stirred at 60 °C for 4 h. The solvent was removed under reduced pressure to 
yield the adipoyl chloride as a yellow residue (bp of product: 105 °C at 3 mbar). 
Adipoyl chloride was dissolved in Et2O (100 mL) and was added dropwise to an ice cold 
solution of tBuOH (78 mL, 841 mmol, 3 equiv) and N,N-dimethylaniline (104 mL, 821 mmol, 
3 equiv) in Et2O (200 mL). During the addition the color changed from yellow to purple. The 
mixture was stirred in the defrosting ice bath for 24 h, diluted with water and the phases were 
separated. The organic layer was washed with 1M HCl (2x), sat. NaHCO3 solution (2x), brine 
(1x), dried over MgSO4 and filtered. The solvent was removed under reduced pressure and 
remaining tBuOH was removed by distillation under ambient pressure. The product was 
obtained after distillation under reduced pressure (bp 130 °C at 1 mbar) as a colorless oil 
which crystallized after standing in the fridge (51.94 g, 201 mmol, 74% over two steps). 
1H NMR (300 MHz, CDCl3) į = 2.28 – 2.18 (m, 4H), 1.69 – 1.57 (m, 4H), 1.44 (s, 18H).
tert-Butyl 2-oxocyclopentane-1-carboxylate (88)24
NaH (12.7 g, 317 mmol, 2 equiv, 60% dispersion in mineral oil) was suspended in toluene 
(270 mL anhydrous) and heated up to 60 °C. A solution of 87 (41.0 g, 158 mmol, 1 equiv) in 
toluene (50 mL anhydrous) was added dropwise via additional funnel and the mixture was 
stirred for 3 h at 100 °C. The mixture was allowed to cool down to ambient temperature 
before being cooled down to 0 °C, followed by the dropwise addition of MeOH and water (5 
mL each). Sat. NH4Cl solution (50 mL) was added, the phases were separated and the organic 
layer was dried over MgSO4, filtered and concentrated. The product was purified by 
distillation under reduced pressure (bp. 55 °C at 0.1 mbar) to yield a colorless oil (24.3 g, 131 
mmol, 83%). 
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1H NMR (300 MHz, CDCl3) į = 3.09 – 3.00 (m, 1H), 2.32 – 2.06 (m, 5H), 1.93 – 1.77 (m, 
1H), 1.47 (s, 9H).
tert-Butyl cyclopent-1-ene-1-carboxylate (20)24
88 (20.80 g, 113 mmol, 1 equiv) was dissolved in EtOH (280 mL) and cooled down to 0 °C. 
NaBH4 (4.27 g, 113 mmol, 1 equiv) was added portionwise and the mixture was stirred at 
ambient temperature for 16 h. After cooling down to 0 °C, water was added till no 
precipitation of a white solid was observed. Sat. NH4Cl solution was added (350 mL, 
vigorous gas evolution) and the suspension was diluted with Et2O (300 mL). Phases were 
separated and the aqueous phase was extracted with Et2O (3x). The combined organic layers 
were dried over MgSO4, filtered and concentrated. 
The residue was dissolved in DCM (280 mL), cooled down to 0 °C and NEt3 (94 mL, 
677 mmol, 6 equiv) and DMAP (1.38 g, 11.3 mmol, 0.1 equiv) was added. A solution of 
MsCl (33.2 mL, 429 mmol, 3.8 equiv) in DCM (140 mL) was added dropwise and the 
mixture was stirred for 1 h at 0 °C, then at ambient temperature for 8 h. The mixture was 
diluted with water (400 mL), the phases were separated and the organic layer was washed 
with 1M HCl (1x), water (1x), sat. NaHCO3 (1x) and brine (1x). The organic phase was dried 
over MgSO4, filtered and the solvent was removed under reduced pressure. 
The residue was dissolved in DCM (280 mL) and cooled down to 0 °C, followed by the 
addition of a solution of DBU (22 mL, 147 mmol, 1.3 equiv) in DCM (22 mL). The mixture 
was stirred for 1 h at 0 °C, then for 3 h at ambient temperature. The mixture was washed with 
1 M HCl (1x) and brine (1x), dried over MgSO4, filtered and concentrated under reduced 
pressure. The product was obtained after distillation under reduced pressure (bp 100 °C at 
10 mbar) as a colorless oil (11.9 g, 70.6 mmol, 63% over three steps). 
1H NMR (300 MHz, CDCl3) į = 6.68 – 6.62 (m, 1H), 2.56 – 2.40 (m, 4H), 1.99 – 1.83 (m, 
2H), 1.52 – 1.40 (m, 9H).
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tert-Butyl-(1R,2S)-2-(benzyl((S)-1-phenylethyl)amino)cyclopentane-1-carboxylate (21)24
In a flame dried flask under N2-atmosphere chiral amine (S)-19 (13.8 g, 65.3 mmol, 1.6 equiv) 
was dissolved in THF (40 mL anhydrous) and cooled down to -78 °C by an acetone/CO2(s)
bath. n-Butyllithium (22.7 mL, 61.3 mmol, 1.5 equiv) was added dropwise and the resulting 
red solution was stirred for 15 min at this temperature. Then the mixture was cooled down to         
-95 °C by an acetone/N2(l) bath and 20 (6.9 g, 40.8 mmol, 1 equiv) in THF (15 mL anhydrous) 
was added dropwise. The mixture was stirred for 3 h at -78 °C before cooling down -95 °C 
again, followed by the dropwise addition of BHT (27.0 g, 122.5 mmol, 3 equiv) in THF (15 
mL anhydrous). The yellow mixture was stirred in the defrosting ice bath for 1.5 h, followed 
by the addition of Et2O (50 mL) and sat. NH4Cl solution (50 mL). The phases were separated 
and the aqueous phase was extracted with Et2O (3x). The combined organic layers were 
washed with 10% citric acid solution (1x), sat. NaHCO3 solution (1x) and brine (1x), dried 
over MgSO4, filtered and concentrated under reduced pressure. The crude was purified by 
column chromatography (PE/EA 30:1 ĺ WRREWDLQ WKHSURGXFWDV DSDOH \HOORZVROLG
(13.6 g, 35.7 mmol, 88%).
Rf = 0.47 (PE/EA 19:1). –
1H NMR (300 MHz, CDCl3) į = 7.46 – 7.14 (m, 10H), 4.31 (q, J =
6.8 Hz, 1H), 4.02 (d, J = 15.5 Hz, 1H), 3.52 (d, J = 15.5 Hz, 1H), 3.16 – 3.04 (m, 1H), 2.95 –
2.86 (m, 1H), 1.90 – 1.60 (m, 6H), 1.51 (s, 9H), 1.38 (d, J = 6.9 Hz, 3H). – 13C NMR (75 
MHz, CDCl3) į = 175.2, 143.0, 142.6, 128.13, 128.06, 128.0, 127.9, 126.8, 126.3, 80.0, 66.1, 
58.0, 51.8, 48.5, 29.1, 28.3, 27.5, 22.2, 17.5.
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(1R,2S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)cyclopentane-1-carboxylic acid 
(80)45
A solution of 21 (7.88 g, 20.76 mmol) in MeOH (30 mL) and acetic acid (10 mL) was 
transferred into an autoclave, charged with Pd/C (288 mg, 4wt% based on starting material, 
10% Pd on charcoal, 1.3 mol% Pd) and stirred rapidly at ambient temperature under 15 bar of 
hydrogen gas for 22 h. The mixture was filtered over a plug of celite, washed with MeOH and 
the solvent was removed under reduced pressure. 
The crude was dissolved in DCM (10 mL), TFA (10 mL) was added and the mixture was 
stirred at ambient temperature for 24 h. The volatiles were removed under reduced pressure 
and 2 M HCl (2 mL) was added. The precipitated solid was washed with cold Et2O (2x) and 
dried under high vacuum. 
The white solid was dissolved in water/dioxane (1:1, 70 mL each), NaHCO3 (3.58 g, 
42.56 mmol, 2.05 equiv) was added and the mixture was cooled down to 0 °C. FmocOSu 
(7.00 g, 20.76 mmol, 1 equiv) was added portionwise and the mixture was stirred in the 
defrosting ice bath for 48 h. The solvent was removed under reduced pressure, and the 
resulting white residue was treated with sat. NH4Cl solution (20 mL) and extracted with DCM 
(2x). The combined organic layers were dried over MgSO4, filtered and concentrated under 
reduced pressure. The crude was purified by column chromatography (DCM/MeOH 95:5) to 
obtain the product as a white fluffy solid (1.55 g, 4.41 mmol, 21% over three steps).
Rf = 0.54 (PE/EA 19:1). –
1H NMR (300 MHz, CDCl3) į = 7.75 (d, J = 7.5 Hz, 2H), 7.57 (d, 
J = 7.5 Hz, 2H), 7.47 – 7.26 (m, 4H), 7.07 – 6.94 (m, 0.5H) + 5.48 – 5.34 (m, 0.5H), 4.51 –
4.40 (m, 1H), 4.39 – 4.14 (m, 2H), 4.14 – 4.00 (m, 1H), 3.13 – 2.83 (m, 1H), 2.13 – 1.43 (m, 
6H) (signal doubling due to rotamers). – 13C NMR (101 MHz, CDCl3) į = 179.1, 178.3, 
158.2, 156.2, 143.9, 141.4, 127.8, 127.2, 125.1, 120.0, 67.8, 67.0, 55.6, 54.3, 47.1, 46.5, 32.1, 
31.8, 27.9, 27.4, 22.6, 22.0 (signal doubling due to rotamers). – >Į@૛૙ࡰ = -27.2 (c 0.5, CHCl3, 
lit240.: -29.0 c 0.5, CHCl3). 
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tert-Butyl (1S,2R)-2-(benzyl((R)-1-phenylethyl)amino)cyclopentane-1-carboxylate ((ent)-
21)24
(ent)-21 was prepared in analogy to its enantiomer 21 by using chiral amine (R)-19 (10.1 g, 
47.6 mmol, 1.6 equiv), n-butyllithium (16.5 mL, 44.6 mmol, 1.5 equiv), 20 (5.0 g, 29.7 mol, 1 
equiv) and BHT (19.7 g, 89.2 mmol, 3 equiv). (ent)-21 (9.0 g, 23.7 mmol, 80%) was obtained 
as colorless solid. Spectroscopic data were identical to those for its enantiomer 21. 
(1S,2R)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)cyclopentane-1-carboxylic acid 
((ent)-80)45
(ent)-80 was prepared in analogy to its enantiomer 80 by using (ent)-21 (6.95 g, 18.3 mmol), 
Pd/C (288 mg, 4wt% based on starting, 10% Pd on charcoal, 1.3 mol% Pd) and AcOH (10 
mL). For the tBu ester hydrolysis TFA (10 mL) was used. For the Fmoc protection NaHCO3 
(3.15 g, 37.5 mmol, 2.05 equiv) and FmocOSu (6.18 g, 18.3 mmol, 1 equiv) was used to 
obtain the product as a white fluffy solid (1.14 g, 3.3 mmol, 18% over three steps). 
Spectroscopic data were identical to those for its enantiomer 80. – >Į@૛૙ࡰ = +27.9 (c 0.5, 
CHCl3, lit
240.: +28.5, c 0.5, CHCl3). 
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(3S,4S)-4-(Benzyl((R)-1-phenylethyl)amino)pyrrolidine-3-carboxylic acid ((ent)-100)
(ent)-78 (875 mg, 1.8 mmol, 1 equiv) was dissolved in DCM (6 mL), TFA (2 mL) was added 
and the mixture was stirred at ambient temperature for 2.5 h. The solvent was removed under 
reduced pressure and the crude TFA salt was dissolved in 0.1 M HCl (4 mL). For removal of 
the counter ion the salt was loaded onto a column with DOWEX 50WX8-200 (2x4 cm, 2x 
activated with 0.1 M HCl). The column was washed with distilled water (200 mL) and the 
product was eluted with 16% NH3 (aq.) to obtain the free amino acid after lyophilization as a 
white fluffy solid (98 mg, 0.3 mmol, 17%). 
1H NMR (400 MHz, CDCl3 + TFA) į = 10.41 – 8.81 (m, 1H), 7.47 – 7.15 (m, 10H), 4.31 –
4.13 (m, 1H), 4.01 – 3.86 (m, 2H), 3.86 – 3.72 (m, 1H), 3.61 – 3.28 (m, 3H), 3.20 – 3.05 (m, 
1H), 2.66 – 2.50 (m, 1H), 1.56 – 1.35 (m, 3H). – 13C NMR (101 MHz, CDCl3 + TFA) į = 
175.1, 138.2, 136.01, 130.1, 129.5, 128.9, 128.8, 128.6, 128.3, 128.2, 127.6, 60.6, 58.9, 52.3, 
46.3, 44.5, 43.6, 13.4. – IR (neat): ৼ (cm-1) = 3026, 2974, 2363, 1617, 1572, 1494, 1449, 
1408, 1319, 1190, 1140, 1069, 969, 849, 786, 734, 700. – mp = 207 °C (decomposition). –
[Į]૛૙ࡰ = +3.1 (c 0.5, MeOH). – LRMS (ESI): m/z = 105.0700 [C8H8]+, 221.1291 [MH+ -C8H8], 
325.1914 [M+H]+. – HRMS (ESI): m/z = 325.1914 [M+H]+; calc. for [C20H25N2O2]
+ = 
325.1911. 
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General procedure for organocatalytic Mannich-type reaction under ambient- and high 
pressure conditions applying (ent)-100
Catalyst (ent)-100 (5 mg, 0.015 mmol, 0.1 equiv) was added to a solution of pentan-3-one 104
(160 µL, 1.5 mmol, 10 equiv) and imine 103 (31 mg, 0.15 mmol, 1 equiv) in the indicated 
solvent (1 mL) and stirred at ambient temperature for 23 h. The reaction was stopped by the 
addition of sat. NH4Cl solution (2 mL), the phases were separated and the aqueous was 
extracted with EA (2x). The combined organic layers were dried over MgSO4, filtered and the 
solvent was removed under reduced pressure. The crude was purified by column 
chromatography (PE/EA 9:1) and the product was analyzed by NMR and chiral HPLC.
For reactions under high pressure conditions apparatus II was used and the reaction mixture 
was transferred into a PTFE vial. Pressure was generated manually and maintained for the 
indicated time period. The reaction was performed without stirring. 
Ethyl (2S,3R)-2-((4-methoxyphenyl)amino)-3-methyl-4-oxohexanoate (105)60
Rf = 0.32 (PE/EA = 5:1). –
1H NMR (400 MHz, CDCl3) į = 6.76 (d, J = 9.0 Hz, 2H), 6.70 –
6.61 (m, 2H), 4.22 – 4.09 (m, 3H), 3.77 – 3.70 (m, 3H), 3.08 – 2.98 (m, 1H), 2.58 – 2.50 (m, 
2H), 1.24 – 1.19 (m, 3H), 1.19 – 1.16 (m, 3H), 1.08 – 1.02 (m, 3H). – HPLC analysis
(Chiracel AS-H, n-heptane/iPrOH 99:1, 1 mL/min, 254 nm) tr = 22.62 min (2S,3R, trans), 
29.52 min (2S, 3S cis), 31.76 min (3S,3R cis), 37.20 min (2R,3S trans). 
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tert-Butyl (3R,4R)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-((S)-2-
((benzyloxy)carbonyl)pyrrolidine-1-carbonyl)pyrrolidine-1-carboxylate (121)
According to literature procedure106 pyridine (107 µL, 1.33 mmol, 3 equiv) was added to a 
suspension of 79 (200 mg, 0.442 mmol, 1 equiv) and (L)-proline benzyl ester hydrochloride 
(118 mg, 0.486 mmol, 1.1 equiv) in EA (10 mL) at -10 °C. After stirring for 15 min, T3P (563 
mg, 50 wt% in EA, 0.884 mmol, 2 equiv) was added dropwise and the mixture was stirred for 
24 h in the defrosting ice bath. Water (10 mL) was added, the phases were separated and the 
aqueous phase was extracted with EA (3x). The combined organic layers were washed with 
brine (1x), dried over MgSO4, filtered and concentrated under reduced pressure. The crude 
was purified by column chromatography (PE/EA 1:2) to afford the product as a white fluffy 
solid (219 mg, 0.342 mmol, 77%). 
Rf = 0.51 (PE/EA 1:2). –
1H NMR (300 MHz, CDCl3) į = 7.76 (d, J = 7.5 Hz, 2H), 7.57 (d, 
J = 7.3 Hz, 2H), 7.44 – 7.26 (m, 4H), 6.01 – 5.61 (m, 1H), 5.29 – 5.03 (m, 2H), 4.60 – 4.45 
(m, 2H), 4.39 – 4.10 (m, 3H), 3.84 – 3.25 (m, 7H), 2.32 – 1.81 (m, 5H), 1.54 – 1.39 (m, 9H)
(signal doubling due to rotamers). – 13C NMR (101 MHz, CDCl3) į = 171.8, 171.5, 170.0, 
169.1, 156.1, 154.2, 143.8, 141.3, 135.6, 128.8, 128.6, 128.5, 128.4, 128.2, 127.8, 127.7, 
127.1, 125.5, 125.3, 125.2, 125.1, 120.05, 119.95, 79.9, 67.2, 67.0, 59.0, 47.3, 47.1, 29.0, 
28.5, 24.8 (signal doubling due to rotamers). – IR (neat): ৼ (cm-1) = 3302, 2974, 2885, 1692, 
1640, 1505, 1446, 1401, 1241, 1162, 1107, 1032, 916, 738, 697. – mp = 67 °C. – >Į@૛૙ࡰ = -
37.7 (c 1, DCM). – LRMS (ESI): m/z = 584.2394 [M+H-C4H8]
+, 640.3019 [M+H]+, 662.2837
[M+Na]+, 1301.5787 [2M+Na]+. – HRMS (ESI): m/z = 640.3019 [M+H]+; calc. for 
[C37H41N3O7]
+ = 640.3017. 
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tert-Butyl (3R,4R)-3-((S)-2-((benzyloxy)carbonyl)pyrrolidine-1-carbonyl)-4-((S)-1-
((benzyloxy)carbonyl)pyrrolidine-2-carboxamido)pyrrolidine-1-carboxylate (122)
N
HN
O
N
O
NBnO2C
Boc
Cbz
121 (317 mg, 0.495 mmol, 1 equiv) was dissolved in DMF (6 mL) at 0 °C, a solution of 
piperidine in DMF (750 µL, 20 vol%) was added dropwise and the mixture was stirred for 
15 min. The solvent was removed under reduced pressure and the resulting residue was 
dissolved in EA (10 mL) again. At -10 °C ((benzyloxy)carbonyl)-L-proline (148 mg, 
0.594 mmol, 1.2 equiv), pyridine (120 µL, 1.49 mmol, 3 equiv) and T3P (630 mg, 50 wt% in 
EA, 0.991 mmol, 2 equiv) were added and the mixture was stirred for 24 h in the defrosting 
ice bath. Water (10 mL) was added, the phases were separated and the aqueous phase was 
extracted with EA (3x). The combined organic layers were washed with brine (1x), dried over 
MgSO4, filtered and concentrated under reduced pressure. The crude was purified by column 
chromatography (DCM/MeOH 95:5) to yield the product as a white fluffy solid (180 mg, 
0.277 mmol, 56%) along with starting material (50 mg, 0.078 mmol, 16%, 72% brsm). 
Rf = 0.29 (DCM/MeOH 95:5). –
1H NMR (300 MHz, CDCl3) į = 7.41 – 7.24 (m, 10H), 5.24 
– 4.95 (m, 4H), 4.70 – 4.55 (m, 1.5H), 4.44 – 4.12 (m, 1.5H), 3.81 – 3.26 (m, 9H), 2.33 – 1.74 
(m, 8H), 1.49 – 1.38 (m, 9H) (signal doubling and broadening due to rotamers). – 13C NMR
(101 MHz, CDCl3) į = 172.5, 172.3, 172.0, 171.8, 171.4, 169.4, 168.6, 167.0, 156.4, 155.6, 
154.6, 154.2, 136.5, 135.7, 128.8, 128.6, 128.5, 128.3, 128.1, 79.8, 67.4, 66.8, 61.0, 59.1, 
53.7, 52.2, 51.7, 47.2, 47.0, 45.1, 43.6, 31.3, 29.8, 29.1, 28.5, 28.4, 27.3, 24.7, 24.4, 23.6, 22.3 
(signal doubling due to rotamers). – IR (neat): ৼ (cm-1) = 3298, 2974, 2881, 2355, 1744, 
1673, 1643, 1543, 1446, 1408, 1356, 1237, 1166, 1133, 1028, 984, 872, 738, 697. – mp = 62
°C. – >Į@૛૙ࡰ = -81.0 (c 1, DCM). – LRMS (ESI): m/z = 593.2610 [M+H-C4H8]+, 649.3241
[M+H]+, 671.3054 [M+Na]+, 1319.6221 [2M+Na]+. – HRMS (ESI): m/z = 649.3241 [M+H]+; 
calc. for [C35H45N4O8]
+ = 649.3232. 
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((3R,4R)-1-(tert-Butoxycarbonyl)-4-((S)-pyrrolidine-2-carboxamido)pyrrolidine-3-
carbonyl)-L-proline (118)
A solution of 122 (101 mg, 0.156 mmol) in MeOH (10 mL) was transferred into an autoclave, 
charged with Pd/C (10 mg, 10 wt% based on starting material, 10% Pd on charcoal, 6.3 mol% 
Pd) and stirred rapidly at ambient temperature under 40 bar of hydrogen gas for 24 h. After 
completion the mixture was filtered over a plug of celite, washed with MeOH and the solvent 
was removed under reduced pressure to obtain the pure product as a pale beige solid (66 mg, 
0.156 mmol, 99%).  
1H NMR (300 MHz, CD3OD) į = 4.31 – 4.13 (m, 1H), 4.13 – 4.01 (m, H), 3.93 – 3.81 (m, 
1H), 3.81 – 3.65 (m, 4H), 3.64 – 3.52 (m, 2H), 3.52 – 3.40 (m, 1H), 2.94 – 2.87 (m, 2H), 2.56 
– 2.43 (m, 1H), 2.41 – 1.82 (m, 8H), 1.47 (s, 9H) (signal doubling due to rotamers). –
13C NMR (75 MHz, CD3OD) į = 169.58, 168.6, 156.2, 156.1, 81.5, 81.4, 69.8, 60.8, 57.6, 
52.9, 52.7, 52.4, 41.1, 31.5, 31.0, 30.5, 28.8, 25.7, 25.0, 24.0, 23.9 (signal doubling due to 
rotamers). – IR (neat): ৼ (cm-1) = 3217, 2974, 2885, 1673, 1628, 1561, 1449, 1401, 1362, 
1252, 1162, 1047, 875, 767. – mp = 101-104 °C. – >Į@૛૙ࡰ = -51.1 (c 1, MeOH). – LRMS
(ESI): m/z = 425.2399 [M+H]+. – HRMS (ESI): m/z = 425.2399 [M+H]+; calc. for 
[C20H32N4O6]
+ = 425.2395. 
E. Experimental Part
125
tert-Butyl (3S,4S)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-((S)-2-
((benzyloxy)carbonyl)pyrrolidine-1-carbonyl)pyrrolidine-1-carboxylate (125)
Pyridine (214 µL, 2.65 mmol, 3 equiv) was added to a suspension of (ent)-79 (400 mg, 0.883
mmol, 1 equiv) and (L)-proline benzyl ester hydrochloride (235 mg, 0.972 mmol, 1.1 equiv) 
in EA (10 mL) at -10 °C. After stirring for 15 min, T3P (1.13 g, 50 wt% in EA, 1.77 mmol, 2 
equiv) was added dropwise and the mixture was stirred for 24 h in the defrosting ice bath. 
Water (10 mL) was added, the phases were separated and the aqueous phase was extracted 
with EA (3x). The combined organic layers were washed with brine (1x), dried over MgSO4, 
filtered and concentrated under reduced pressure. The crude was purified by column 
chromatography (PE/EA 1:2) to afford the product as a white fluffy solid (399 mg, 0.623 
mmol, 71%). 
Rf = 0.59 (PE/EA 1:2). –
1H NMR (300 MHz, CDCl3) į = 7.75 (d, J = 7.5 Hz, 2H), 7.65 (d, 
J = 7.4 Hz, 2H), 7.43 – 7.27 (m, 9H), 6.51 – 6.22 (m, 1H), 5.31 – 5.20 (m, 1H), 5.11 – 5.02 
(m, 1H), 4.77 – 4.52 (m, 2H), 4.46 – 4.29 (m, 2H), 4.25 – 4.14 (m, 1H), 3.82 – 3.60 (m, 3H), 
3.58 – 3.43 (m, 2H), 3.41 – 3.33 (m, 1H), 3.27 – 3.12 (m, 1H), 2.31 – 2.12 (m, 1H), 2.07 –
1.86 (m, 3H), 1.52 – 1.39 (m, 9H). – 13C NMR (101 MHz, CDCl3) į = 172.5, 170.2, 156.4, 
154.3, 144.0, 143.9, 143.8, 141.3, 135.3, 128.8, 128.7, 128.5, 128.2, 127.74, 127.71, 127.1, 
126.9, 125.4, 125.3, 120.04, 119.95, 79.6, 67.3, 67.1, 59.2, 51.8, 49.0, 47.5, 47.2, 46.9, 43.9, 
42.9, 40.9, 29.0, 28.5, 24.9 (signal doubling due to rotamers). – IR (neat): ৼ (cm-1) = 3313, 
2974, 2881, 1692, 1640, 1539, 1446, 1401, 1326, 1230, 1166, 1118, 1131, 875, 738, 697. –
mp = 87 °C. – >Į@૛૙ࡰ = -22.8 (c 1, DCM). – LRMS (ESI): m/z = 584.2405 [M+H-C4H8]+, 
640.3032 [M+H]+, 662.2849 [M+Na]+, 1301.5817 [2M+Na]+. – HRMS (ESI): m/z = 
640.3032 [M+H]+; calc. for [C37H41N3O7]
+ = 640.3017. 
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tert-Butyl (3S,4S)-3-((S)-2-((benzyloxy)carbonyl)pyrrolidine-1-carbonyl)-4-((S)-1-
((benzyloxy)carbonyl)pyrrolidine-2-carboxamido)pyrrolidine-1-carboxylate (126)
N
HN
O
N
O
NBnO2C
Boc
Cbz
125 (468 mg, 0.731 mmol, 1 equiv) was dissolved in DMF (4 mL) at 0 °C, a solution of 
piperidine in DMF (750µL, 20 vol%) was added dropwise and the mixture was stirred for 
20 min. The solvent was removed under reduced pressure and the resulting residue was 
dissolved in EA (10 mL) again. At -10 °C ((benzyloxy)carbonyl)-L-proline (218 mg, 
0.877 mmol, 1.2 equiv), pyridine (177 µL, 2.19 mmol, 3 equiv) and T3P (931 mg, 50 wt% in 
EA, 1.46 mmol, 2 equiv) were added and the mixture was stirred for 24 h in the defrosting ice 
bath. Water (10 mL) was added, the phases were separated and the aqueous phase was 
extracted with EA (3x). The combined organic layers were washed with brine (1x), dried over 
MgSO4, filtered and the solvent was removed under reduced pressure. The crude was purified 
by column chromatography (DCM/MeOH 98:2) to yield the product as a white fluffy solid 
(254 mg, 0.391 mmol, 54%).
Rf = 0.11 (DCM/MeOH 98:2). –
1H NMR (400 MHz, CDCl3) į = 7.43 – 7.26 (m, 10H), 5.27 
– 5.02 (m, 4H), 5.01 – 4.85 (m, 1H), 4.81 – 4.67 (m, 0.5H), 4.65 – 4.48 (m, 1H), 4.32 – 4.18 
(m, 1H), 3.97 – 3.83 (m, 0.5H), 3.76 – 3.25 (m, 7H), 3.25 – 3.06 (m, 1.5H), 2.28 – 1.74 (m, 
8H), 1.49 – 1.38 (m, 9H) (signal broadening and doubling due to rotamers). – 13C NMR
(101 MHz, CDCl3) į = 173.1, 172.8, 172.7, 170.4, 155.1, 154.8, 154.2, 153.9, 136.9, 135.3, 
128.8, 128.6, 128.5, 128.4, 128.1, 127.91, 127.85, 127.8, 79.7, 79.6, 67.3, 67.0, 66.9, 60.67, 
59.2, 58.9, 49.5, 49.3, 49.1, 48.9, 48.5, 47.7, 47.5, 47.1, 47.0, 46.9, 42.8, 42.5, 31.5, 31.2, 
30.6, 29.1, 28.9, 28.5, 25.0, 24.8, 24.4, 23.6 (signal doubling due to rotamers). – IR (neat): ৼ
(cm-1) = 3317, 2974, 2881, 1692, 1640, 1520, 1446, 1401, 1356, 1252, 1162, 1110, 984, 916, 
875, 738, 697. – mp = 50 °C. – >Į@૛૙ࡰ = -33.3 (c 1, DCM). – LRMS (ESI): m/z = 593.2614
[M+H-C4H8]
+, 649.3243 [M+H]+, 671.3057 [M+Na]+, 1319.6226 [2M+Na]+. – HRMS (ESI): 
m/z = 649.3243 [M+H]+; calc. for [C35H45N4O8]
+ = 649.3232. 
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((3S,4S)-1-(tert-butoxycarbonyl)-4-((S)-pyrrolidine-2-carboxamido)pyrrolidine-3-
carbonyl)-L-proline (127)
A solution of 126 (100 mg, 0.154 mmol) in MeOH (10 mL) was transferred into an autoclave, 
charged with Pd/C (10 mg, 10 wt% based on starting material, 10% Pd on charcoal, 6.1 mol% 
Pd) and stirred rapidly at ambient temperature under 40 bar of hydrogen gas for 24 h. After 
completion the mixture was filtered over a plug of celite, washed with MeOH and 
concentrated under reduced pressure to obtain the pure product as a pale white solid (64 mg, 
0.150 mmol, 98%).  
1H NMR (400 MHz, (CD3)2SO) į = 4.87 – 4.71 (m, 1H), 4.35 – 4.26 (m, 1H), 4.24 – 4.13 (m, 
1H), 3.57 – 3.25 (m, 7H), 3.24 – 3.05 (m, 2H), 2.87 – 2.73 (m, 1H), 2.30 – 2.15 (m, 1H), 2.05 
– 1.59 (m, 8H), 1.38 (s, 9H) (signal doubling due to rotamers). – 13C NMR (101 MHz, 
(CD3)2SO) į = 177.3, 170.5, 169.2, 169.1, 153.8, 153.7, 78.9, 78.8, 61.2, 58.1, 49.6, 49.0, 
48.8, 47.5, 47.3, 47.1, 46.1, 43.0, 42.0, 31.5, 29.9, 28.6, 24.7, 24.6 (signal doubling due to 
rotamers). – IR (neat): ৼ (cm-1) = 3400, 3200, 2974, 2881, 1677, 1625, 1576, 1449, 1394, 
1289, 1244, 1162, 1114, 1043, 879, 767. – mp = 149-150 °C. – >Į@૛૙ࡰ = -49.2 (c 1, MeOH). –
LRMS (ESI): m/z = 425.2401 [M+H]+, 849.4711 [2M+Na]+. – HRMS (ESI): m/z = 425.2401
[M+H]+; calc. for [C20H32N4O6]
+ = 425.2395. 
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Benzyl ((1R,2S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)cyclopentane-1-
carbonyl)-L-prolinate (128)
Pyridine (277 µL, 3.43 mmol, 3 equiv) was added to a suspension of 80 (402 mg, 1.14 mmol, 
1 equiv) and (L)-proline benzyl ester hydrochloride (304 mg, 1.26 mmol, 1.1 equiv) in EA (20 
mL) at -10 °C. After stirring for 15 min, T3P (1.46 g, 50 wt% in EA, 2.29 mmol, 2 equiv) was 
added dropwise and the mixture was stirred for 24 h in the defrosting ice bath. Water (10 mL) 
was added, the phases were separated and the aqueous phase was extracted with EA (3x). The 
combined organic layers were washed with brine (1x), dried over MgSO4, filtered and 
concentrated under reduced pressure. The crude was purified by column chromatography 
(PE/EA 1:2) to yield the product as a white fluffy solid (450 mg, 0.83 mmol, 73%). 
Rf = 0.59 (PE/EA 1:2). –
1H NMR (300 MHz, CDCl3) į = 7.76 (d, J = 7.4 Hz, 2H), 7.62 –
7.55 (m, 2H), 7.44 – 7.28 (m, 9H), 5.76 (d, J = 9.2 Hz, 1H), 5.27 (d, J = 12.3 Hz, 1H), 5.10 (d, 
J = 12.3 Hz, 1H), 4.51 (dd, J = 8.2, 4.1 Hz, 1H), 4.40 – 4.14 (m, 4H), 3.66 – 3.55 (m, 2H), 
3.20 – 3.07 (m, 1H), 2.21 – 1.71 (m, 11H), 1.65 – 1.47 (m, 1H) (signal doubling due to 
rotamers). – 13C NMR (75 MHz, CDCl3) į = 173.0, 172.2, 156.2, 144.1, 144.0, 141.3, 135.8, 
128.8, 128.6, 128.4, 128.2, 127.8, 127.1, 125.3, 125.2, 120.0, 67.0, 66.9, 58.9, 53.9, 47.24, 
47.19, 44.9, 33.1, 29.2, 28.5, 24.9, 22.9. – IR (neat): ৼ (cm-1) = 3313, 3063, 3034, 2952, 2873, 
1714, 1632, 1505, 1438, 1382, 1326, 1237, 1166, 1088, 1028, 913, 738. – mp = 42 °C. –
>Į@૛૙ࡰ = -69.8 (c 1, DCM). – LRMS (ESI): m/z = 539.2549 [M+H]+, 561.2358 [M+Na]+,
1099.4831 [2M+Na]+. – HRMS (ESI): m/z = 539.2548 [M+H]+; calc. for [C33H35N2O5]
+ = 
539.2540. 
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Benzyl ((1S,2R)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)cyclopentane-1-
carbonyl)-L-prolinate (130) 
Pyridine (275 µL, 3.41 mmol, 3 equiv) was added to a suspension of (ent)-80 (40 mg, 1.14
mmol, 1 equiv) and (L)-proline benzyl ester hydrochloride (303 mg, 1.25 mmol, 1.1 equiv) in 
EA (20 mL) at -10 °C. After stirring for 15 min, T3P (1.45 g, 50 wt% in EA, 2.28 mmol, 2 
equiv) was added dropwise and the mixture was stirred for 24 h in the defrosting ice bath. 
Water (10 mL) was added, the phases were separated and the aqueous phase was extracted 
with EA (3x). The combined organic layers were washed with brine (1x), dried over MgSO4, 
filtered and concentrated under reduced pressure. The crude was purified by column 
chromatography (PE/EA 2:1) to yield the product as a white fluffy solid (374 mg, 0.69 mmol, 
61%). 
Rf = 0.19 (PE/EA 2:1). –
1H NMR (400 MHz, CDCl3) į = 7.75 (d, J = 7.5 Hz, 2H), 7.69 –
7.60 (m, 2H), 7.45 – 7.19 (m, 9H), 6.13 (d, J = 9.0 Hz, 1H), 5.24 (d, J = 12.3 Hz, 1H), 5.07 (d, 
J = 12.3 Hz, 1H), 4.59 – 4.52 (m, 1H), 4.43 – 4.29 (m, 3H), 4.27 – 4.14 (m, 1H), 3.72 – 3.64 
(m, 1H), 3.54 – 3.41 (m, 1H), 3.22 – 3.11 (m, 1H), 2.25 – 2.14 (m, 1H), 2.12 – 2.03 (m, 1H), 
1.99 – 1.49 (m, 11H) (signal doubling due to rotamers). – 13C NMR (101 MHz, CDCl3) į = 
172.93, 172.88, 172.7, 172.5, 158.0, 156.5, 144.3, 144.2, 141.8, 141.7, 141.3, 140.8, 135.6, 
135.5, 130.1, 130.1, 130.01, 129.98, 128.7, 128.6, 128.42, 128.39, 128.3, 128.2, 127.8, 
127.64, 127.61, 127.6, 127.09, 127.06, 127.04, 126.96, 126.91, 126.88, 126.85, 126.82, 125.5, 
125.4, 120.02, 119.99, 119.9, 67.23, 67.15, 67.1, 66.8, 64.6, 59.6, 59.1, 59.0, 55.2, 55.0, 
47.54, 47.47, 47.3, 47.1, 44.12, 44.07, 32.0, 31.9, 29.1, 27.6, 27.1, 25.0, 22.3, 22.1 (signal 
doubling due to rotamers). – IR (neat): ৼ (cm-1) = 3324, 3063, 3034, 2952, 2873, 1714, 1632, 
1520, 1435, 1349, 1323, 1237, 1170, 1080, 1028, 909, 738. – mp = 44 °C. – >Į@૛૙ࡰ = -8.8 (c 1, 
DCM). – LRMS (ESI): m/z = 539.2549 [M+H]+, 561.2360 [M+Na]+, 1099.4829 [2M+Na]+. –
HRMS (ESI): m/z = 539.2549 [M+H]+; calc. for [C33H35N2O5]
+ = 539.2540. 
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Methyl (1S,2R)-2-(benzyl((R)-1-phenylethyl)amino)cyclopentane-1-carboxylate ((ent)-
134)
(ent)-21 (515 mg, 1.36 mmol, 1 equiv) and Et3SiH (433 µL, 2.71 mmol, 2 equiv) were 
dissolved in DCM (4 mL) at 0 °C, TFA (2 mL) was added and the mixture was stirred in the 
defrosting ice bath for 24 h. The volatiles were removed under reduced pressure and the 
resulting residue was dried under high vacuum for 12 h. The crude was dissolved in DCM 
(6 mL anhydrous) and DMAP (33.2 mg, 0.27 mmol, 0.2 equiv) and MeOH (165 µL
anhydrous, 4.07 mmol, 3 equiv) were added. A solution of DCC (294 mg, 1.43 mmol, 
1.05 equiv) in DCM (2 mL anhydrous) was added dropwise at 0 °C and the mixture was 
stirred for 48 h at ambient temperature. The precipitate was filtered off, washed with DCM 
and the solvent was removed under reduced pressure. The crude was purified by column 
chromatography (PE/EA 50:1) to yield the product as a colorless oil (194 mg, 0.57 mmol,    
42% over two steps). 
Rf = 0.6 (PE/EA 9:1). –
1H NMR (300 MHz, CDCl3) į = 7.44 – 7.15 (m, 10H), 4.10 (q, 
J = 6.9 Hz, 1H), 3.86 (d, J = 14.9 Hz, 1H), 3.67 (s, 1H), 3.31 – 3.19 (m, 1H), 2.90 (td, J =
8.0, 4.5 Hz, 1H), 1.96 – 1.47 (m, 6H), 1.34 (d, J = 6.9, 3H). – 13C NMR (75 MHz, CDCl3) į = 
178.0, 143.2, 142.1, 128.1, 128.11, 128.08, 127.99, 126.7, 126.5, 64.3, 57.2, 51.7, 51.4, 47.5, 
28.5, 27.4, 22.9, 15.19. – IR (neat): ৼ (cm-1) = 3060, 3026, 2952, 2870, 1725, 1494, 1449, 
1367, 1293, 1241, 1196, 1162, 1073, 1028, 965, 909, 842, 812, 734. – >Į@૛૙ࡰ = +73.3 (c 1, 
DCM). – LRMS (ESI): m/z = 338.2139 [M+H]+. – HRMS (ESI): m/z = 338.2116 [M+H]+; 
calc. for [C22H28NO2]
+ = 338.2115. 
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tert-Butyl (1S,2R)-2-(1H-imidazole-1-carboxamido)cyclopentane-1-carboxylate (138)
According to literature procedure110 1,1'-carbonyldiimidazole (325 mg, 2.00 mmol, 1.5 equiv) 
was dissolved in DCM (15 mL) and cooled down to -10 °C by the use of a cryostat. A 
solution of (ent)-132 (247 mg, 1.34 mmol, 1 equiv) and DIPEA (233 µL, 1.34 mmol, 1 equiv) 
in DCM (3 mL) was added dropwise by an additional funnel over a period of 30 min and the 
mixture was stirred for 20 h at -10 °C. Water was added, the phases were separated and the 
aqueous phase was extracted with DCM (1x). The combined organic layers were dried over 
MgSO4, filtered and the solvent was removed under reduced pressure (cooling trap/high 
vacuum) at ambient temperature. The product was obtained as a white solid (189 mg, 
0.67 mmol, 51%). 
Rf = 0.14 (PE/EA 1:1). –
1H NMR (300 MHz, CDCl3) į = 8.12 (s, 1H), 7.52 (d, J = 7.6 Hz, 
1H), 7.37 – 7.31 (m, 1H), 6.99 (s, 1H), 4.46 – 4.32 (m, 1H), 2.98 – 2.83 (m, 1H), 2.05 – 1.85 
(m, 3H), 1.83 – 1.67 (m, 2H), 1.63 – 1.46 (m, 1H), 1.36 – 1.28 (m, 9H). – 13C NMR (75 
MHz, CDCl3) į = 174.3, 148.5, 136.1, 130.2, 115.9, 81.5, 53.6, 46.9, 31.9, 28.5, 27.9, 22.3. –
IR (neat): ৼ (cm-1) = 3544, 3198, 3123, 2974, 2873, 1718, 1666, 1513, 1476, 1364, 1319, 
1285, 1244, 1218, 1144, 1099, 1066, 1010, 842, 745. – mp = 73-75 °C. – >Į@૛૙ࡰ = +10.9 (c 1, 
DCM). – LRMS (ESI): m/z = 280.1659 [M+H]+. 
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di-tert-Butyl 2,2'-(carbonylbis(azanediyl))(1S,1'S,2R,2'R)-bis(cyclopentane-1-
carboxylate) (139)
1,1'-Carbonyldiimidazole (533 mg, 3.29 mmol, 1.0 equiv) was dissolved in DCM (6 mL)  and 
cooled down to 0 °C. A solution of (ent)-132 (609 mg, 3.29 mmol, 1 equiv) and DIPEA 
(573 µL, 3.29 mmol, 1 equiv) in DCM (12 mL) was added dropwise via additional funnel 
over a period of 30 min and the mixture was stirred for 20 h in the defrosting ice bath. Water 
was added, the phases were separated and the aqueous phase was extracted with DCM (1x). 
The combined organic layers were dried over MgSO4, filtered and the solvent was removed 
under reduced pressure. The product was obtained as a white solid (350 mg, 1.25 mmol, 
38%). 
Rf = 0.64 (PE/EA 1:1). –
1H NMR (300 MHz, CDCl3) į = 4.96 (d, J = 8.4 Hz, 2H), 4.33 –
4.22 (m, 2H), 2.88 – 2.74 (m, 2H), 1.91 – 1.45 (m, 12H), 1.42 – 1.32 (m, 18H). – 13C NMR
(75 MHz, CDCl3) į = 174.2, 156.7, 80.5, 53.2, 47.5, 32.7, 28.1, 27.8, 22.2. – IR (neat): 
ৼ (cm-1) = 3302, 2974, 2870, 2363, 1722, 1632, 1558, 1364, 1215, 1148, 943, 898, 846. – mp
= 160-162 °C. – >Į@૛૙ࡰ = +55.4 (c 1, DCM). – LRMS (ESI): m/z = 397.2702 [M+H]+,
419.2514 [M+Na]+, 815.5130 [2M+Na]+. – HRMS (ESI): m/z = 397.2702 [M+H]+; calc. for 
[C21H37N2O5]
+ = 397.2697. 
(1R,2S)-2-(((Allyloxy)carbonyl)amino)cyclopentane-1-carboxylic acid (144)
Hydrochloride salt 22 (1.18, 7.14 mmol, 1 equiv) was dissolved in water/dioxane (1:1, 20 mL 
each), NaHCO3 (2.40 g, 28.56 mmol, 4 equiv) was added and the mixture was cooled down to 
0 °C. Subsequently, AllocCl (1.14 mL, 10.71 mmol, 1.5 equiv) in dioxane (20 mL) was added 
dropwise and the mixture was stirred at ambient temperature for 48 h. Afterwards, EA (10 
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mL) was added, the phases were separated and the aqueous phase was extracted with EA (2x). 
The combined organic layers were back extracted with sat. NaHCO3 solution (1x) and the 
combined aqueous phases were acidified to a pH of 2-3 by the addition of 2M HCl. The 
aqueous phase was extracted with EA (3x) and the combined organic layers were dried over 
MgSO4, filtered and the solvent was removed under reduced pressure. The crude was purified 
by column chromatography (DCM/MeOH 19:1) to obtain the product as a colorless oil (458 
mg, 2.15 mmol, 30%). 
Rf = 0.51 (DCM/MeOH 9:1). –
1H NMR (400 MHz, CDCl3) į = 10.67 – 10.07 (m, 1H), 7.00 
– 6.81 (m, 0.5H) + 5.58 – 5.41 (m, 0.5H), 5.98 – 5.80 (m, 1H), 5.37 – 5.13 (m, 2H), 4.57 (d, 
J = 25.1 Hz, 1H), 4.29 – 4.10 (m, 1H), 3.11 – 2.92 (m, 1H), 2.12 – 1.34 (m, 6H). – 13C NMR
(101 MHz, CDCl3) į = 179.3, 178.4, 177.8, 163.6, 158.0, 155.9, 153.8, 132.8, 132.4, 130.9, 
119.9, 117.8, 67.8, 66.4, 65.7, 55.2, 54.2, 52.0, 46.4, 45.6, 32.0, 31.7, 29.4, 28.3, 27.9, 27.4, 
24.0, 22.6, 21.9 (signal doubling due to rotamers). – IR (neat): ৼ (cm-1) = 3309, 3086, 2955, 
2877, 1699, 1513, 1449, 1400, 1334, 1222, 1162, 1058, 991, 924, 775. – >Į@૛૙ࡰ = -45.0 (c 1, 
CHCl3). – LRMS (ESI): m/z = 196.0971 [M+H-H2O]
+, 214.1077 [M+H]+, 236.0897
[M+Na]+, 449.1885 [2M+Na]+. – HRMS (ESI): m/z = 214.1077 [M+H]+; calc. for 
[C10H16NO4]
+ = 214.1074.
(1S,2R)-2-(((Allyloxy)carbonyl)amino)cyclopentane-1-carboxylic acid ((ent)-144)
(ent)-144 was synthesized in analogy to its enantiomer 144 by using (ent)-22 (483 mg, 2.92 
mmol, 1 equiv), NaHCO3 (981 mg, 11.68 mmol, 4 equiv) and AllocCl (467 µL, 4.38 mmol, 
1.5 equiv) to yield the product as a colorless oil (378 mg, 0.17 mmol, 65%). Spectroscopic 
data were identical to those for its enantiomer 144. – >Į@૛૙ࡰ = +40.0 (c 1, CHCl3).
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Benzyl ((1R,2S)-2-(((allyloxy)carbonyl)amino)cyclopentane-1-carbonyl)-L-prolinate 
(145)
Pyridine (572 µL, 6.44 mmol, 3 equiv) was added to a suspension of 144 (458 mg, 2.15
mmol, 1 equiv) and (L)-proline benzyl ester hydrochloride (571 mg, 2.36 mmol, 1.1 equiv) in 
EA (20 mL) at -10 °C. After stirring for 15 min, T3P (2.73 g, 50 wt% in EA, 2.36 mmol, 2 
equiv) was added dropwise and the mixture was stirred for 24 h in the defrosting ice bath. 
Water (10 mL) was added, the phases were separated and the aqueous phase was extracted 
with EA (3x). The combined organic layers were washed with brine (1x), dried over MgSO4, 
filtered and concentrated under reduced pressure. The crude was purified by column 
chromatography (DCM/MeOH 9:1) to yield the product as a colorless oil (576 mg, 1.44 
mmol, 67%). 
Rf = 0.73 (DCM/MeOH 9:1). –
1H NMR (300 MHz, CDCl3) į = 7.40 – 7.27 (m, 5H), 5.97 –
5.78 (m, 1H), 5.68 – 5.54 (m, 1H), 5.32 – 5.01 (m, 4H), 4.50 (d, J = 5.9 Hz, 3H), 4.29 – 4.15 
(m, 1H), 3.67 – 3.54 (m, 2H), 3.08 (dd, J = 14.8, 7.8 Hz, 1H), 2.23 – 1.45 (m, 12H) (signal 
doubling due to rotamers). – 13C NMR (75 MHz, CDCl3) į = 172.8, 172.1, 155.9, 135.7, 
133.0, 128.7, 128.5, 128.3, 128.2, 117.4, 77.5, 77.3, 77.1, 76.7, 66.8, 65.3, 58.8, 53.7, 47.1, 
44.9, 33.0, 29.10, 28.3, 24.8, 22.7. – IR (neat): ৼ (cm-1) = 3309, 2955, 2877, 1714, 1632, 
1502, 1435, 1326, 1237, 1162, 1092, 1043, 995, 920, 738, 700. – >Į@૛૙ࡰ = +94.6 (c 1, DCM). –
LRMS (ESI): m/z = 401.2073 [M+H]+, 423.1894 [M+Na]+, 823.3891 [2M+Na]+. – HRMS
(ESI): m/z = 401.2073 [M+H]+; calc. for [C22H29N2O5]
+ = 401.2071.
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Benzyl (S)-2-(((1S,2R)-2-((S)-2-((benzyloxy)carbonyl)pyrrolidine-1-
carbonyl)cyclopentyl)carbamoyl)pyrrolidine-1-carboxylate (129) 
According to literature procedure113 in a flame dried Schlenk flask under N2-atmosphere 
((benzyloxy)carbonyl)-L-proline (500 mg, 2.01 mmol, 3 equiv) was activated by stirring in 
DCM (10 mL anhydrous, degassed) with EDC·HCl (385 mg, 2.01 mmol, 3 equiv) and 
HOBt·H2O (307 mg, 2.01 mmol, 3 equiv) for 1 h at 0 °C and for 1 h at ambient temperature. 
This solution was added to a Schlenk-flask charged with Pd(PPh3)4 (77 mg, 0.067 mmol, 
0.1 equiv), followed by the addition of 145 (268 mg, 0.699 mmol, 1 equiv) in DCM (6 mL 
anhydrous, degassed). Finally, DABCO (375 mg, 3.55 mmol, 5 equiv) was added and the 
mixture was stirred at ambient temperature for 20 min. After dilution with DCM, the organic 
phase was washed with sat. NaHCO3 (1x), sat. KHSO4 (1x) and sat. NaHCO3 (1x), dried over 
MgSO4, filtered and concentrated under reduced pressure. The crude was purified by column 
chromatography (DCM/MeOH 50:1) to yield the product as a white fluffy solid (224 mg, 
0.409 mmol, 61%).
Rf = 0.23 (EA). –
1H NMR (400 MHz, CDCl3) į = 7.35 – 6.97 (m, 12H), 5.23 – 4.90 (m, 4H), 
4.61 – 4.26 (m, 2H), 4.24 – 4.07 (m, 1H), 3.64 – 3.22 (m, 4H), 3.14 – 2.87 (m, 1H), 2.27 –
1.37 (m, 16H) (signal doubling due to rotamers). – 13C NMR (101 MHz, CDCl3) į = 172.7, 
172.5, 172.2, 171.8, 171.5, 155.4, 154.5, 136.6, 135.8, 132.1, 132.01, 131.96, 128.7, 128.6, 
128.5, 128.4, 128.2, 128.02, 127.95, 127.7, 127.1, 67.2, 66.7, 66.6, 61.1, 60.8, 58.8, 58.6, 
51.4, 47.3, 47.2, 47.0, 44.9, 44.8, 33.4, 32.9, 31.2, 30.0, 29.2, 28.9, 28.7, 24.8, 24.6, 24.3, 
23.6, 23.1, 22.9, 22.4 (signal doubling due to rotamers). – IR (neat): ৼ (cm-1) = 3324, 2955, 
2877, 1744, 1703, 1669, 1632, 1513, 1412, 1353, 1267, 1241, 1162, 1118, 1028, 984, 916, 
745, 697. – mp = 90-91 °C. – >Į@૛૙ࡰ = -111.0 (c 1, DCM). – LRMS (ESI): m/z = 548.2761 
[M+H]+, 570.2577 [M+Na]+, 1117.5252 [2M+Na]+. – HRMS (ESI): m/z = 548.2761 [M+H]+; 
calc. for [C31H38N3O6]
+ = 548.2755.
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((1R,2S)-2-((S)-Pyrrolidine-2-carboxamido)cyclopentane-1-carbonyl)-L-proline (119)
A solution of 129 (181 mg, 0.331 mmol) in MeOH (20 mL) was transferred into an autoclave, 
charged with Pd/C (36 mg, 20 wt% based on starting material, 10% Pd on charcoal, 10.2 
mol% Pd) and stirred rapidly at ambient temperature under 40 bar of hydrogen gas for 24 h. 
After completion the mixture was filtered over a plug of celite, washed with MeOH and 
concentrated under reduced pressure to obtain the pure product as a pale golden solid (104 
mg, 0.321 mmol, 97%).  
1H NMR (300 MHz, CDCl3) į = 4.59 – 4.42 (m, 1H), 4.40 – 4.16 (m, 2H), 3.68 – 3.55 (m, 
1H), 3.55 – 3.33 (m, 2H), 3.32 – 3.20 (m, 1H), 3.15 – 2.98 (m, 1H), 2.49 – 1.38 (m, 14H). –
13C NMR (75 MHz, CDCl3) į = 178.0, 176.3, 173.4, 172.2, 170.1, 168.2, 62.3, 60.9, 59.8, 
59.4, 52.3, 51.8, 47.6, 46.7, 45.7, 45.4, 44.6, 33.7, 32.8, 31.7, 30.9, 29.8, 29.7, 29.5, 28.6, 
25.0, 24.8, 24.5, 23.6, 23.3, 23.0 (signal doubling due to rotamers). – IR (neat): ৼ (cm-1) = 
3257, 3056, 2952, 2873, 1669, 1606, 1442, 1386, 1334, 1293, 1192, 1047, 976, 920, 875, 745, 
663. – mp =  95-110 °C. – >Į@૛૙ࡰ = -92.7 (c 1, DCM). – LRMS (ESI): m/z = 324.1923
[M+H]+, 647.3760 [2M+H]+. – HRMS (ESI): m/z = 324.1923 [M+H]+; calc. for 
[C16H26N3O4]
+ = 324.1918. 
Benzyl ((1S,2R)-2-(((allyloxy)carbonyl)amino)cyclopentane-1-carbonyl)-L-prolinate 
(146)
Pyridine (303 µL, 3.45 mmol, 3 equiv) was added to a suspension of (ent)-144 (245 mg, 1.15
mmol, 1 equiv) and (L)-proline benzyl ester hydrochloride (306 mg, 1.26 mmol, 1.1 equiv) in 
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EA (20 mL) at -10 °C. After stirring for 15 min, T3P (1.46 g, 50 wt% in EA, 2.3 mmol, 2 
equiv) was added dropwise and the mixture was stirred for 24 h in the defrosting ice bath. 
Water (10 mL) was added, the phases were separated and the aqueous phase was extracted 
with EA (3x). The combined organic layers were washed with brine (1x), dried over MgSO4, 
filtered and concentrated under reduced pressure. The crude was purified by column 
chromatography (DCM/MeOH 9:1) to yield the product as a colorless oil (313 mg, 
0.781 mmol, 68%).
Rf = 0.86 (DCM/MeOH 9:1). –
1H NMR (300 MHz, CDCl3) į = 7.42 – 7.28 (m, 5H), 6.00 –
5.78 (m, 2H), 5.35 – 5.09 (m, 5H), 4.65 – 4.43 (m, 3H), 4.36 – 4.23 (m, 1H), 3.75 – 3.60 (m, 
1H), 3.57 – 3.41 (m, 1H), 3.21 – 3.06 (m, 1H), 2.30 – 1.46 (m, 14H) (signal doubling due to 
rotamers). – 13C NMR (75 MHz, CDCl3) į = 172.8, 172.7, 172.3, 172.2, 171.8, 169.6, 164.3, 
156.2, 136.0 135.7, 135.3, 133.2, 131.7, 128.6, 128.51, 128.47, 128.3, 128.2, 128.11, 128.05, 
127.9, 118.9, 117.3, 117.0, 67.5, 67.1, 66.8, 66.3, 65.2, 61.3, 59.5, 59.0, 58.6, 54.7, 53.7, 51.6, 
48.0, 47.3, 46.8, 46.3, 45.7, 44.1, 33.4, 31.9, 29.6, 29.3, 29.0, 28.8, 27.2, 24.9, 23.2, 22.5, 22.0
(signal doubling due to rotamers). – IR (neat): ৼ (cm-1) = 3824, 2952, 2877, 1714, 1632, 
1509, 1431, 1382, 1323, 1233, 1162, 1092, 1028, 991, 816, 749, 700. – >Į@૛૙ࡰ = -9.5 (c 1, 
DCM). – LRMS (ESI): m/z = 401.2076 [M+H]+, 823.3886 [2M+Na]+. – HRMS (ESI): m/z = 
401.2076 [M+H]+; calc. for [C22H29N2O5]
+ = 401.2071.
Benzyl (S)-2-(((1R,2S)-2-((S)-2-((benzyloxy)carbonyl)pyrrolidine-1-
carbonyl)cyclopentyl)carbamoyl)pyrrolidine-1-carboxylate (131)
According to literature procedure113 in a flame dried Schlenk flask under N2-atmosphere 
((benzyloxy)carbonyl)-L-proline (295 mg, 1.18 mmol, 3 equiv) was activated by stirring in 
DCM (10 mL anhydrous, degassed) with EDC·HCl (227 mg, 1.18 mmol, 3 equiv) and 
HOBt·H2O (181 mg, 1.18 mmol, 3 equiv) for 1 h at 0 °C and for 1 h at ambient temperature. 
This solution was added to a Schlenk-flask charged with Pd(PPh3)4 (46 mg, 0.039 mmol, 
0.1 equiv), followed by the addition of 146 (158 mg, 0.394 mmol, 1 equiv) in DCM (6 mL 
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anhydrous, degassed). Finally, DABCO (221 mg, 1.97 mmol, 5 equiv) was added and the 
mixture was stirred at ambient temperature for 20 min. After dilution with DCM, the organic 
phase was washed with sat. NaHCO3 (1x), sat. KHSO4 (1x) and sat. NaHCO3 (1x), dried over 
MgSO4, filtered and concentrated under reduced pressure. The crude was purified by column 
chromatography (DCM/MeOH 50:1) to yield the product as a colorless oil (188 mg, 0.343 
mmol, 87%).
Rf = 0.32 (DCM/MeOH 19:1). –
1H NMR (300 MHz, CDCl3) į = 7.39 – 7.24 (m, 12H), 5.26 
– 4.94 (m, 5H), 4.68 – 4.36 (m, 2H), 4.35 – 4.18 (m, 1.5H), 3.89 – 3.75 (m, 0.5H), 3.65 – 3.30 
(m, 4H), 3.29 – 3.17 (m, 0.5H), 3.17 – 2.88 (m, 1H), 2.81 – 2.63 (m, 0.5H), 2.28 – 1.40 (m, 
17H) (signal doubling due to rotamers). – 13C NMR (75 MHz, CDCl3) į = 173.0, 172.6, 
172.2, 155.01, 154.96, 137.0, 136.9, 135.5, 135.4, 132.1, 132.00, 131.98, 131.9, 128.66, 
128.59, 128.5, 128.4, 128.3, 128.0, 127.8, 127.7, 67.1, 67.0, 66.9, 66.8, 60.8, 59.5, 59.1, 58.8, 
52.6, 51.7, 47.6, 47.5, 47.1, 46.8, 46.4, 46.0, 43.7, 33.4, 32.0, 31.5, 31.2, 30.5, 29.1, 29.0, 
27.8, 27.2, 25.0, 24.8, 24.3, 23.6, 23.3, 22.5, 22.2. – IR (neat): ৼ (cm-1) = 3332, 2955, 2877, 
1736, 1703, 1632, 1513, 1408, 1353, 1170, 1114, 1028, 984, 916, 745, 697. – >Į@૛૙ࡰ = -32.9 (c
1, DCM). – LRMS (ESI): m/z = 548.2765 [M+H]+, 570.2586[M+Na]+. – HRMS (ESI): m/z = 
548.2765 [M+H]+; calc. for [C31H38N3O6]
+ = 548.2755.
((1S,2R)-2-((S)-Pyrrolidine-2-carboxamido)cyclopentane-1-carbonyl)-L-proline (147)
A solution of 131 (166 mg, 0.303 mmol) in MeOH (20 mL) was transferred into an autoclave, 
charged with Pd/C (32 mg, 20 wt% based on starting material, 10% Pd on charcoal, 9.9 mol% 
Pd) and stirred rapidly at ambient temperature under 40 bar of hydrogen gas for 24 h. After 
completion the mixture was filtered over a plug of celite, washed with MeOH and 
concentrated under reduced pressure to obtain the pure product as a pale white solid (98 mg, 
0.303 mmol, >99%).  
E. Experimental Part
139
1H NMR (300 MHz, CDCl3) į = 9.37 (d, J = 8.8 Hz, 1H), 9.27 – 9.01 (m, 1H), 8.94 – 8.49 
(m, 1H), 5.07 – 4.92 (m, 1H), 4.85 – 4.65 (m, 1H), 4.14 – 4.01 (m, 1H), 3.97 – 3.79 (m, 1H), 
3.63 – 3.47 (m, 1H), 3.46 – 3.30 (m, 2H), 2.98 – 2.77 (m, 1H), 2.33 – 1.58 (m, 14H), 1.55 –
1.36 (m, 1H) (signal doubling due to rotamers). – 13C NMR (75 MHz, CDCl3) į = 178.0, 
171.1, 167.6, 60.9, 59.5, 50.6, 48.9, 47.3, 33.3, 29.0, 28.9, 27.3, 25.1, 24.6, 22.7. – IR (neat): 
ৼ (cm-1) = 3049, 2952, 2873, 1673, 1617, 1561, 1438, 1326, 1382, 1244, 1192, 1039, 979, 
916, 723, 697, 667. – mp = 150 °C (decomposition). – >Į@૛૙ࡰ = -49.2 (c 1, DCM). – LRMS
(ESI): m/z = 324.1933 [M+H]+, 647.3763 [2M+H]+. – HRMS (ESI): m/z = 324.1923 [M+H]+; 
calc. for [C16H26N3O4]
+ = 324.1918. 
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General procedure for organocatalytic aldol reactions under ambient and high pressure 
conditions applying tripeptide catalysts 118, 119, 127, 147. 
Tripeptide catalyst (0.01 mmol, 0.01 equiv) was added to a solution of p-nitrobenzaldehyde 
149 (151 mg, 1 mmol, 1 equiv) in acetone/water (2 mL, 10:1, (v/v)) and the mixture stirred 
for 24 h at ambient temperature. Acetone was removed under reduced pressure and the 
resulting residue was treated with EA (10 mL) and water (5 mL). The phases were separated 
and the organic layer was washed with water (1x), dried over MgSO4, filtered and 
concentrated under reduced pressure. The crude was purified by column chromatography 
(PE/EA 2:1) to obtain the product as a pale yellow solid.
For recycling of the catalyst, the aqueous phase was washed with Et2O (1x) and lyophilized. 
For reactions under high pressure conditions apparatus II was used and the reaction mixture 
was transferred into a PTFE vial. Pressure was generated manually and maintained for 6 h. 
The reaction was performed without stirring. 
(R)-4-Hydroxy-4-(4-nitrophenyl)butan-2-one (150)
1H NMR (300 MHz, CDCl3) į = 8.24 – 8.17 (m, 2H), 7.57 – 7.49 (m, 2H), 5.26 (dd, J = 7.7, 
4.6 Hz, 2H), 3.74 – 3.41 (m, 1H), 2.88 – 2.82 (m, 2H), 2.22 (s, 3H). – HPLC analysis
(Chiracel AS-H, n-heptane/iPrOH 70:30, 0.5 mL/min, 254 nm) tr = 24.24 min (R), 29.50 min 
(S). 
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General procedure (1) for peptide synthesis
The peptides were obtained by using automated solid phase synthesis on a Syro I synthesizer 
(Prof. Cabrele laboratory, University of Salzburg, Austria). Rink amide MBHA resin (30 mg, 
loading 0.59 mmol/g) was used. Double couplings (2 x 40 min) with Fmoc-amino 
acid/HOBt/HBTU (4 equiv) and DIPEA (8 equiv) were applied.  Fmoc cleavage was 
performed with piperidine/DMF (40% (v/v) for 3 min and 20% (v/v) for 10 min. For N-
terminal acetylation acetic anhydride and DIPEA in DMF (10 equiv each for 30 min) was 
used if desired. Simultaneously side-chain deprotection and cleavage from the resin was 
performed by treating with a mixture of TFA/TIS/water (90/5/5 v/v) for 3 h. The crude 
peptides were obtained after precipitation in ice-cold Et2O and centrifugation at 4 °C for 5 
min followed by purification by preparative reversed phase HPLC.  
Ac-[(L)-Ala-(3S,4S)-APC-(L)-Ala-(1S,2R)-ACPC]3-(L)-Ala-CONH2 (151)
The title compound was synthesized according general procedure 1. Purification by 
preparative RP-HPLC (Phenomenex Luna C18, MeCN + 0.06% TFA 3 – 98% over 20 min, 
21 mL/min, 220 nm, tr = 7.9 min) yielded 151 as a white fluffy solid (6.1 mg). – HPLC 
analysis (Machery-Nagel EC 250/4 Nucleodur 100-5 C18ec, MeCN + 0.05% TFA 3 – 98% in 
40 min, 0.8 mL/min, 220 nm, tr = 15.3 min) – LRMS (ESI): m/z = 409.5734 [M+3H]
3+,
613.8545 [M+2H]2+. – HRMS (ESI): m/z = 409.5734 [M+3H]2+; calc. for [C56H94N17O14]
5+ = 
409.5717. 
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(2R,7R)-Diethyl 2,7-bis((tert-butoxycarbonyl)amino)oct-4-enedioate (166)146
According to literature procedure in a flame-dried Schlenk flask (R)-165 (106 mg, 0.43 mmol, 
2 equiv) was dissolved in DCM (8 mL anhydrous) under N2-atmosphere. Grubbs´ II catalyst 
(18.5 mg, 0.022 mmol, 0.1 equiv) was added and the reaction mixture was stirred under reflux 
for 11 h until all starting material was consumed. The solvent was removed under reduced 
pressure and the crude was purified by column chromatography (PE/EA 5:1) to obtain 166
(89 mg, 0.19 mmol, 89%) as a colorless oil. 
Rf = 0.23 (PE/EA 5:1). –
1H NMR (300 MHz, CDCl3) į = 5.44 – 5.31 (m, 2H), 5.11 – 5.00 
(m, 2H), 4.32 – 4.20 (m, 2H), 4.13 (qd, J = 7.1, 1.8 Hz, 4H), 2.51 – 2.31 (m, 4H), 1.42 – 1.32 
(m, 18H), 1.21 (t, J = 7.1 Hz, 6H). – 13C NMR (75 MHz, CDCl3) į = 171.9, 155.2, 128.5, 
79.9 + 79.8, 61.44, 61.3, 53.1 + 53.0, 35.5, 28.3, 14.2 (signal doubling due to rotamers). – IR
(neat): ৼ (cm-1) = 3369, 2978, 2937, 1703, 1498, 1367, 1330, 1248, 1159, 1095, 1051, 1021, 
969, 857, 779. – >Į@૛૙ࡰ = -27.0 (c 1, CHCl3). – LRMS (ESI): m/z = 459.2711 [M+H]+, 
481.2533 [M+Na]+, 939.5163 [2M+Na]+. – HRMS (ESI) m/z = 459.2711 [M+H]+; calc. for 
[C22H39N2O8]
+ = 459.2701.
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(2R,7R)-Diethyl 2,7-bis((tert-butoxycarbonyl)amino)octanedioate (167)146
Method applying Grubbs´II catalyst: According to literature procedure241 in a flame dried 
Schlenk flask under N2-atmosphere (R)-165 (300 mg, 1.23 mmol, 2 equiv) was dissolved in 
DCM (18 mL anhydrous). Grubbs´ II catalyst (52 mg, 0.06 mmol, 0.1 equiv) was added and 
the reaction mixture was stirred under reflux for 12 h. After all starting material was 
consumed the solvent was removed under reduced pressure and EtOH (10 mL) was added. 
Then the mixture was transferred into an autoclave and stirred under 20 atm of hydrogen gas 
at ambient temperature for 15 h. The reaction mixture was filtered and the solvent was 
removed under reduced pressure. The crude was purified by column chromatography (PE/EA 
3:1) to yield 167 (268 mg, 0.58 mmol, 95% over two steps) as colorless oil.   
Method applying Pd/C: Compound 166 (67 mg, 0.148 mmol) was dissolved in EtOH (6 mL, 
0.02 M) and Pd/C (6 mg, 10 wt% based on starting material, 10% Pd on charcoal, 3.8 mol% 
Pd) was added. The flask was flushed ten times with hydrogen gas and the mixture was stirred 
for 6 h at ambient temperature. When all starting material was consumed the mixture was 
filtered over a plug of celite, washed with EA and concentrated in vacuo. The crude product 
was purified by column chromatography (PE/EA 9:1 ĺ  WR REWDLQ WKH SURGXFW DV D
colorless oil (48 mg, 0.104 mmol, 70%). 
Rf = 0.3 (PE/EA 3:1). –
1H NMR (300 MHz, CDCl3) į = 5.04 – 4.94 (m, 2H), 4.24 – 4.06 (m, 
4H + 2H), 1.79 – 1.46 (m, 4H), 1.42 – 1.34 (m, 18H), 1.33 – 1.17 (m, 4H + 6H). – 13C NMR
(75 MHz, CDCl3) į = 172.8, 155.4, 79.8, 61.3, 53.3, 32.6, 28.3, 24.9, 14.2. – IR (neat):           
ৼ (cm-1) = 3354, 2978, 2937, 2870, 1699, 1505, 1457, 1367, 1248, 1159, 1021, 861, 779. –
>Į@૛૙ࡰ = -14.8 (c 1, CHCl3). – LRMS (ESI): m/z = 461.2866 [M+H]+, 483.2684 [M+Na]+, 
943.5473 [2M+Na]+. – HRMS (ESI) m/z = 461.2865 [M+H]+; calc. for [C22H41N2O8]
+ = 
461.2857.
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(2R,7R)-2,7-Bis((tert-Butoxycarbonyl)amino)octanedioic acid (164)146
According to literature procedure242 (R,R)-167 (268 mg, 0.58 mmol, 1 equiv) was dissolved in 
EtOH (8 mL) and a 1M NaOH solution (1.2 mL, 1.16 mmol, 2 equiv) was added dropwise. 
The reaction was stirred at ambient temperature for 21 h till all starting material was 
consumed. Afterwards the pH of the solution was adjusted to pH 2 by the addition of 1M HCl 
solution, H2O and EA were added and the phases were separated. The aqueous layer was 
extracted with EA (3x) and the combined organic phases were dried over MgSO4, filtered and 
concentrated under reduced pressure to yield the product as a white solid (238 mg, 
0.58 mmol, quant)
Rf = 0.1 (PE/EA + AcOH 1:1). –
1H NMR (300 MHz, CD3OD) į = 4.13 – 3.91 (m, 2H), 1.97 
– 1.72 (m, 2H), 1.71 – 1.57 (m, 2H), 1.51 – 1.36 (m, 22H). – 13C NMR (75 MHz, CD3OD) 
į = 176.4, 158.2, 80.5, 54.9, 32.7, 28.8, 26.6. – IR (neat): ৼ (cm-1) = 3295, 2978, 2933, 2363, 
1789, 1707, 1680, 1509, 1449, 1394, 1370, 1312, 1244, 1159, 1077, 1047, 1017, 946, 846, 
790, 758, 697. – >Į@૛૙ࡰ = +11.2 (c 1, DMF). – LRMS (ESI): m/z = 403.2096 [M-H]-, 807.4236 
[2M-H]-. – HRMS (ESI) m/z = 403.2096 [M-H]-; calc. for [C18H31N2O8]
+ = 403.2086.
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(2S,7S)-Diethyl 2,7-bis((tert-butoxycarbonyl)amino)oct-4-enedioate (166)146
Compound (S,S)-(+)-166 was prepared according to (R,R)-(-)-166 by using (S)-165 (105 mg, 
0.43 mmol. 2 equiv) as starting material to obtain the product as  colorless oil (47.3 mg, 0.1 
mmol, 49%). Spectroscopic data were identical to those for its enantiomer (R,R)-(-)-166. –
>Į@૛૙ࡰ = +27.9 (c 1, CHCl3).
(2S,7S)-Diethyl 2,7-bis((tert-butoxycarbonyl)amino)octanedioate (167)146
Compound (S,S)-(+)-167 was prepared according to (R,R)-(-)-167 by using (S)-165 (303 mg, 
1.2 mmol, 2 equiv) as starting material to obtain the product as a colorless oil (212 mg, 0.46 
mmol, 74%). The spectroscopic data were identical to those for its enantiomer (R,R)-(-)-167. 
– >Į@૛૙ࡰ = +16.9 (c 1, CHCl3).
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(2S,7S)-2,7-bis((tert-Butoxycarbonyl)amino)octanedioic acid (164)146
Compound (S,S)-(+)-164 was prepared according to (R,R)-164 by using (S,S)-167 (212 mg, 
0.46 mmol, 2 equiv) as starting material to obtain the product as a white solid (190 mg, 0.46 
mmol, quant). The spectroscopic data were identical to those for its enantiomer (R,R)-164. –
>Į@૛૙ࡰ = -9.8 (c 1, DMF, ref243.: -15.2, 5% in DMF).
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Ac-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-((3R,4R)APC)-Arg-Tyr-NH2 (170) 
The title compound was synthesized according general procedure 1. Purification by 
preparative RP-HPLC (Machery-Nagel Nucleodur 250/21 100 C18, MeCN 15 – 50% over 30 
min, 15 mL/min, 220 nm, tr = 16.1 min) yielded 170 as a white fluffy solid (8.3 mg). – HPLC 
analysis (Machery-Nagel EC 250/4 Nucleodur 100-5 C18ec, MeCN + 0.05% TFA 10 – 60%
over 13 min, 0.8 mL/min, 220 nm, tr = 12.3 min) – LRMS (ESI): m/z = 332.3958 [M+5H]
5+, 
415.2422 [M+4H]4+, 553.3190 [M+3H]3+, 829.4739 [M+3H]2+. – HRMS (ESI): m/z = 
553.3190 [M+5H]3+; calc. for [C75H123N2O17]
3+ = 553.3181.
Ac-Arg-His-Tyr-Ile-Asn-Leu-Ile-((3R,4R)APC)-Arg-((3R,4R)APC)-Arg-Tyr-NH2 (171) 
The title compound was synthesized according general procedure 1. Purification by 
preparative RP-HPLC (Machery-Nagel VP 250/10 Nucleodur 100-5 C18ec, MeCN + 0.05% 
TFA 10 – 32% over 25 min, 5 mL/min, 220 nm, tr = 12.7 min) yielded 171 as a white fluffy 
solid (5 mg). – HPLC analysis (Machery-Nagel EC 250/4 Nucleodur 100-5 C18ec, MeCN + 
0.05% TFA 10 – 60% over 13 min, 0.8 mL/min, 220 nm, tr = 11.7 min) – LRMS (ESI): m/z = 
334.5990 [M+5H]5+, 417.9959 [M+4H]4+, 556.9909 [M+3H]3+. – HRMS (ESI): m/z = 
334.5990 [M+5H]5+; calc. for [C76H126N27O16]
5+ = 334.5970. 
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Ac-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-((3S,4S)APC)-Arg-Tyr-NH2 (172) 
The title compound was synthesized according general procedure 1. Purification by 
preparative RP-HPLC (Machery-Nagel Nucleodur 250/21 100 C18, MeCN 15 – 50% over 30 
min, 15 mL/min, 220 nm, tr = 15.5 min) yielded 172 as a white fluffy solid (8.6 mg). – HPLC 
analysis (Machery-Nagel EC 250/4 Nucleodur 100-5 C18ec, MeCN + 0.05% TFA 10 – 60%
over 13 min, 0.8 mL/min, 220 nm, tr = 12.2 min) – LRMS (ESI): m/z = 332.3959 [M+5H]
5+, 
415.2416 [M+4H]4+, 553.391 [M+3H]3+, 829.9747 [M+2H]2+. – HRMS (ESI): m/z = 
415.2416 [M+4H]4+; calc. for [C75H124N26O17]
5+ = 415.2404.
Ac-Arg-His-Tyr-Ile-Asn-Leu-Ile-((3S,4S)APC)-Arg-((3S,4S)APC)-Arg-Tyr-NH2 (173) 
The title compound was synthesized according general procedure 1. Purification by 
preparative RP-HPLC (Machery-Nagel VP 250/10 Nucleodur 100-5 C18ec, MeCN + 0.05% 
TFA 10 – 32% over 25 min, 5 mL/min, 220 nm, tr = 12.8 min) yielded 173 as a white fluffy 
solid (1.3 mg). – HPLC analysis (Machery-Nagel EC 250/4 Nucleodur 100-5 C18ec, MeCN 
+ 0.05% TFA 10 – 60% over 13 min, 0.8 mL/min, 220 nm, tr = 11.6 min) – LRMS (ESI): m/z 
= 334.5987 [M+5H]5+, 417.9956 [M+4H]4+, 556.9907 [M+3H]3+. – HRMS (ESI): m/z = 
334.5988 [M+5H]5+; calc. for [C76H126N27O16]
5+ = 334.5970. 
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Ac-Arg-His-Tyr-Ile-Asn-Leu-Ile-((1R,2S)ACPC)-Arg-((3R,4R)APC)-Arg-Tyr-NH2
(174) 
The title compound was synthesized according general procedure 1. Purification by 
preparative RP-HPLC (Machery-Nagel VP 250/10 Nucleodur 100-5 C18ec, MeCN + 0.05% 
TFA 10 – 32% over 25 min, 5 mL/min, 220 nm, tr = 15.8 min) yielded 174 as a white fluffy 
solid (2.4 mg). – HPLC analysis (Machery-Nagel EC 250/4 Nucleodur 100-5 C18ec, MeCN 
+ 0.05% TFA 10 – 60% over 13 min, 0.8 mL/min, 220 nm, tr = 12.2 min) – LRMS (ESI): m/z 
= 334.4005 [M+5H]5+, 417.7469 [M+4H]4+, 556.6601 [M+3H]3+, 834.4849 [M+2H]2+. –
HRMS (ESI): m/z = 834.4840 [M+2H]2+; calc. for [C77H124N26O16]
5+ = 834.4839. 
Ac-Arg-His-Tyr-Ile-Asn-Leu-Ile-((1R,2S)ACPC)-Arg-((3R,4R)APC)-Arg-Tyr-NH2
(175) 
The title compound was synthesized according general procedure 1. Purification by 
preparative RP-HPLC (Machery-Nagel VP 250/10 Nucleodur 100-5 C18ec, MeCN + 0.05% 
TFA 10 – 32% over 25 min, 5 mL/min, 220 nm, tr = 15.5 min) yielded 175 as a white fluffy 
solid (4 mg). – HPLC analysis (Machery-Nagel EC 250/4 Nucleodur 100-5 C18ec, MeCN + 
0.05% TFA 10 – 60% over 13 min, 0.8 mL/min, 220 nm, tr = 12.1 min) – LRMS (ESI): m/z = 
334.3997 [M+5H]5+, 417.7468 [M+4H]4+, 556.6603 [M+3H]3+, 834.4845 [M+2H]2+. –
HRMS (ESI): m/z = 834.4840 [M+2H]2+; calc. for [C77H124N26O16]
5+ = 834.4839. 
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tert-Butyl (1S,2S)-2-(benzyl((S)-1-phenylethyl)amino)cyclopentane-1-carboxylate (23)24
According to literature procedure24 21 (1.0 g, 2.63 mmol, 1 equiv) was dissolved in tBuOH 
(30 mL), KOtBu (400 mg, 3.56 mmol, 1.35 equiv) was added and the mixture was stirred 
under reflux for 8.5 h. The mixture was allowed to cool down to ambient temperature, 
acidified with sat. NH4Cl solution (20 mL), diluted with Et2O (20 mL) and the phases were 
separated. The aqueous layer was extracted with Et2O (1x) and the combined organic layers 
were washed with brine (1x), dried over MgSO4, filtered and the solvent was removed under 
reduced pressure. The crude was purified by column chromatography (PE/Et2O 20:1 ĺ
to obtain the product as a colorless oil (696 mg, 1.83 mmol, 70%). 
Rf = 0.37 (PE/Et2O 20:1). –
1H NMR (300 MHz, CDCl3) į = 7.48 – 7.12 (m, 10H), 3.89 (q, J
= 6.8 Hz, 1H), 3.78 (d, J = 14.9 Hz, 1H), 3.68 (d, J = 14.9 Hz, 1H), 3.62 – 3.50 (m, 1H), 2.69 
– 2.56 (m, 1H), 1.83 – 1.54 (m, 6H), 1.38 (s, 9H), 1.32 (d, J = 6.9, 3H). – 13C NMR (75 MHz, 
CDCl3) į = 175.6, 144.6, 142.1, 128.5, 128.2, 128.0, 127.9, 126.7, 126.6, 79.7, 64.0, 58.1, 
50.2, 49.2, 29.7, 28.7, 28.2, 24.6, 16.2.
tert-Butyl (1S,2S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)cyclopentane-1-
carboxylate (184)
A solution of 23 (672 mg, 1.77 mmol, 1 equiv) in MeOH (15 mL) was transferred into an 
autoclave, charged with Pd(OH)2/C (168 mg, 25wt%, 20% on charcoal, 14.0 mol%) and was 
stirred rapidly at ambient temperature under 20 bar of hydrogen gas for 14 h. After 
completion the mixture was filtered over a plug of celite, washed with MeOH and 
concentrated under reduced pressure (min. applied pressure 200 mbar). 
The residue was dissolved in water/dioxane (1:1, 10 mL each), NaHCO3 (305 mg, 3.63 mmol, 
2.05 equiv) was added and the mixture was cooled down to 0 °C. FmocOSu (597 mg, 1.77 
mmol, 1 equiv) was added portionwise and the mixture was stirred for 48 h in the defrosting 
ice bath. Water (5 mL) and EA were added (10 mL), the phases were separated and the 
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aqueous phase was extracted with EA (2x). The combined organic layers were dried over 
MgSO4, filtered and the solvent was removed under reduced pressure. The crude was purified 
by column chromatography (PE/EA 5:1) to yield the product as a white fluffy solid (471 mg, 
1.16 mmol, 65%). 
Rf = 0.34 (PE/EA 5:1). –
1H NMR (300 MHz, CDCl3) į = 7.75 (d, J = 7.4 Hz, 2H), 7.60 (d, J
= 7.3 Hz, 2H), 7.44 – 7.23 (m, 4H), 5.16 (d, J = 7.4 Hz, 1H), 4.53 – 4.33 (m, 2H), 4.29 – 4.09 
(m, 2H), 2.61 – 2.44 (m, 1H), 2.21 – 2.05 (m, 1H), 2.02 – 1.78 (m, 2H), 1.76 – 1.61 (m, 2H), 
1.57 – 1.47 (m, 1H), 1.45 (s, 9H). – 13C NMR (75 MHz, CDCl3) į = 173.8, 160.6 + 155.8, 
144.0, 141.3, 127.7, 127.1, 125.1, 120.0, 80.6, 66.5 +61.3, 56.3, 51.5, 47.3, 33.2, 28.1, (28.0 
hidden) 22.8. – IR (neat): ৼ (cm-1) = 3350, 2955, 2873, 1722, 1688, 1535, 1446, 1367, 1392, 
1244, 1148, 1036, 929, 849, 734. – mp = 114 °C. – >Į@૛૙ࡰ = +32.3 (c 1, DCM). – LRMS
(ESI): m/z = 352.1548 [M+H-C4H8]
+, 408.2168 [M+H]+, 430.1994 [M+Na]+, 837.4085
[2M+Na]+. – HRMS (ESI): m/z = 408.2168 [M+H]+; calc. for [C25H30NO4]
+ = 408.2169. 
(1S,2S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)cyclopentane-1-carboxylic acid 
(185)244
A solution of 185 (538 mg, 1.32 mmol, 1 equiv) and Et3SiH (422 µL, 2.64 mmol, 2 equiv) 
was treated with TFA (2 mL) at 0 °C and stirred for 24 h at ambient temperature. The 
volatiles were removed under reduced pressure, the resulting residue was dissolved in CHCl3
and n-pentane alternately and the solvent was removed again. This co-evaporation step was 
repeated 5 times. The crude was purified by column chromatography (DCM/MeOH 98:2) to 
afford the product as a white fluffy solid (429 mg, 1.22 mmol, 92%).
Rf = 0.5 (DCM/MeOH 95:5). –
1H NMR (300 MHz, CD3OD) į = 7.78 (d, J = 7.4 Hz, 2H), 
7.64 (d, J = 7.4 Hz, 2H), 7.42 – 7.26 (m, 4H), 4.39 – 4.29 (m, 2H), 4.23 – 4.06 (m, 2H), 2.62 
(q, J = 7.8, 1H), 2.10 – 1.93 (m, 2H), 1.89 – 1.62 (m, 3H), 1.60 – 1.44 (m, 1H). – 13C NMR
(75 MHz, CD3OD) į = 179.7, 158.5, 145.4, 145.3, 142.6, 128.8, 128.2, 126.2, 121.0, 67.8, 
57.3, 52.1, 48.5 (hidden by solvent peak), 33.7, 30.0, 24.2. – >Į@૛૙ࡰ = +32.3 (c 1.21, MeOH, 
lit244.: +36.3, c 1.21, MeOH). – LRMS (ESI): m/z = 352.1554 [M+H]+, 374.1367 [M+Na]+, 
725.2833 [2M+Na]+.
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4-Methylbenzenesulfonyl azide (290)245
According to literature procedure245 tosylchloride (35.2 g, 184.7 mmol, 1 equiv) was 
dissolved in acetone/water (250 mL/200 mL) and cooled down to 0 °C. NaN3 (12.6 g, 193.9 
mmol, 1.05 equiv) was added portionwise and the mixture was stirred for 2.5 h at 0 °C. 
Subsequently, the volume was reduced to its half under reduced pressure (water bath 38 °C, 
min. applied pressure 170 mbar) and the residue was extracted with Et2O (3x). The combined 
organic layers were dried over MgSO4 and concentrated under reduced pressure (water bath 
38 °C, min. applied pressure 600 mbar). Further residues of solvent can be removed by drying 
under high vacuum. The product was obtained as a colorless oil (32.8 g, 166 mmol, 90%) 
which crystalizes during storage in the freezer. 
1H NMR (300 MHz, CDCl3) į = 7.84 (d, J = 8.4 Hz, 2H), 7.41 (d, J = 8.0 Hz, 2H), 2.48 (s, 
3H).
tert-Butyl-2-diazoacetate (192)246
According to literature procedure246 to an ice-cold solution of n-pentane (900 mL), tert-butyl 
acetoacetate (62.2 mL, 380 mmol, 1.0 equiv), tosyl azide (75.0 g, 380 mmol, 1.0 equiv) and 
TBAB (2.45 g, 7.61 mmol, 0.02 equiv) a precooled solution of NaOH (42.6 g in 354 mL 
water, 1.06 mol, 2.8 equiv) was added over 45 min. After complete addition, the mixture was 
allowed to warm up to ambient temperature and stirred for 15 h. Then the mixture was filtered 
through a plug of celite and the filtrate was transferred into a separating funnel. The phases 
were separated and the aqueous layer was extracted with n-pentane (3x). The combined 
organic layers were washed with water (2x) and brine (1x), dried over MgSO4 and finally 
concentrated under reduced pressure (15 °C water bath, min applied pressure 110 mbar) to
yield tert-butyl-2-diazoacetate (53.3 g, 375 mmol, 99%) as a yellow oil. The product was 
diluted with anhydrous DCM to the required concentration. 
1H NMR (300 MHz, CDCl3) į = 4.61 (bs, 1H), 1.48 (s, 9H).
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(S)-4-(tert-Butyl)oxazolidin-2-one (197)189
Sodium (902 mg, 39.25 mmol, 1.0 equiv) was dissolved in EtOH (70 mL, 99%) and (S)-tert-
leucinol (4.60 g, 39.25 mmol, 1.0 equiv) and diethylcarbonate (5.22 mL, 43.18 mmol, 
1.1 equiv) were added. Then the mixture was refluxed for 24 h. The solvent was removed 
under reduced pressure and the residue was treated with DCM and sat. NH4Cl. The phases 
were separated and the aqueous phase was extracted with DCM (2x). The combined organic 
layers were dried over MgSO4, filtered and concentrated under reduced pressure to give a 
white solid that was recrystallized from Et2O to yield 197 (4.56 g, 31.85 mmol, 81%) as a 
white solid.
1H NMR (300 MHz, CDCl3) į = 6.34 (bs, 1H), 4.42 – 4.31 (m, 1H), 4.19 (dd, J = 9.0, 5.8 Hz, 
1H), 3.59 (ddd, J = 9.0, 5.8, 1.0 Hz, 1H), 0.90 (s, 9H).
(S)-4-(tert-Butyl)-2-ethoxy-4,5-dihydrooxazole (198)189
Oxazolidinone 197 (6.41 g, 44.7 mmol, 1.0 equiv) was dissolved in DCM (80 mL anhydrous) 
and cooled to 0 °C. At this temperature a solution of triethyloxonium tetrafluoroborate (10.21 
g, 53.72 mmol, 1.2 equiv) in DCM (50 mL anhydrous) was added dropwise. The mixture was 
allowed to warm to ambient temperature and stirred for 48 h. Aferwards, the reaction mixture 
was poured into an ice-cold solution of Na2CO3 (50 mL) and extracted with DCM (3x). After 
drying over MgSO4 and filtration, the solvent was removed under reduced pressure to give 
198 (7.03 g, 41.05 mmol, 92%) as a yellow oil that was used without further purification.
1H NMR (300 MHz, CDCl3) į = 4.31 – 4.27 (m, 1H), 4.22 – 4.15 (m, 1H), 3.76 (dd, J = 9.4, 
6.6 Hz, 1H), 1.34 (t, J = 7.1 Hz, 6H), 0.88 (s, 9H).
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(S)-4-(tert-Butyl)-4,5-dihydrooxazol-2-amine (199)189
BrCN (5.80 g, 54.8 mmol, 1.08 equiv) was dissolved in MeOH (40 mL anhydrous) and 
cooled down to 0 °C. A solution of (S)-tert-leucinol 196 (5.93, 50.6 mmol, 1 equiv) in MeOH 
(80 mL anhydrous) was added dropwise and the mixture was stirred for 1 h at 0 °C. 
Subsequently, aqueous ammonia (25% (w/w), 30 mL) was added and the mixture was 
concentrated under reduced pressure. The residue was treated with NaOH (20% (w/w), 
50 mL) and extracted with EA (4x). The combined organic phases were dried over MgSO4, 
filtrated and concentrated under reduced pressure. Remaining starting material can be 
removed by drying under high vacuum in a water bath (50 °C) and the desired product 199 
was obtained (4.82 g, 33.86 mmol, 67%) as a white solid.
1H NMR (300 MHz, CDCl3) į = 4.22 (dd, J = 9.2, 8.3 Hz, 1H), 4.07 (dd, J = 8.3, 7.1 Hz, 
1H), 3.74 (dd, J = 9.2, 7.1 Hz, 1H), 0.87 (s, 9H).
(S)-Bis((S)-4-(tert-butyl)-4,5-dihydrooxazol-2-yl)amine (193)189
Aminooxazoline 199 (1.34 g, 9.44 mmol, 1.0 equiv) and ethoxyoxazoline 198 (1.94 g, 11.33 
mmol, 1.2 equiv) were dissolved in toluene (20 mL anhydrous) and p-TSA (163 mg, 0.94 
mmol, 0.1 equiv) was added. Then the reaction mixture was refluxed under N2- atmosphere 
for 19 h. The solvent was removed under reduced pressure and the crude was purified by 
column chromatography (PE/EA = 1:9) to obtain 193 (1.2 g, 4.48 mmol, 40%) as a colorless 
crystalline solid that can be recrystallized from acetone.
1H NMR (300 MHz, CDCl3) į = 4.35 – 4.27 (m, 2H), 4.15 (dd, J = 8.8, 6.7 Hz, 2H), 3.81 (dd, 
J = 9.4, 6.7 Hz, 2H), 0.90 (s, 18H).
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di-tert-Butyl (1S,5S,6S)-2-azabicyclo[3.1.0]hex-3-ene-2,6-dicarboxylate (190)196
According to literature procedure196 in a flame dried Schlenk flask under N2-atmosphere 
Cu(OTf)2 (324 mg, 0.89 mmol, 0.01 equiv) and tert-butyl aza-box ligand 193 (479 mg, 
1.79 mmol, 0.02 equiv) were dissolved in DCM (25 mL anhydrous) and stirred for 2 h. A 
solution of N-Boc-pyrrole 191 (15.0 g, 89.7 mmol, 1 equiv) in DCM (45 mL anhydrous) was 
also prepared under N2-atmosphere and cooled down to -20 °C by the use of a cryostat. The 
Cu/ligand mixture was added via syringe to this flask and phenylhydrazine (88.2 µL, 
0.89 mmol, 0.01 equiv) was added dropwise. tert-Butyldiazoacetate (168.1 g, 134.6 mmol, 
1.5 equiv, 11.38 wt% solution in DCM anhydrous) was added via an electronically controlled 
dropping system (wait: 10 s, pulse 0.5 s) over 36 h. The reaction mixture was stirred for 
additionally 6 h, filtered through basic alumina and washed with DCM (600 mL). The solvent 
was evaporated and the crude product was purified by column chromatography (PE/EA 50:1) 
to obtain 190 (9.32 g, 33.13 mmol, 37%, 55% ee) as a white solid. To obtain enantiopure 
material the product was recrystallized five times in refluxing hexanes (2 mL/g) to yield 190
(3.61 g, 12.8 mmol, 14%, >99% ee). 
Rf = 0.45 (PE/EA = 9:1) –
1H NMR (300 MHz, CDCl3) į = 6.54 – 6.29 (m, 1H), 5.34 – 5.21 
(m, 1H), 4.34 – 4.06 (m, 1H), 2.71 – 2.57 (m, 1H), 1.42 (s, 9H), 1.37 (s, 9H), 0.85 – 0.74 (m, 
1H). – 13C NMR (75 MHz, CDCl3) į = 172.3, 172.0, 151.2, 151.0, 129.6, 129.4, 110.0, 81.4, 
80.6, 44.0, 43.7, 31.6, 30.6, 28.2, 28.1, 24.0 (signal doubling due to rotamers). – HPLC 
analysis (Phenomenex Lux Cellulose-2, n-heptane/iPrOH 98:2, 0.5 mL/min, 254 nm): tr = 
10.95 min, 19.02 min, >99% ee.
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(1S,5S,6S)-di-tert-butyl 2-azabicyclo[3.1.0]hexane-2,6-dicarboxylate (194)196
N
H
H
CO2tBu
Boc
Method applying autoclave and Pd/C: A solution of 190 (269 mg, 0.96 mmol) in THF (6 mL 
anhydrous) was transferred into an autoclave, charged with Pd/C (25 mg, 10 wt% based on 
starting material, 10% Pd on carbon, 2.4 mol%) and was stirred rapidly at ambient 
temperature under 20 bar of hydrogen gas for 4 h. After completion the mixture was filtered 
over a plug of celite and washed with DCM. The solvent was removed under reduced pressure 
to obtain the pure product as a white solid (268 mg, 0.95 mmol, 99%).  
Method applying Rh/C: In a flame dried flask 190 (1.07 g, 3.8 mmol) was dissolved in THF 
(20 mL anhydrous) and Rh/C (100 mg, 10wt% based on starting material, 5% Rh on charcoal, 
1.3 mol%) was added. Subsequently, a balloon with hydrogen gas was attached and the 
atmosphere in the flask was flushed ten times with hydrogen gas. The mixture was stirred at 
room temperature for 1 h under hydrogen atmosphere (1 bar) and after full consumption of 
starting material the reaction mixture was filtered through a plug of celite. The solvent was 
removed under reduced pressure to obtain pure 194 (1.07 g, 3.79 mmol, >99%) as a white 
solid. 
Rf = 0.54 (PE/EA = 5:1) –
1H NMR (300 MHz, CDCl3) į = 3.89 – 3.52 (m, 2H), 2.98 – 2.84 
(m, 1H), 2.24 – 1.95 (m, 3H), 1.62 (dd, J = 3.7, 1.6 Hz, 1H), 1.45 (s, 9H), 1.42 (s, 9H). –
13C NMR (75 MHz, CDCl3) į = 170.4, 154.8, 80.7, 80.0, 44.2, 44.0, 28.5, 28.2, 27.0 25.5, 
24.8. – HPLC analysis (Phenomenex Lux Cellulose-2, n-heptane/iPrOH 70:30, 0.5 mL/min, 
215 nm): tr = 6.87 min, 10.54 min, >99% ee.
(S)-tert-Butyl 3-(2-(tert-butoxy)-2-oxoethyl)pyrrolidine-1-carboxylate (189)196
Method applying TFA: 194 (107 mg, 0.37 mmol, 1 equiv) was dissolved in DCM (2 mL 
anhydrous) and cooled down to 0 °C by the use of a cryostat. Et3SiH (181 µL, 1.13 mmol, 
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3 equiv) and TFA (58 µL, 0.75 mmol, 2 equiv) were added dropwise and the solution was 
stirred for 7 days at 0 °C. The solvent was removed under reduced pressure and the crude was 
purified by column chromatography (PE/EA 9:1) to afford 189 (35 mg, 0.12 mmol, 33%) as a 
white solid. Starting material 194 (57 mg, 0.2 mmol, 53%) was reisolated as a white solid. 
Method applying BF3·OEt2: 194 (208 mg, 0.73 mmol, 1 equiv) and Et3SiH (1.17 mL, 7.27 
mmol, 10 equiv) were dissolved in DCM (6 mL) and cooled down to 0 °C by the use of a 
cryostat. Then BF3·OEt2 (93 µL, 0.72 mmol, 1 equiv) was added dropwise and the mixture 
was stirred for 40 h at 0 °C. Subsequently, sat. NaHCO3 (2 mL) and water (2 mL) were added 
and the phases were separated. The aqueous phase was extracted with DCM (1x), dried over 
MgSO4 and filtered. The solvent was removed under reduced pressure and the crude product 
was purified by column chromatography (PE/EA 9:1) to obtain 189 (112 mg, 0.39 mmol, 
53%) as a white solid. 
Rf = 0.47 (PE/EA = 5:1) –
1H NMR (300 MHz, CDCl3) į = 3.61 – 3.49 (m, 1H), 3.48 – 3.34 
(m, 7.4, 1H), 3.32 – 3.17 (m, 1H), 2.99 – 2.82 (m, 1H), 2.48 (sept, J = 7.7 Hz, 1H), 2.31 –
2.23 (m, 2H), 2.09 – 1.95 (m, 1H), 1.59 – 1.47 (m, 1H), 1.46 – 1.37 (m, 18H). – 13C NMR
(75 MHz, CDCl3) į = 171.5, 154.6, 80.6, 79.2, 51.2, 50.8, 45.4, 45.0, 39.0, 35.5, 34.7, 31.5, 
30.8, 28.5, 28.1 (signal doubling due to rotamers). – [Į]૛૙ࡰ = +18.9 (c 1, DCM, > 99% ee). –
HPLC analysis (Phenomenex Lux Cellulose-1, n-heptane/iPrOH 99:1, 0.5 mL/min, 200 nm): 
tr = 18.16 min, 22.52 min, > 99% ee.
(S)-2-(Pyrrolidin-3-yl)acetic acid (188)196
Method deprotection of 189: 189 (66 mg, 0.23 mmol, 1 equiv) was dissolved in DCM (4 mL) 
and cooled down to 0 °C. TFA (178 µL, 2.31 mmol, 10 equiv) was added and the mixture was 
stirred at ambient temperature for 24 h. The volatiles were removed in vacuo and the crude 
TFA salt of 188 was dissolved in 0.1 M HCl (8 mL). For removal of the counter ion the salt 
was loaded onto a column with DOWEX 50WX8-400 (2x4 cm, 2x activated with 0.1 M HCl). 
The column was washed with distilled water (250 mL) and finally eluted with 16% NH3 (aq.) 
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to obtain the product after lyophilization as a slight beige colored solid (29.5 mg, 0.23 mmol, 
99%). 
Method applying TFA: In a flame dried Schlenk flask 190 (1.0 g, 3.55 mmol, 1 equiv) was 
dissolved in THF (20 mL anhydrous) and Rh/C (10 mg, 1wt% based on starting material, 5% 
Rh on charcoal, 0.14 mol%) was added. A balloon with hydrogen gas (1 bar) was attached to 
the flask, the atmosphere was flushed 10 times with hydrogen gas and the mixture was stirred 
at ambient temperature for 8 h. After complete consumption of the starting material, the 
mixture was filtered over a plug of celite and the solvent was removed in vacuo. 
The resulting white solid (1.0 g, 3.53 mmol) was dissolved in DCM (40 mL) and cooled down 
to 0 °C by the use of a cryostat. Et3SiH (1.69 mL, 10.6 mmol, 3 equiv) and TFA (545 µL, 
7.1 mmol, 2 equiv) was added dropwise and the mixture was stirred for 17 d at 0 °C. After 6, 
14 and 16 d the same amount of Et3SiH and TFA was added again. When all starting material 
was consumed, the mixture was allowed to warm up to ambient temperature, an excess of 
TFA (10 mL) was added and the mixture was stirred for 24 h at ambient temperature. 
The volatiles were removed in vacuo and the crude was dissolved in 0.1 M HCl. The solution 
was loaded onto a column of DOWEX 50WX8-400 (4x2 cm, 2 times activated with 0.1 M 
HCl) and the resin was washed with distilled water (500 mL). The product was eluted with 
16% NH3 (aq.) and fractions were concentrated and lyophilized. The product 188 (457 mg, 
3.54 mmol, >99%) was obtained as a slight beige-colored amorphous solid. 
Method applying BF3·OEt2: 194 (206 mg, 0.727 mmol, 1 equiv) and Et3SiH (1.16 mL, 7.27 
mmol, 10 equiv) were dissolved in DCM (6 mL anhydrous) and cooled down to 0 °C by the 
use of a cryostat. Then BF3·OEt2 (92 µL, 0.72 mmol, 1 equiv) was added dropwise and the 
mixture was stirred for 48 h at 0 °C. When all starting material was consumed, an excess of 
TFA (4 mL) was added and the mixture was stirred for 24 h at ambient temperature. 
The volatiles were removed in vacuo and the crude was dissolved in 0.1 M HCl. The solution 
was loaded onto a column of DOWEX 50WX8-400 (2x2 cm, 2 times activated with 0.1 M 
HCl) and the resin was washed with distilled water (500 mL). The product was eluted with 
16% NH3 (aq.) and the fractions were concentrated and lyophilized. The product 188 (93 mg, 
0.72 mmol, 99%) was obtained as a slight beige-colored amorphous solid. 
1H NMR (400 MHz, D2O) į = 3.51 (dd, J = 11.7, 7.7 Hz, 1H), 3.46 – 3.39 (m, 1H), 3.33 –
3.24 (m, 1H), 2.92 (dd, J = 11.7, 8.9 Hz, 1H), 2.65 (sept, J = 7.4 Hz, 1H), 2.36 (d, J = 1.4 Hz, 
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1H), 2.34 (d, J = 2.1 Hz, 1H), 2.28 – 2.17 (m, 1H), 1.74 – 1.62 (m, 1H). – 13C NMR (101 
MHz, D2O) į = 180.6, 49.9, 45.2, 40.1, 35.2, 29.7. – >Į@૛૙ࡰ = +9.5 (c 1, H2O; Lit176c.: +9.6, c 1, 
H2O). – LRMS (ESI): m/z = 130.1 [M+H]
+. – HRMS (ESI): m/z = 130.0866 [M+H]+; calc. 
for [C6H12NO2]
+ = 130.0863.
di-tert-Butyl-(1S,3S,4R,5S,6S)-4-azido-3-methoxy-2-azabicyclo[3.1.0]hexane-2,6-
dicarboxylate (213)
According to literature procedure197 in a flame dried Schlenk-flask 190 (800 mg, 2.84 mmol, 
1 equiv) and NaN3 (277 mg, 4.27 mmol, 1.5 equiv) were dissolved in MeCN/MeOH (35 mL, 
4:1, 0.08 M, anhydrous) and cooled down to 0 °C. A solution of cerium ammonium nitrate 
(4.68 g, 8.53 mmol, 3 equiv) in MeCN (85 mL, 0.1 M, anhydrous) was added dropwise and 
the solution was stirred at ambient temperature for 40 h. The mixture was diluted with water 
and extracted with Et2O (2x). The organic phases were washed with water (1x) and brine (1x), 
dried over Mg2SO4, filtered and concentrated under reduced pressure. The crude was purified 
by column chromatography (PE/EA 50:1 ĺWRREWDLQWKHSURduct as a white solid (436 
mg, 1.23 mmol, 43%). 
Rf = 0.44 (PE/EA 9:1). –
1H NMR (400 MHz, CDCl3) į = 5.17 – 4.90 (m, 1H), 4.16 – 3.93 
(m, 1H), 3.80 – 3.68 (m, 1H), 3.31 – 3.20 (m, 3H), 2.16 – 2.09 (m, 1H), 2.04 – 1.94 (m, 1H), 
1.46 – 1.41 (m, 9H), 1.41 – 1.34 (m, 9H). – 13C NMR (101 MHz, CDCl3) į = 169.4, 169.0, 
153.7, 153.2, 93.6, 93.4, 81.5, 81.3, 65.5, 64.6, 56.5, 56.3, 42.9, 42.8, 28.3, 28.11, 28.05, 26.4, 
25.7, 25.6 (signal doubling due to rotamers). – IR (neat): ৼ (cm-1) = 2978, 2937, 2098, 1714, 
1698, 1690, 1476, 1460, 1408, 1367, 1315, 1252, 1159, 1118, 1084, 1028, 939, 875, 842, 764, 
723. – mp = 66 °C. – >Į@૛૙ࡰ = -53.8 (c 1, DCM). – LRMS (ESI): m/z = 377.1805 [M+Na]+. –
HRMS (ESI): m/z = 377.1805 [M+Na]+; calc. for [C16H26N4NaO5]
+ = 377.1795. 
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di-tert-Butyl (1S,3S,4R,5R,6S)-4-amino-3-methoxy-2-azabicyclo[3.1.0]hexane-2,6-
dicarboxylate (214)
213 (230 mg, 0.648 mmol) was dissolved in THF (6 mL anhydrous) and Pd/C (23 mg, 10 
wt% based on starting material, 10% Pd on charcoal, 3.3 mol% Pd) was added. The flask was 
flushed ten times with hydrogen gas and the mixture was stirred at ambient temperature for 19 
h. The mixture was filtered over a plug of celite and washed with MeOH. The solvent was 
removed under reduced pressure to obtain the pure product as colorless oil (209 mg, 0.636 
mmol, 98%). 
Rf = 0.05 (PE/EA 9:1). –
1H NMR (300 MHz, CDCl3) į = 4.94 – 4.71 (m, 1H), 4.06 – 3.82 
(m, 1H), 3.40 – 3.31 (m, 1H), 3.29 – 3.17 (m, 3H), 1.98 – 1.90 (m, 1H), 1.89 – 1.80 (m, 1H), 
1.42 (s, 9H), 1.36 (s, 9H), 1.31 – 1.21 (m, 1H). – 13C NMR (75 MHz, CDCl3) į = 168.9, 
153.4, 153.0, 95.8, 79.9, 79.7, 57.2, 56.4, 55.2, 41.6, 29.2, 28.7, 27.3, 27.1, 25.0. – IR (neat): 
ৼ (cm-1) = 2978, 2937, 1699, 1499, 1475, 1394, 1364, 1300, 1252, 1148, 1114, 1077, 1021, 
939, 872, 842, 764, 723. – >Į@૛૙ࡰ = -10.5 (c 1, DCM). – LRMS (ESI): m/z = 241.1185 [M+H-
C4H8-MeOH]
+, 297.1809 [M+H-MeOH]+, 351.1891 [M+Na]+. – HRMS (ESI): m/z = 
351.1891 [M+Na]+; calc. for [C16H28N2NaO5]
+ = 351.1899. 
di-tert-Butyl (1S,3S,4R,5R,6S)-4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-
methoxy-2-azabicyclo[3.1.0]hexane-2,6-dicarboxylate (215)
Amine 214 (188 mg, 0.572 mmol, 1 equiv) was dissolved in dioxane/water (1:1, 5 mL each), 
NaHCO3 (96 mg, 1.14 mmol, 2 equiv) was added and the mixture was cooled down to 0 °C. 
FmocOSu (289 mg, 0.858 mmol, 1.5 equiv) in dioxane (10 mL) was added dropwise via 
additional funnel and the mixture was stirred at ambient temperature for 24 h. Water and EA 
(5 mL each) were added, the phases separated and the aqueous phase was extracted with EA 
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(2x). The combined organic phases were dried over MgSO4, filtered and concentrated under 
reduced pressure. The crude was purified by column chromatography (PE/EA 9:1) and the 
product was obtained as a white fluffy solid (285 mg, 0.517 mmol, 90%). 
Rf = 0.51 (PE/EA 9:1). –
1H NMR (300 MHz, CDCl3) į = 7.76 (d, J = 7.4 Hz, 2H), 7.67 –
7.54 (m, 2H), 7.47 – 7.26 (m, 4H), 5.27 – 4.76 (m, 2H), 4.56 – 4.34 (m, 2H), 4.28 – 3.88 (m, 
3H), 3.42 – 3.16 (m, 3H), 2.20 – 2.10 (m, 1H), 2.01 – 1.92 (m, 1H), 1.50 (s, 9H), 1.44 (s, 9H).
– 13C NMR (75 MHz, CDCl3) į = 169.5, 155.3, 153.8, 144.5, 143.8, 143.7, 141.5, 141.4, 
127.8, 127.6, 127.11, 127.06, 125.01, 124.98, 124.8, 120.1, 94.8, 81.3, 81.2, 66.8, 65.2, 56.5, 
50.4, 47.2, 42.8, 28.4, 28.1, 26.2 (signal doubling due to rotamers). – IR (neat): ৼ (cm-1) = 
3313, 2978, 2937, 1703, 1524, 1449, 1394, 1367, 1297, 1244, 1151, 1080, 1032, 939, 838, 
738. – mp = 90-91 °C. – >Į@૛૙ࡰ = +5.0 (c 1, DCM). – HPLC analysis (Phenomenex Lux 
Cellulose-2, n-heptane/iPrOH 90:10, 1.0 mL/min, 215 nm): tr = 11.88 min, 15.52 min, >99% 
ee. – LRMS (ESI): m/z = 519.2497 [M+H-MeOH]+, 573.2581 [M+Na]+, 1123.5270
[2M+Na]+. – HRMS (ESI): m/z = 573.2581 [M+Na]+; calc. for [C31H38N2NaO7]
+ = 573.2571. 
tert-Butyl-(3R,4S)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(2-(tert-butoxy)-2-
oxoethyl)pyrrolidine-1-carboxylate (216)
215 (96 mg, 0.174 mmol, 1 equiv) was dissolved in DCM (4 mL anhydrous), Et3SiH (278 µL, 
1.74 mmol, 10 equiv) was added and the flask was cooled down to -78 °C in an acetone/CO2(s)
bath and stirred for 15 min. Then BF3·OEt2 (44 µL, 0.348 mmol, 2 equiv) was added dropwise 
and the solution was stirred for 1 h at -78 °C and then for 23 h at 0 °C by the use of a cryostat. 
When all starting material was consumed the reaction was stopped by the addition of water (6 
mL) and stirred for 10 min at ambient temperature. The phases were separated and the organic 
layer was dried over MgSO4, filtered and concentrated under reduced pressure. After 
purification by column chromatography (PE/EA 5:1) the product was obtained as a colorless 
oil (28 mg, 0.053 mmol, 31%). 
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Rf = 0.55 (PE/EA 2:1). –
1H NMR (300 MHz, CDCl3) į = 7.81 – 7.73 (m, 2H), 7.63 – 7.52 
(m, 2H), 7.45 – 7.37 (m, 2H), 7.35 – 7.27 (m, 2H), 5.31 – 5.21 + 5.00 – 4.89 (m, 1H), 4.48 –
4.35 (m, 2H), 4.26 – 4.15 (m, 1H), 3.95 – 3.77 (m, 2H), 3.74 – 3.61 (m, 1H), 3.11 – 2.89 (m, 
2H), 2.52 – 2.20 (m, 3H), 1.45 (m, 18H). – 13C NMR (75 MHz, CDCl3) į = 171.5, 156.2, 
154.3, 143.8, 143.7, 141.3, 127.8, 127.1, 125.0, 120.0, 81.4, 79.7, 66.8, 55.5, 53.5, 51.3, 49.0, 
47.2, 39.2, 37.1 (signal doubling due to rotamers). – IR (neat): ৼ (cm-1) = 3309, 2970, 2140, 
1722, 1673, 1531, 1476, 1449, 1408, 1380, 1256, 1148, 1080, 1025, 943, 878, 842, 797, 738. 
– >Į@૛૙ࡰ = +20.4 (c 0.5, DCM). – HPLC analysis (Phenomenex Lux Cellulose-1, n-
heptane/iPrOH 80:20, 1.0 mL/min, 215 nm): tr = 14.72 min, 16.89 min, >99% ee. – LRMS
(ESI): m/z = 424.2315 [M+H-CO2-C4H8]
+, 467.2179 [M+H-C4H8]
+, 523.2803 [M+H]+,
545.2620 [M+Na]+, 1067.5364 [2M+Na]+. – HRMS (ESI): m/z = 523.2803 [M+H]+; calc. for 
[C30H39N2O6]
+ = 523.2803. 
2-((3S,4R)-4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-1-
(tert-butoxycarbonyl)pyrrolidin-3-yl)acetic acid (217)
215 (108 mg, 0.196 mmol, 1 equiv) was dissolved in DCM (4 mL anhydrous), Et3SiH (313 
µL, 1.96 mmol, 10 equiv) was added and the solution was cooled down to -78 °C in an 
acetone/CO2(s) and stirred for 15 min. Then BF3·OEt2 (49 µL, 0.392 mmol, 2 equiv) was 
added dropwise and the solution was stirred for 1 h at -78 °C and then for 21 h at 0 °C by the 
use of a cryostat. Then Et3SiH (157 µL, 0.981 mmol, 5 equiv) and BF3·OEt2 (26 µL, 0.196 
mmol, 1 equiv) was added again and stirred for additional 4 h. When all starting material was 
consumed, TFA (4 mL, excess) was added dropwise and stirred for 1 h at 0 °C. The mixture 
was allowed to warm up to ambient temperature and stirred for 24 h. The solvent was 
removed under reduced pressure and the resulting brown solid was dissolved in CHCl3 and n-
pentane alternately and concentrated under reduced pressure. This step was repeated five 
times and the resulting yellowish fluffy solid was dried under high vacuum for 24 h. 
For Boc-protection the crude was dissolved in dioxane/water (1:1, 5 mL each), NaHCO3
(82 mg, 0.980 mmol, 5 equiv) was added and the mixture was cooled down to 0 °C. Boc2O 
(128 mg, 0.588 mmol, 3 equiv) was added as a solution in dioxane (6 mL) via an additional 
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funnel. The mixture was stirred for 1 h at 0 °C and then for 24 h at ambient temperature. EA 
(5 mL) was added, the phases separated and the aqueous phase was extracted with EA (2x). 
The combined organic layers were washed with sat. NaHCO3 solution (1x) and the combined 
aqueous phases were treated with 2M HCl to adjust pH 2-3. The aqueous phase was extracted 
with EA (3x) and the combined organic phases were dried over MgSO4, filtered and 
concentrated under reduced pressure. The product was obtained after column chromatography 
(DCM/MeOH 19:1) as a white fluffy solid (47 mg, 0.099 mmol, 51% over 4 steps). 
Rf = 0.41 (DCM/MeOH 9:1). –
1H NMR (400 MHz, CD3OD) į = 7.78 (d, J = 7.5 Hz, 2H), 
7.64 (d, J = 7.4 Hz, 2H), 7.42 – 7.24 (m, 4H), 4.44 – 4.34 (m, 2H), 4.26 – 4.14 (m, 1H), 3.92 
– 3.79 (m, 1H), 3.74 – 3.61 (m, 2H), 3.10 – 2.96 (m, 2H), 2.53 – 2.35 (m, 2H), 2.28 – 2.15 (m, 
1H), 1.45 (s, 9H). – 13C NMR (75 MHz, CD3OD) į = 158.7, 156.3, 145.3, 142.7, 128.9, 
128.2, 126.2, 121.0, 81.1, 67.8, 56.0, 55.3, 51.3, 50.8, 50.6, 42.2, 41.4, 39.3, 37.9, 28.8 (signal 
doubling due to rotamers). – IR (neat): ৼ (cm-1) = 3280, 3067, 2974, 2359, 1669, 1558, 1476, 
1420, 1367, 1240, 1189, 1140, 842, 801, 738. – mp = 159-162 °C. – >Į@૛૙ࡰ = +8.7 (c 1, DCM). 
– LRMS (ESI): m/z = 367.1663 [M+H-CO2-C4H8]
+, 411.1562 [M+H-C4H8]
+, 467.2186
[M+H]+, 489.2007 [M+Na]+, 955.4119 [2M+Na]+. – HRMS (ESI): m/z = 467.2186 [M+H]+; 
calc. for [C26H31N2O6]
+ = 467.2177. 
(±)-tert-Butyl-2-oxohexahydro-6H-furo[2,3-b]pyrrole-6-carboxylate (222)
To a solution of (±)-194 (99 mg, 0.349 mmol, 1 equiv) in DCM (2 mL) TFA (54 µL, 0.698 
mmol, 2 equiv) was added dropwise and the mixture was stirred at ambient temperature for 
48 h. The volatiles were evaporated and the crude was purified by column chromatography 
(PE/EA 1:1) to yield the product as a white solid (42 mg, 0.184 mmol, 53%).
Rf = 0.42 (PE/EA = 1:1). –
1H NMR (300 MHz, CDCl3) į = 6.10 – 5.90 (m, 1H), 3.56 – 3.39 
(m, 2H), 3.10 – 2.94 (m, 1H), 2.74 (dd, J = 18.0, 8.9 Hz, 1H), 2.37 (d, J = 18.0 Hz, 1H), 2.27 
– 2.09 (m, 1H), 1.76 – 1.60 (m, 1H), 1.39 (s, 9H). – 13C NMR (101 MHz, CDCl3) į = 175.3, 
175.0, 153.6, 153.1, 92.4, 92.2, 81.3, 81.2, 45.9, 45.3, 38.7, 37.7, 35.1, 30.0, 29.2, 28.2 (signal 
doubling due to roatmers). – IR (neat): ৼ (cm-1) = 2989, 2940, 2873, 1770, 1692, 1461, 1386, 
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1237, 1148, 1080, 1032, 931, 879, 779, 700, 674. – mp = 101-102 °C. – LRMS (ESI): m/z = 
172.0605 [M+H-C4H8]
+, 228.1230 [M+H]+, 250.1049 [M+Na]+, 477.2209 [2M+Na]+. –
HRMS (ESI): m/z = 228.1230 [M+H]+; calc. for [C11H18NO4]
+ = 228.1230. 
tert-Butyl (3aS,6aR)-2-oxohexahydro-6H-furo[2,3-b]pyrrole-6-carboxylate (222)
To a solution of 194 (113 mg, 0.398 mmol, 1 equiv) in DCM (2 mL) TFA (61 µL, 0.797 
mmol, 2 equiv) was added dropwise and the solution was stirred at 0 °C for 7 d. After 2 and 6 
d the same amount of TFA was added again. The volatiles were removed under reduced 
pressure and the crude was purified by column chromatography (PE/EA 1:1) to yield the 
product as a white solid (14 mg, 0.063 mmol, 16%).
Spectroscopic data were identical to those of its racemate (±)-222. – >Į@૛૙ࡰ = -75.9 (c 1, 
DCM). – HPLC analysis (Chiracel ASH, n-heptane/iPrOH 70:30, 0.5 mL/min, 215 nm): tr = 
16.77 min, 20.60 min, 39% ee.
2-((3S)-2-Allyl-1-(tert-butoxycarbonyl)pyrrolidin-3-yl)acetic acid (224)
194 (212 mg, 0.748 mmol, 1 equiv) and allyltrimethylsilane (1.19 mL, 7.48 mmol, 10 equiv) 
were dissolved in DCM (6 mL anhydrous) and cooled down to 0 °C by the use of a cryostat. 
Then BF3·OEt2 (95 µL, 0.748 mmol, 1 equiv) was added dropwise and the mixture was stirred 
for 6 d at 0 °C. After 3, 4, 5 d the same volume of BF3·OEt2 was added again. When all 
starting material was consumed, an excess of TFA (4 mL) was added and the mixture was 
stirred for 24 h at ambient temperature. 
The volatiles were removed in vacuo and the crude was dissolved in 0.1 M HCl. The solution 
was loaded onto a column of DOWEX 50WX8-400 (2x2 cm, 2 times activated with 0.1 M 
HCl) and the resin was washed with distilled water (500 mL). The product was eluted with 
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16% NH3 (aq) and the fractions were concentrated and lyophilized. The product (83 mg, 
0.49 mmol, 66% over two steps) was obtained as a slight beige-colored amorphous solid and 
directly used in the next step.
The solid (83 mg, 0.49 mmol, 1 equiv) was dissolved in dioxane/water (1:1, 3 mL each), 
NaHCO3 (82 mg, 0.981 mmol, 2 equiv) was added and the mixture was cooled down to 0 °C. 
A solution of Boc2O (161 mg, 0.735 mmol, 1.5 equiv) in dioxane (4 mL) was added dropwise 
and the mixture was stirred for 20 h at ambient temperature. Afterwards, EA (10 mL) was 
added, the phases separated and the aqueous phase was extracted with EA (2x). The combined 
organic layers were back extracted with sat. NaHCO3 solution (1x) and the combined aqueous 
phases were acidified to a pH of 2-3 by the addition of 2M HCl. The aqueous phase was 
extracted with EA (3x) and the combined organic layers were dried over MgSO4, filtered and 
the solvent was removed under reduced pressure. The crude was purified by column 
chromatography (DCM/MeOH 19:1) to obtain the product as a colorless oil (66 mg, 
0.25 mmol, 50% over 3 steps, inseparable mixture of diastereomers, dr 1:1.2). 
Rf = 0.22 (DCM/MeOH 19:1). –
1H NMR (300 MHz, CDCl3) į = 5.79 – 5.60 (m, 1H), 5.07 
– 4.90 (m, 2H), 3.61 – 3.15 (m, 3H), 2.58 – 2.33 (m, 3H), 2.33 – 2.15 (m, 2H), 2.11 – 1.89 (m, 
1H), 1.67 – 1.47 (m, 1H), 1.39 (s, 9H). – 13C NMR (75 MHz, CDCl3) į = 177.3, 154.7, 154.6, 
135.4, 134.5, 134.4, 117.74, 117.65, 117.0, 116.8, 79.8, 79.5, 62.1, 61.9, 45.1, 44.7, 38.9, 
38.4, 38.3, 38.0, 37.9, 37.5, 34.2, 28.9, 28.5 (signal doubling due to rotamers and 
diastereomers). – IR (neat): ৼ (cm-1) = 3078, 2974, 2937, 1729, 1692, 1640, 1479, 1394, 
1252, 1162, 1118, 995, 913, 875, 771. – >Į@૛૙ࡰ = +17.9 (c 1, DCM). – LRMS (ESI): m/z = 
214.1072 [M+H-C4H8]
+, 270.1704 [M+H]+, 292.1525 [M+Na]+, 561.3140 [2M+Na]+. –
HRMS (ESI): m/z = 270.1702 [M+H]+; calc. for [C14H24NO4]
+ = 270.1700.
(1S,5S,6S)-2-tert-Butyl 6-methyl 2-azabicyclo[3.1.0]hex-3-ene-2,6-dicarboxylate (201)196
According to literature procedure196 a freshly prepared solution of NaOMe in MeOH (250 µL
anhydrous, 0.49 mmol, 1.2 equiv, 2 M) was added to a solution of 190 (117 mg, 0.42 mmol, 1 
equiv) in MeOH (5 mL anhydrous) and the mixture was refluxed under N2-atmosphere for 8 
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h. The mixture was allowed to cool down to ambient temperature, then sat. NH4Cl solution (5 
mL) was added and the phases were separated. The aqueous phase was extracted with DCM 
(1x) and the combined organic layers were dried over MgSO4, filtered and evaporated. After 
purification of the crude by column chromatography (PE/EA 9:1) the product was isolated as 
a white solid (67 mg, 0.28 mmol, 67%) as well as remaining starting material (22 mg, 0.08 
mmol, 19%). 
Rf = 0.33 (PE/EA = 9:1) –
1H NMR (300 MHz, CDCl3) į – 6.39 (m, 1H), 5.44 – 5.29 
(m, 1H), 4.50 – 4.23 (m, 1H), 3.74 – 3.61 (m, 3H), 2.86 – 2.74 (m, 1H), 1.55 – 1.44 (m, 9H), 
1.01 – 0.91 (m, 1H) – 13C NMR (75 MHz, CDCl3 į= 173.6, 173.3, 151.3, 151.0, 129.9,
129.7, 109.9, 81.7, 51.8, 44.3, 44.2, 32.3, 31.0, 28.2, 22.9, 22.8 (signal doubling due to 
rotamers) – HPLC analysis (Phenomenex Lux Cellulose-1, n-heptane/iPrOH 99:1, 
1 mL/min, 240 nm): tr = 6.02 min, 10.12 min; >99% ee. 
di-tert-Butyl-(S)-piperidine-1,3-dicarboxylate (200)
Compound 190 (1.00 g, 3.55 mmol) was dissolved in THF (15 mL anhydrous, 0.2 M) and 
Pd/C (100 mg, 10 wt% based on starting material, 10% Pd on charcoal, 2.6 mol%) was added. 
The flask was flushed ten times with hydrogen gas and the mixture was stirred for 3 h at 
ambient temperature. When all starting material was consumed the mixture was filtered over a 
plug of celite, washed with DCM and concentrated in vacuo. The crude product was purified 
by column chromatography (PE/EA 50:1) to obtain the product as a white solid (190 mg, 0.66 
mmol, 19%). 
Rf = 0.5 (PE/EA 5:1). –
1H NMR (300 MHz, CDCl3) į = 4.16 – 4.00 (m, 1H), 3.94 – 3.82 (m, 
1H), 2.89 (dd, J = 13.0, 10.6 Hz, 1H), 2.82 – 2.70 (m, 1H), 2.37 – 2.25 (m, 1H), 2.03 – 1.92 
(m, 1H), 1.71 – 1.46 (m, 3H), 1.44 (s, 9H), 1.42 (s, 9H). – 13C NMR (75 MHz, CDCl3) į = 
172.8, 154.7, 80.6, 79.6, 45.8, 44.0, 42.3, 28.4, 28.0, 27.3, 24.3. – IR (neat): ৼ (cm-1) = 2978, 
2937, 2866, 1684, 1722, 1423, 1367, 1312, 1267, 1220, 1177, 1140, 1036, 1002, 925, 849, 
767. – mp = 77-79 °C. – >Į@૛૙ࡰ = +45.2 (c 1, DCM). – HPLC analysis (Phenomenex Lux 
Cellulose-2, n-heptane/iPrOH 99:1, 0.5 mL/min, 200 nm): tr = 15.96 min, 17.97 min, >99% 
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ee. – LRMS (ESI): m/z = 286.2017 [M+H]+, 308.1836 [M+Na]+, 593.3779 [2M+Na]+. –
HRMS (ESI): m/z = 282.2014 [M+H]+; calc. for [C15H27NO4]
+ = 286.2013. 
(S)-Piperidine-3-carboxylic acid (237)207
200 (120 mg, 0.42 mmol) was dissolved in DCM (4 mL) and TFA (2 mL) was added. The 
mixture was stirred at ambient temperature for 24 h, then the volatiles were removed under 
reduced pressure. For removal of the counter ion the crude was dissolved in 0.1 M HCl. The 
solution was loaded onto a column of DOWEX 50WX8-400 (2x2 cm, 2 times activated with 
0.1 M HCl) and the resin was washed with distilled water (250 mL). The product was eluted 
with 16% NH3 (aq.) and the fractions were concentrated and lyophilized. The product 237
(42.6 mg, 0.32 mmol, 78%) was obtained as a white solid. 
1H NMR (400 MHz, D2O) į = 3.35 (dd, J = 12.6, 3.7 Hz, 1H), 3.29 – 3.21 (m, 1H), 3.16 –
3.00 (m, 2H), 2.66 – 2.57 (m, 1H), 2.07 – 1.98 (m, 1H), 1.96 – 1.84 (m, 1H), 1.81 – 1.64 (m, 
2H). – 13C NMR (101 MHz, D2O) į = 180.2, 45.8, 44.0, 40.9, 25.7, 21.0. – >Į@૛૙ࡰ = +4.7 (c 1, 
H2O, Lit
207.: 4.7 c 1, H2O). – LRMS (ESI): m/z = 130.0865 [M+H]
+.
(±)-tert-Butyl-6-(hydroxymethyl)-2-azabicyclo[3.1.0]hex-3-ene-2-carboxylate (248)225
In a flame dried flask under N2-atmosphere LiAlH4 (162 mg, 4.27 mmol, 1.5 equiv) was 
suspended in THF (30 mL anhydrous) at 0 °C. 190 (800 mg, 2.84 mmol, 1 equiv) in THF (20 
mL anhydrous) was added dropwise via an additional funnel and the reaction mixture was 
stirred at 0 °C for 1 h, then at ambient temperature for 20 h. The mixture was cooled down to 
0 °C, EA (10 mL) was added and the reaction was quenched by the dropwise addition of sat. 
NH4Cl solution, till no gas evolution was observed anymore. The phases were separated and 
the aqueous phase was extracted with EA (3x). The combined organic layers were dried over 
MgSO4, filtered and concentrated under reduced pressure. The crude was purified by column 
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chromatography (PE/EA 1:1) and the product was obtained as a colorless oil (308 mg, 
1.46 mmol, 51%).
Rf = 0.26 (PE/EA 1:1). –
1H NMR (300 MHz, CDCl3) į = 6.40 – 6.19 (m, 1H), 5.29 – 5.17 +
5.11 – 4.99 (m, 1H), 3.79 – 3.25 (m, 4H), 2.18 – 2.01 (m, 1H), 1.42 (s, 9H), 0.60 – 0.49 (m, 
1H). – 13C NMR (75 MHz, CDCl3) į = 152.4, 151.9, 129.6, 128.3, 128.0, 111.3, 106.1, 81.3, 
80.9, 62.9, 55.3, 40.1, 40.0, 28.3, 25.2, 24.0, 23.8 (signal doubling due to diastereomers and 
rotamers).
(±)-tert-Butyl-6-(hydroxymethyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (249)
249 was obtained as a by-product during the hydrogenation of 248. The crude was purified by 
column chromatography (PE/EA 1:1) and the product was obtained as a colorless oil (72 mg, 
0.37 mmol, 26%).
Rf = 0.16 (PE/EA 1:1). –
1H NMR (300 MHz, CDCl3) į = 3.67 – 3.55 (m, 1H), 3.52 – 3.30 
(m, 2H), 3.30 – 3.19 (m, 1H), 3.06 – 2.91 (m, 1H), 2.78 (bs, 1H), 2.18 – 2.02 (m, 1H), 2.01 –
1.88 (m, 1H), 1.53 – 1.46 (m, 1H), 1.45 (s, 9H), 1.26 – 1.17 (m, 1H). – 13C NMR (101 MHz, 
CDCl3) į = 155.5, 79.8, 62.8, 45.3, 40.4, 28.6, 26.1, 21.5, 20.1. – IR (neat): ৼ (cm-1) = 3377, 
2974, 2933, 2877, 1669, 1390, 1363, 1252, 1170, 1121, 1032, 849, 801, 767. – LRMS (ESI): 
m/z = 140.0708 [M+H-H2O-C4H10O]
+, 214.1439 [M+H]+, 236.1259 [M+Na]+, 427.2809 
[2M+Na]+. – HRMS (ESI): m/z = 214.1439 [M+H]+; calc. for [C11H20NO3]
+ = 214.1438.
(±)-tert-Butyl 3-(hydroxymethyl)piperidine-1-carboxylate (250)
Compound 248 (270 mg, 1.28 mmol) was dissolved in MeOH (5 mL anhydrous, 0.2 M) and 
Pd/C (30 mg, 10 wt% based on starting material, 10% Pd on charcoal, 2.2 mol%) was added. 
The flask was flushed ten times with hydrogen gas and the mixture was stirred at ambient 
temperature for 15 h. When all starting material was consumed the mixture was filtered over a 
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plug of celite, washed with MeOH and concentrated in vacuo. The crude product was purified 
by column chromatography (PE/EA 1:1) to obtain the product as a colorless oil (84 mg, 0.39 
mmol, 31%). 
Rf = 0.26 (PE/EA 1:1). –
1H NMR (300 MHz, (CD3)2CO) į = 4.11 – 4.00 (m, 1H), 3.93 –
3.82 (m, 1H), 3.72 – 3.60 (m, 1H), 3.53 – 3.28 (m, 3H), 2.85 – 2.48 (m, 1H), 1.82 – 1.70 (m, 
1H), 1.67 – 1.51 (m, 3H), 1.42 (s, 9H), 1.24 – 1.10 (m, 1H). – 13C NMR (101 MHz, 
(CD3)2CO) į = 154.3, 78.3, 64.2, 47.3, 46.9, 44.7, 44.0, 38.9, 27.7, 27.1, 24.5 (signal doubling 
due to rotamers). – IR (neat): ৼ (cm-1) = 3440, 2974, 2929, 2862, 1682, 1669, 1420, 1372, 
1263, 1174, 1148, 1077, 1036, 965, 857, 767. – LRMS (ESI): m/z = 142.0864 [M+H-H2O-
C4H8]+, 160.0967 [M+H-C4H8]
+, 216.1595 [M+H]+, 238.1416 [M+Na]+, 453.2938
[2M+Na]+. – HRMS (ESI): m/z = 216.1595 [M+H]+; calc. for [C11H22NO3]
+ = 216.1594. 
(±)-Piperidin-3-ylmethanol (251)247
250 (40 mg, 0.185 mmol) was dissolved in DCM (3 mL), TFA (1 mL) was added and the 
mixture was stirred at ambient temperature for 24 h. The volatiles were removed under 
reduced pressure and the resulting brown solid was dissolved in 0.1 M HCl.  For removal of 
the counter ion the crude was loaded onto a column of DOWEX 50WX8-400 (2x2 cm, 2 
times activated with 0.1 M HCl) and the resin was washed with distilled water (200 mL). The 
product was eluted with 16% NH3 (aq.) and the fractions were concentrated and lyophilized. 
The product was obtained as a colorless liquid (volatile, 11 mg, 0.095 mmol, 51%). 
1H NMR (300 MHz, D2O) į = 3.42 – 3.26 (m 2H), 3.21 – 3.06 (m, 2H), 2.63 (td, J = 12.7, 3.2
Hz, 1H), 2.45 (t, J = 12.0 Hz, 1H), 1.80 – 1.62 (m, 3H), 1.57 – 1.38 (m, 1H), 1.16 – 0.98 (m, 
1H).
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(±)-Ethyl-2-tosyl-2-azabicyclo[3.1.0]hexane-6-carboxylate (253)
252 (50 mg, 0.16 mmol) was dissolved in THF (2 mL anhydrous, 0.08 M), Pd/C (5 mg, 10 
wt%, 10% Pd on charcoal, 0.029 mol%) was added. The flask was flushed ten times with 
hydrogen gas and the mixture was stirred at ambient temperature. After 3 h all starting 
material was consumed and the mixture was filtered over a plug of celite, washed with DCM 
and concentrated in vacuo. The pure product was obtained as a white solid (49 mg, 0.15 
mmol, 97%). 
Rf = 0.18 (PE/EA 5:1). –
1H NMR (300 MHz, CDCl3) į = 7.74 – 7.63 (m, 2H), 7.38 – 7.28 
(m, 2H), 4.18 – 3.94 (m, 2H), 3.71 (dd, J = 6.3, 1.7 Hz, 1H), 3.55 – 3.44 (m, 1H), 2.45 (s, 
3H), 2.39 – 2.27 (m, 1H), 2.25 – 2.08 (m, 2H), 1.96 – 1.85 (m, 1H), 1.23 (t, J = 7.1 Hz, 3H), 
1.07 – 1.02 (m, 1H). – 13C NMR (75 MHz, CDCl3) į = 170.2, 144.2, 131.7, 129.7, 128.4, 
60.6, 45.2, 44.5, 25.6, 24.5, 21.7, 20.7, 14.3. – IR (neat): ৼ (cm-1) = 2989, 2881, 1714, 1595, 
1446, 1414, 1326, 1285, 1237, 1185, 1148, 1088, 984, 924, 902, 849, 805, 749, 708, 663. –
mp = 118-120 °C. – LRMS (ESI): m/z = 264.0691[M+H-EtOH]+, 310.1126 [M+H]+, 
332.0929 [M+Na]+, 641.1963 [2M+Na]+. – HRMS (ESI): m/z = 310.1108 [M+H]+; calc. for 
[C15H20NO4S]
+ = 310.1108. 
(±)-tert-butyl-5-(hydroxymethyl)-1,3-dioxo-2-phenyl-1,2,3,3a,4,5,8,8a-octahydro-4,8-
epiminocyclohepta[c]pyrrole-9-carboxylate (287)
In a flame dried Schlenk-flask 248 (38 mg, 0.179 mmol, 1 equiv) and N-phenylmaleimide (84 
mg, 0.485 mmol, 2.7 equiv) in toluene (5 mL anhydrous) were stirred for 17 h at 100 °C. The 
solvent was removed under reduced pressure and the crude was purified by column 
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chromatography (PE/EA 2:1) to yield the product as a colorless viscous oil (29 mg, 
0.075 mmol, 42%).
Rf = 0.33 (PE/EA 1:1). –
1H NMR (400 MHz, CDCl3) į = 7.50 – 7.35 (m, 3H), 7.19 – 7.13 
(m, 2H), 6.06 (dd, J = 9.4, 4.8, 1H), 5.73 (ddd, J = 9.7, 3.9, 1.1, 1H), 4.94 – 4.85 (m, 2H), 
3.87 (t, J = 8.9, 1H), 3.75 (dd, J = 9.4, 7.0, 1H), 3.69 (dd, J = 11.5, 5.1, 1H), 3.55 – 3.43 (m, 
1H), 2.79 – 2.70 (m, 1H), 1.51 – 1.44 (m, 9H). – 13C NMR (101 MHz, CDCl3) į = 174.8, 
173.9, 153.0, 131.6, 129.3, 129.00, 126.5, 81.4, 63.4, 54.3, 53.5, 48.9, 41.8, 28.5, 28.3. – IR
(neat): ৼ (cm-1) = 3466, 2974, 2933, 1703, 1498, 1423, 1367, 1326, 1244, 1155, 1103, 1054, 
1006, 939, 909, 872, 730, 693. – LRMS (ESI): m/z = 329.1132 [M+H-C4H8]
+, 407.1573
[M+Na]+, 791.3267 [2M+Na]+. – HRMS (ESI): m/z = 385.1765 [M+H]+; calc. for 
[C21H25N2O5]
+ = 385.1758.
(±)-8-(tert-butyl) 6,7-diethyl-4-(hydroxymethyl)-8-azabicyclo[3.2.1]octa-2,6-diene-6,7,8-
tricarboxylate (288) 
In a flame dried Schlenk-flask 248 (85 mg, 0.402 mmol, 1 equiv) and diethyl 
acetylendicarboxylate (173 µL mg, 1.09 mmol, 2.7 equiv) in toluene (4 mL anhydrous) were 
stirred for 14 h at 100 °C. The solvent was removed under reduced pressure and the crude was 
purified by column chromatography (PE/EA 2:1) to yield the product as a colorless viscous 
oil (91 mg, 0.238 mmol, 59%).
Rf = 0.32 (PE/EA 1:1). –
1H NMR (400 MHz, CDCl3) į = 6.27 (dd, J=8.7, 4.7, 1H), 5.40 
(ddd, J=9.6, 3.3, 1.7, 1H), 5.07 – 5.03 (m, 1H), 4.89 – 4.76 (m, 1H), 4.20 (qd, J=7.1, 2.6, 5H), 
3.74 (dd, J=11.3, 5.3, 1H), 3.64 – 3.53 (m, J=15.4, 1H), 2.42 – 2.35 (m, 1H), 1.40 (s, 11H), 
1.25 (td, J=7.1, 2.1, 8H). – 13C NMR (101 MHz, CDCl3) į = 163.0, 162.5, 152.3, 131.5, 
131.1, 127.6, 127.4, 81.0, 63.7, 61.6, 61.5, 60.5, 58.4, 40.5, 28.3, 14.4. – IR (neat): ৼ (cm-1) = 
3440, 2981, 2937, 2128, 1699, 1416, 1367, 1304, 1256, 1166, 1110, 1077, 1028, 868, 764, 
723. – LRMS (ESI): m/z = 282.1340 [M+H-C5H8O2]
+, 404.1686 [M+Na]+, 785.3482 
[2M+Na]+. – HRMS (ESI): m/z = 382.1860 [M+H]+; calc. for [C19H28NO7]
+ = 382.1860.
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F. Appendix
1. NMR Spectra
1H NMR spectra: upper image
13C NMR spectra (DEPT135 integrated): lower image
Solvent and frequency are stated each spectrum.
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di-tert-Butyl (3R,4R)-4-(benzyl((S)-1-phenylethyl)amino)pyrrolidine-1,3-dicarboxylate 
(78) (300 MHz, CDCl3)
(101 MHz, CDCl3)
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di-tert-Butyl (3R,4R)-4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)pyrrolidine-1,3-
dicarboxylate (85) (300 MHz, CDCl3)
(75 MHz, CDCl3)
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(3R,4R)-4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-1-(tert-
butoxycarbonyl)pyrrolidine-3-carboxylic acid (79)  (400 MHz, CDCl3)
(101 MHz, CDCl3)
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tert-Butyl (1R,2S)-2-(benzyl((S)-1-phenylethyl)amino)cyclopentane-1-carboxylate
(21) (300 MHz, CDCl3)
(75 MHz, CDCl3)
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(1R,2S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)cyclopentane-1-carboxylic acid 
(80) (300 MHz, CDCl3) 
(101 MHz, CDCl3)
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(3S,4S)-4-(Benzyl((R)-1-phenylethyl)amino)pyrrolidine-3-carboxylic acid ((ent)-100)
(400 MHz, CDCl3)
(101 MHz, CDCl3)
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tert-Butyl (3R,4R)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-((S)-2-
((benzyloxy)carbonyl)pyrrolidine-1-carbonyl)pyrrolidine-1-
carboxylate (121) (300 MHz, CDCl3)
(101 MHz, CDCl3)
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tert-Butyl-(3R,4R)-3-((S)-2-((benzyloxy)carbonyl)pyrrolidine-1-carbonyl)-4-((S)-1-
((benzyloxy)carbonyl)pyrrolidine-2-carboxamido)pyrrolidine-1-carboxylate (122) 
(300 MHz, CDCl3)
(101 MHz, CDCl3)
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((3R,4R)-1-(tert-Butoxycarbonyl)-4-((S)-pyrrolidine-2-carboxamido)pyrrolidine-3-
carbonyl)-L-proline (118) (300 MHz, CD3OD)
(75 MHz, CD3OD)
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tert-Butyl (3S,4S)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-((S)-2-
((benzyloxy)carbonyl)pyrrolidine-1-carbonyl)pyrrolidine-1-carboxylate (125) (300 MHz, 
CDCl3)
(101 MHz, CDCl3) 
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tert-Butyl (3S,4S)-3-((S)-2-((benzyloxy)carbonyl)pyrrolidine-1-carbonyl)-4-((S)-1-
((benzyloxy)carbonyl)pyrrolidine-2-carboxamido)pyrrolidine-1-carboxylate (126) 
(400 MHz, CDCl3)
(101 MHz, CDCl3)
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((3S,4S)-1-(tert-Butoxycarbonyl)-4-((S)-pyrrolidine-2-carboxamido)pyrrolidine-3-
carbonyl)-L-proline (127) (400 MHz, (CD3)2SO)
(101 MHz, (CD3)2SO)
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Benzyl-((1R,2S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)cyclopentane-1-
carbonyl)-L-prolinate (128) (300 MHz, CDCl3)
(75 MHz, CDCl3)
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Benzyl-((1S,2R)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)cyclopentane-1-
carbonyl)-L-prolinate (130) (400 MHz, CDCl3)
(101 MHz, CDCl3)
F. Appendix
187
Methyl (1S,2R)-2-(benzyl((R)-1-phenylethyl)amino)cyclopentane-1-carboxylate ((ent)-
134) (300 MHz, CDCl3)
(75 MHz, CDCl3)
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tert-Butyl (1S,2R)-2-(1H-imidazole-1-carboxamido)cyclopentane-1-carboxylate (138)
(300 MHz, CDCl3)
(75 MHz, CDCl3)
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di-tert-Butyl 2,2'-(carbonylbis(azanediyl))(1S,1'S,2R,2'R)-bis(cyclopentane-1-
carboxylate) (139) (300 MHz, CDCl3)
(75 MHz, CDCl3)
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(1R,2S)-2-(((Allyloxy)carbonyl)amino)cyclopentane-1-carboxylic acid (144)
(400 MHz, CDCl3)
(101 MHz, CDCl3)
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Benzyl ((1R,2S)-2-(((allyloxy)carbonyl)amino)cyclopentane-1-carbonyl)-L-prolinate 
(145) (300 MHz, CDCl3)
(75 MHz, CDCl3)
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Benzyl (S)-2-(((1S,2R)-2-((S)-2-((benzyloxy)carbonyl)pyrrolidine-1-
carbonyl)cyclopentyl)carbamoyl)pyrrolidine-1-carboxylate (129) (400 MHz, CDCl3)
(101 MHz, CDCl3)
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((1R,2S)-2-((S)-Pyrrolidine-2-carboxamido)cyclopentane-1-carbonyl)-L-proline (119)
(300 MHz, CDCl3)
(75 MHz, CDCl3)
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Benzyl ((1S,2R)-2-(((allyloxy)carbonyl)amino)cyclopentane-1-carbonyl)-L-prolinate 
(146) (300 MHz, CDCl3)
(75 MHz, CDCl3)
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Benzyl (S)-2-(((1R,2S)-2-((S)-2-((benzyloxy)carbonyl)pyrrolidine-1-
carbonyl)cyclopentyl)carbamoyl)pyrrolidine-1-carboxylate (131) (300 MHz, CDCl3) 
(75 MHz, CDCl3)
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((1S,2R)-2-((S)-Pyrrolidine-2-carboxamido)cyclopentane-1-carbonyl)-L-proline (147)
(300 MHz, CDCl3)
(75 MHz, CDCl3)
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(2R,7R)-Diethyl 2,7-bis((tert-butoxycarbonyl)amino)oct-4-enedioate (166)                  
(300 MHz, CDCl3)
(75 MHz, CDCl3)
OEt
O
BocHN
NHBoc
O
EtO
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(2R,7R)-Diethyl 2,7-bis((tert-butoxycarbonyl)amino)octanedioate (167) 
(300 MHz, CDCl3)
(75 MHz, CDCl3)
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(2R,7R)-2,7-Bis((tert-Butoxycarbonyl)amino)octanedioic acid (164) (300 MHz, CD3OD)
(75 MHz, CD3OD)
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tert-Butyl (1S,2S)-2-(benzyl((S)-1-phenylethyl)amino)cyclopentane-1-carboxylate
(23) (300 MHz, CDCl3)
(75 MHz, CDCl3)
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tert-Butyl (1S,2S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)cyclopentane-1-
carboxylate (184) (300 MHz, CDCl3)
(75 MHz, CDCl3)
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(1S,2S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)cyclopentane-1-carboxylic acid 
(185) (300 MHz, CD3OD)
(75 MHz, CD3OD)
FmocHN CO2H
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di-tert-Butyl (1S,5S,6S)-2-azabicyclo[3.1.0]hex-3-ene-2,6-dicarboxylate (190)          
(300 MHz, CDCl3)
(75 MHz, CDCl3)
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(1S,5S,6S)-di-tert-butyl 2-azabicyclo[3.1.0]hexane-2,6-dicarboxylate (194)              
(300 MHz, CDCl3)
(75 MHz, CDCl3)
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(S)-tert-Butyl 3-(2-(tert-butoxy)-2-oxoethyl)pyrrolidine-1-carboxylate (189)                       
(300 MHz, CDCl3) 
(75 MHz, CDCl3)
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(S)-2-(pyrrolidin-3-yl)acetic acid (188) (400 MHz, D2O)
(101 MHz, D2O)
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di-tert-Butyl (1S,3S,4R,5S,6S)-4-azido-3-methoxy-2-azabicyclo[3.1.0]hexane-2,6-
dicarboxylate (213) (400 MHz, CDCl3)
(101 MHz, CDCl3)
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NOESY (400 MHz, CDCl3)
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di-tert-Butyl (1S,3S,4R,5R,6S)-4-amino-3-methoxy-2-azabicyclo[3.1.0]hexane-2,6-
dicarboxylate (214) (300 MHz, CDCl3)
(75 MHz, CDCl3)
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di-tert-Butyl (1S,3S,4R,5R,6S)-4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-
methoxy-2-azabicyclo[3.1.0]hexane-2,6-dicarboxylate (215) (300 MHz, CDCl3)
(75 MHz, CDCl3)
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tert-Butyl-(3R,4S)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(2-(tert-butoxy)-2-
oxoethyl)pyrrolidine-1-carboxylate (216) (300 MHz, CDCl3)
(75 MHz, CDCl3)
N
Boc
FmocHN CO2tBu
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2-((3S,4R)-4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-1-(tert-
butoxycarbonyl)pyrrolidin-3-yl)acetic acid (217) (400 MHz, CD3OD)
(75 MHz, CD3OD)
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tert-Butyl (3aS,6aR)-2-oxohexahydro-6H-furo[2,3-b]pyrrole-6-carboxylate (222)   
(300 MHz, CDCl3)
(101 MHz, CDCl3)
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2-((3S)-2-Allyl-1-(tert-butoxycarbonyl)pyrrolidin-3-yl)acetic acid (224) (dr = 1:1.2)
(300 MHz, CDCl3)
NMR (75 MHz, CDCl3)
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(1S,5S,6S)-2-tert-Butyl 6-methyl 2-azabicyclo[3.1.0]hex-3-ene-2,6-dicarboxylate
(201) (300 MHz, CDCl3)
(75 MHz, CDCl3)
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di-tert-Butyl (S)-piperidine-1,3-dicarboxylate (200) (300 MHz, CDCl3)
(75 MHz, CDCl3)
N
CO2tBu
Boc
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(S)-Piperidine-3-carboxylic acid (237) (400 MHz, D2O)
(101 MHz, D2O)
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(±)-tert-Butyl-6-(hydroxymethyl)-2-azabicyclo[3.1.0]hex-3-ene-2-carboxylate (248)
(300 MHz, CDCl3) 
(75 MHz, CDCl3)
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(±)-tert-Butyl-6-(hydroxymethyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (249)
(300 MHz, CDCl3)
(101 MHz, CDCl3)
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(±)-tert-Butyl-3-(hydroxymethyl)piperidine-1-carboxylate (250)                                    
(300 MHz, (CD3)2CO)
(101 MHz, (CD3)2CO)
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(±)-Piperidin-3-ylmethanol (251) (300 MHz, D2O)
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(±)-Ethyl-2-tosyl-2-azabicyclo[3.1.0]hexane-6-carboxylate (253) (300 MHz, CDCl3)
(75 MHz, CDCl3)
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(±)-tert-butyl 5-(hydroxymethyl)-1,3-dioxo-2-phenyl-1,2,3,3a,4,5,8,8a-octahydro-4,8-
epiminocyclohepta[c]pyrrole-9-carboxylate (286) (400 MHz, CDCl3) 
(101 MHz, CDCl3)
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(±)-8-(tert-butyl) 6,7-diethyl-4-(hydroxymethyl)-8-azabicyclo[3.2.1]octa-2,6-diene-6,7,8-
tricarboxylate (288) (400 MHz, CDCl3)
(101 MHz, CDCl3)
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2. HPLC Chromatograms
di-tert-Butyl-4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)pyrrolidine-1,3-
dicarboxylate ((rac)-(±)-(85)
di-tert-Butyl (3R,4R)-4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)pyrrolidine-1,3-
dicarboxylate (85)
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di-tert-Butyl (3S,4S)-4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)pyrrolidine-1,3-
dicarboxylate ((ent)-85)
Ac-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-((3R,4R)APC)-Arg-Tyr-NH2 (170) 
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Ac-Arg-His-Tyr-Ile-Asn-Leu-Ile-((3R,4R)APC)-Arg-((3R,4R)APC)-Arg-Tyr-NH2 (171) 
Ac-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-((3S,4S)APC)-Arg-Tyr-NH2 (172) 
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Ac-Arg-His-Tyr-Ile-Asn-Leu-Ile-((3S,4S)APC)-Arg-((3S,4S)APC)-Arg-Tyr-NH2 (173) 
Ac-Arg-His-Tyr-Ile-Asn-Leu-Ile-((1R,2S)ACPC)-Arg-((3R,4R)APC)-Arg-Tyr-NH2
(174) 
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Ac-Arg-His-Tyr-Ile-Asn-Leu-Ile-((1R,2S)ACPC)-Arg-((3R,4R)APC)-Arg-Tyr-NH2
(175) 
di-tert-Butyl (1S,5S,6S)-2-azabicyclo[3.1.0]hex-3-ene-2,6-dicarboxylate (190)
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(1S,5S,6S)-di-tert-butyl 2-azabicyclo[3.1.0]hexane-2,6-dicarboxylate (194)
tert-Butyl 3-(2-(tert-butoxy)-2-oxoethyl)pyrrolidine-1-carboxylate ((rac)-(±)-189) 
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(S)-tert-Butyl 3-(2-(tert-butoxy)-2-oxoethyl)pyrrolidine-1-carboxylate (189)
Ring-opening at 0 °C
Ring-opening at ambient temperature
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tert-Butyl-2-oxohexahydro-6H-furo[2,3-b]pyrrole-6-carboxylate (rac-(±)-222)
tert-Butyl (3aS,6aR)-2-oxohexahydro-6H-furo[2,3-b]pyrrole-6-carboxylate (222)
N
O
O
Boc
H
H
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2-(tert-Butyl) 6-methyl-2-azabicyclo[3.1.0]hex-3-ene-2,6-dicarboxylate ((rac)-(±)-201)
(1S,5S,6S)-2-tert-Butyl 6-methyl 2-azabicyclo[3.1.0]hex-3-ene-2,6-dicarboxylate (201)
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di-tert-Butyl-piperidine-1,3-dicarboxylate ((rac)-(±)-(200))
di-tert-Butyl (S)-piperidine-1,3-dicarboxylate (200)
N
CO2tBu
Boc
N
CO2tBu
Boc
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di-tert-Butyl-4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-methoxy-2-
azabicyclo[3.1.0]hexane-2,6-dicarboxylate ((rac)-(±)-215)
di-tert-Butyl (1S,3S,4R,5R,6S)-4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-
methoxy-2-azabicyclo[3.1.0]hexane-2,6-dicarboxylate (215)
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tert-Butyl-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(2-(tert-butoxy)-2-
oxoethyl)pyrrolidine-1-carboxylate ((rac)-(±)-216)
tert-Butyl-(3R,4S)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(2-(tert-butoxy)-2-
oxoethyl)pyrrolidine-1-carboxylate (216)
N
Boc
FmocHN CO2tBu
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3. X-ray crystallographic data
(±)-di-tert-Butyl-piperidine-1,3-dicarboxylate (200)
Table 1. Crystal data and structure refinement for 200. 
Identification code 200
Empirical formula C15H27NO4
Formula weight 285.37 
Temperature/K 123.00(10) 
Crystal system monoclinic 
Space group Ia 
a/Å 15.9418(9) 
b/Å 8.8090(5) 
c/Å 11.6098(7) 
Į 90 
ȕ 98.582(6) 
Ȗ 90 
Volume/Å3 1612.13(16) 
Z 4 
ȡcalcg/cm3 1.176 
ȝPP-1 0.684 
F(000) 624.0 
Crystal size/mm3 0.246 × 0.123 × 0.046 
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Radiation &X.ĮȜ 
2Ĭ range for data collection/° 11.226 to 146.74 
Index ranges -19 K-10 N-10 O
Reflections collected 4547 
Independent reflections 2316 [Rint = 0.0173, Rsigma = 0.0219] 
Data/restraints/parameters 2316/217/242 
Goodness-of-fit on F2 1.084 
Final R indexes [I>=2ı (I)] R1 = 0.0543, wR2 = 0.1476 
Final R indexes [all data] R1 = 0.0616, wR2 = 0.1571 
Largest diff. peak/hole / e Å-3 0.64/-0.26 
Flack parameter 0.4(5)
Table 2. Fractional Atomic Coordinates (×104) and Equivalent Isotropic Displacement 
Parameters (Å2×103) for 200. Ueq is defined as 1/3 of of the trace of the orthogonalised UIJ
tensor.
Atom x y z U(eq)
O2 4631(3) 11091(5) 2838(5) 32.6(9)
O4 2721(3) 11076(5) 5531(5) 30.2(9)
O3 2161(4) 8857(6) 6064(5) 41.0(11)
O1 5185(4) 8886(5) 2295(5) 40.9(11)
C2 3944(6) 8874(9) 3295(7) 32.1(6)
C9 5142(5) 11820(8) 1024(6) 39.4(15)
C11 2651(4) 9564(7) 5601(6) 32.0(12)
C2A 3400(9) 8825(11) 5024(10) 32.4(6)
C12 2099(5) 12058(7) 6037(6) 29.2(13)
C14 1218(4) 11739(8) 5443(7) 39.9(15)
C6 4664(4) 9558(7) 2795(5) 31.8(12)
C7 5225(5) 12043(7) 2318(6) 31.5(13)
C5 3371(7) 7176(8) 5198(6) 32.7(6)
C10 6135(4) 11750(8) 2939(7) 39.8(15)
C13 2390(5) 13657(8) 5749(7) 40.5(14)
C8 4943(5) 13613(8) 2578(7) 39.7(14)
C1A 3442(6) 9562(14) 3827(8) 32.0(6)
C15 2198(5) 11817(8) 7354(6) 39.4(15)
C5A 3955(10) 7189(10) 3243(8) 32.9(6)
C4 3377(4) 6435(11) 3994(6) 33.4(6)
N1A 4208(5) 8796(9) 3505(8) 32.6(6)
C3A 3092(5) 7176(10) 4789(11) 33.0(6)
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C3 4089(5) 7143(9) 3402(9) 32.9(6)
C1 3910(4) 9601(10) 4497(6) 32.1(6)
C4A 3888(5) 6430(14) 4424(8) 33.2(6)
N1 3256(5) 8853(7) 5097(8) 32.6(6)
Table 3. Anisotropic Displacement Parameters (Å2×103) for 200. The Anisotropic 
displacement factor exponent takes the form: -2ʌ2[h2a*2U11+2hka*b*U12+…].
Atom U11 U22 U33 U23 U13 U12
O2 39(2) 25(2) 39(2) -0.3(19) 20.2(17) -0.6(18)
O4 34.5(18) 20(2) 40(2) -1.5(18) 17.3(16) 2.7(17)
O3 50(2) 33(3) 45(3) 2(2) 24.0(19) -2(2)
O1 50(2) 28(2) 52(3) 1(2) 33(2) 4(2)
C2 34.3(14) 21.5(10) 43.0(13) 0.0(17) 14.4(10) 2.3(16)
C9 47(3) 39(4) 36(3) 6(3) 15(3) -8(3)
C11 34(2) 29(3) 37(3) -4(3) 17(2) 1(2)
C2A 34.9(14) 21.9(10) 43.3(13) -0.3(17) 14.7(10) 2.7(16)
C12 34(3) 28(3) 30(3) 0(2) 17(2) 8(2)
C14 43(3) 45(4) 33(3) -1(3) 10(2) 8(3)
C6 44(3) 24(3) 30(3) -3(2) 13(2) 0(3)
C7 35(3) 30(3) 31(3) 4(2) 9(2) -2(2)
C5 35.1(14) 21.8(10) 43.8(13) 0.0(17) 13.9(10) 2.4(16)
C10 33(3) 47(4) 42(3) 7(3) 11(2) -6(3)
C13 52(3) 29(3) 43(3) 4(3) 17(3) 2(3)
C8 55(4) 22(3) 46(4) 6(3) 22(3) -8(3)
C1A 34.6(14) 21.3(10) 43.0(13) -0.1(17) 14.9(10) 2.7(16)
C15 52(4) 41(4) 27(3) 2(2) 8(3) 2(3)
C5A 35.2(14) 21.9(10) 44.0(13) -0.4(17) 14.1(11) 2.7(16)
C4 35.7(14) 22(1) 44.5(13) 0.0(17) 13.3(10) 2.4(16)
N1A 35.3(14) 21.6(10) 43.8(13) -0.1(17) 15.3(11) 2.4(16)
C3A 35.7(14) 21.8(10) 44.0(13) 0.2(17) 14.5(11) 2.6(16)
C3 35.5(14) 21.8(10) 44.0(13) -0.5(17) 14.3(10) 2.7(16)
C1 34.7(14) 21.5(10) 43.1(13) -0.3(17) 14.9(10) 2.3(16)
C4A 35.6(14) 21.9(10) 44.4(13) -0.1(17) 13.3(11) 2.7(16)
N1 35.2(14) 21.9(10) 43.4(13) -0.2(16) 15(1) 2.7(16)
Table 4. Bond Lengths for 200.
Atom Atom Length/Å Atom Atom Length/Å
O2 C6 1.352(7) C12 C14 1.495(8)
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O2 C7 1.462(8) C12 C13 1.535(9)
O4 C11 1.340(7) C12 C15 1.529(8)
O4 C12 1.501(7) C6 N1A 1.356(6)
O3 C11 1.187(8) C7 C10 1.541(8)
O1 C6 1.233(7) C7 C8 1.499(9)
C2 C6 1.489(12) C5 C4 1.544(3)
C2 C3 1.544(3) C5 N1 1.491(4)
C2 C1 1.544(3) C1A N1A 1.491(4)
C9 C7 1.501(9) C5A N1A 1.491(4)
C11 C2A 1.594(15) C5A C4A 1.544(3)
C11 N1 1.355(6) C4 C3 1.544(3)
C2A C1A 1.544(3) C3A C4A 1.544(3)
C2A C3A 1.544(3) C1 N1 1.490(4)
Table 5. Bond Angles for 200.
Atom Atom Atom Angle/Û Atom Atom Atom Angle/Û
C6 O2 C7 121.7(4) O1 C6 C2 127.0(5)
C11 O4 C12 118.8(4) O1 C6 N1A 120.6(6)
C6 C2 C3 108.4(6) O2 C7 C9 111.9(5)
C6 C2 C1 108.5(6) O2 C7 C10 109.5(5)
C1 C2 C3 111.2(8) O2 C7 C8 102.4(5)
O4 C11 C2A 107.8(5) C9 C7 C10 112.5(6)
O4 C11 N1 111.2(5) C8 C7 C9 109.7(5)
O3 C11 O4 128.0(5) C8 C7 C10 110.4(5)
O3 C11 C2A 124.1(6) N1 C5 C4 111.4(7)
O3 C11 N1 120.8(6) N1A C1A C2A 100.5(8)
C1A C2A C11 110.0(8) N1A C5A C4A 106.4(8)
C1A C2A C3A 107.0(10) C5 C4 C3 109.7(8)
C3A C2A C11 102.7(8) C6 N1A C1A 117.5(7)
O4 C12 C13 101.8(5) C6 N1A C5A 120.0(8)
O4 C12 C15 109.6(5) C1A N1A C5A 105.9(10)
C14 C12 O4 110.0(5) C4A C3A C2A 101.3(9)
C14 C12 C13 111.5(5) C4 C3 C2 108.9(8)
C14 C12 C15 112.7(5) N1 C1 C2 111.1(7)
C15 C12 C13 110.8(5) C3A C4A C5A 103.2(10)
O2 C6 C2 110.7(5) C11 N1 C5 120.7(6)
O2 C6 N1A 116.4(6) C11 N1 C1 126.2(6)
O1 C6 O2 122.0(5) C1 N1 C5 112.9(7)
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Table 6. Torsion Angles for 200.
A B C D Angle/Û A B C D Angle/Û
O2 C6 N1A C1A 27.4(13) C12 O4 C11 N1 179.5(6)
O2 C6 N1A C5A 158.6(9) C6 O2 C7 C9 62.4(7)
O4 C11 C2A C1A -48.5(11) C6 O2 C7 C10 -63.0(7)
O4 C11 C2A C3A -162.1(8) C6 O2 C7 C8 179.9(5)
O4 C11 N1 C5 172.4(8) C6 C2 C3 C4 176.3(6)
O4 C11 N1 C1 -1.9(13) C6 C2 C1 N1 -174.3(6)
O3 C11 C2A C1A 135.5(8) C7 O2 C6 O1 -1.6(10)
O3 C11 C2A C3A 21.9(13) C7 O2 C6 C2 -175.0(6)
O3 C11 N1 C5 -5.3(14) C7 O2 C6 N1A 166.7(6)
O3 C11 N1 C1 -179.6(8) C5 C4 C3 C2 -57.8(11)
O1 C6 N1A C1A -164.1(8) C1A C2A C3A C4A 73.1(12)
O1 C6 N1A C5A -33.0(14) C4 C5 N1 C11 128.8(9)
C2 C1 N1 C11 -130.9(9) C4 C5 N1 C1 -56.2(12)
C2 C1 N1 C5 54.4(11) N1A C5A C4A C3A 70.2(12)
C11 O4 C12 C14 -60.5(7) C3A C2A C1A N1A -73.2(12)
C11 O4 C12 C13 -178.8(5) C3 C2 C6 O2 -171.3(6)
C11 O4 C12 C15 63.9(7) C3 C2 C6 O1 15.8(12)
C11 C2A C1A N1A 176.0(8) C3 C2 C1 N1 -55.1(11)
C11 C2A C3A C4A -171.1(9) C1 C2 C6 O2 -50.4(9)
C2A C1A N1A C6 -152.0(9) C1 C2 C6 O1 136.7(7)
C2A C1A N1A C5A 70.7(11) C1 C2 C3 C4 57.1(11)
C2A C3A C4A C5A -68.0(11) C4A C5A N1A C6 151.1(9)
C12 O4 C11 O3 -3.0(10) C4A C5A N1A C1A -72.8(13)
C12 O4 C11 C2A -178.8(7) N1 C5 C4 C3 57.6(11)
Table 7. Hydrogen Atom Coordinates (Å×104) and Isotropic Displacement Parameters 
(Å2×103) for 200.
Atom x y z U(eq)
H5 3412 9077 2778 38
H9A 4567 12008 677 59
H9B 5295 10797 860 59
H9C 5513 12513 707 59
H2A 3946 8873 5539 39
H14A 1050 10744 5655 60
H14B 1205 11788 4614 60
H14C 836 12480 5678 60
H13A 2914 6745 5558 39
H13B 3901 6955 5696 39
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H10A 6280 10705 2845 60
H10B 6166 11978 3753 60
H10C 6524 12387 2605 60
H13C 2393 13741 4926 61
H13D 2951 13835 6155 61
H13E 2008 14396 5988 61
H8A 5022 13767 3405 60
H8B 4354 13735 2268 60
H8C 5273 14344 2226 60
H1AA 2939 9340 3273 38
H1AB 3519 10653 3891 38
H15A 2786 11914 7681 59
H15B 2000 10821 7515 59
H15C 1872 12565 7694 59
H5AA 4377 6677 2861 39
H5AB 3413 7146 2736 39
H20A 2833 6593 3511 40
H20B 3470 5351 4087 40
H3AA 2939 6707 5485 40
H3AB 2612 7128 4169 40
H19C 4084 6702 2635 39
H19D 4637 6937 3862 39
H17C 4461 9509 4976 39
H17D 3779 10672 4398 39
H4AA 3817 5340 4339 40
H4AB 4388 6637 4989 40
Table 8. Atomic Occupancy for 200.
Atom Occupancy Atom Occupancy Atom Occupancy
C2 0.570(8) H5 0.570(8) C2A 0.430(8)
H2A 0.430(8) C5 0.570(8) H13A 0.570(8)
H13B 0.570(8) C1A 0.430(8) H1AA 0.430(8)
H1AB 0.430(8) C5A 0.430(8) H5AA 0.430(8)
H5AB 0.430(8) C4 0.570(8) H20A 0.570(8)
H20B 0.570(8) N1A 0.430(8) C3A 0.430(8)
H3AA 0.430(8) H3AB 0.430(8) C3 0.570(8)
H19C 0.570(8) H19D 0.570(8) C1 0.570(8)
H17C 0.570(8) H17D 0.570(8) C4A 0.430(8)
H4AA 0.430(8) H4AB 0.430(8) N1 0.570(8)
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